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Prior to the 1980`s, stress and lifestyle issues were thought of as the main causes of 
peptic ulcer disease and gastritis. In 1982, Marshall and Warren discovered that 
Helicobacter pylori were present in patients with chronic gastritis and gastric ulcers. 
Since that time it has been found that H. pylori infection occurs in up to 15 to 20% 
of the population and that the bacteria is also linked to development of duodenal 
ulcers and gastric cancer world-wide. Current treatment guidelines for the 
eradication of  H. pylori infection recommend the combination of a proton pump 
inhibitor and antibiotics which has successfully treated up to 90% of H. pylori-
positive cases. However, cases of H. pylori resistance have been reported world-
wide. Bacterial resistance and other issues such as poor compliance, low gastric pH 
and high bacteria load contribute to the increasing episodes of eradication failure. 
 
P-glycoprotein is believed to be associated with H. pylori eradication therapy failure. 
This drug efflux protein is present along the intestinal epithelial lining and functions 
as a biological barrier by pushing toxins and xenobiotics out of cells. As most of the 
drugs used to treat H. pylori infection are involved with P-glycoprotein pathway, 
their pharmacodynamic and pharmacokinetic may be affected by alterations of P-
glycoprotein expression. The variability of P-glycoprotein gene polymorphisms, 
particularly MDR1 C3435T may potentially influence the therapy outcomes. In 
addition, P-glycoprotein expression may be manipulated to prevent H. pylori 
attachment to the human intestinal epithelium which may limit its potential to cause 
gastrointestinal disease.  
 
This study was divided into two phases: – Phase 1 (Helicobacter pylori and P-
glycoprotein expression) and Phase 2 (Helicobacter pylori attachment to 
gastrointestinal cell lines). Phase 1 of the study aimed to evaluate the P-glycoprotein 
level expressed in human antral and duodenal tissue in the presence of H. pylori, to 
examine the relationship between P-glycoprotein expression and its genetic variant, 
particularly MDR1 C3435T as well as to assess the level of P-glycoprotein 
expression and the potential influence of CYP2C19 polymorphisms in subjects who 
experienced resistance towards H. pylori eradication therapy. Phase 2 of the study 
was designed to investigate the extent of H. pylori attachment to the human 
xiii 
 
gastrointestinal cell lines, namely LS174T and Caco-2, in the presence of a potent 
inducer and a potent inhibitor for P-glycoprotein. 
 
In Phase 1 of the study, 91 participants who were referred for upper gastroendoscopy 
at the Endoscopy Unit, Sir Charles Gairdner Hospital, Nedlands, Western Australia 
from October 2010 to July 2011 were recruited. Participants were required to answer 
two questions prior to the endoscopy procedure and their medical records were 
reviewed to get further information regarding their past medical and medication 
history. Antral and duodenal biopsies were collected during the endoscopies and 
their level of P-glycoprotein expression was quantified using Western Blot analysis. 
The H. pylori infection status was determined through various methods including 
bacterial culture and polymerase chain reaction. Participants` venous blood were 
also analyzed to determine their MDR1 C3435T polymorphisms. In addition, a 
subgroup of participant (n =11) who had failed H. pylori eradication therapy also had 
antibiotic sensitivity testing and CYP2C19 polymorphisms undertaken. 
 
This study had a total of 33 participants who were classified as H. pylori –positive 
including 11 whom had been diagnosed with failure of H. pylori eradication therapy. 
The remaining 58 participants were H. pylori – negative. Dyspepsia was the most 
common indications for endoscopy in this study followed by anaemia and epigastric 
pain. In this study, gender and age were found to have no association with human 
gastrointestinal P-glycoprotein. P-glycoprotein expression was significantly higher 
in the duodenum than the antrum and interestingly, a significant difference was 
found in P-glycoprotein expression between H. pylori-positive and H. pylori-
negative subjects (p = 0.028).  
 
For MDR1 C3435T polymorphisms, the 3435TT genotype appeared to have a 
significantly lower P-glycoprotein expression than 3435CC genotype in the antrum 
(p=0.041). The homozygous 3435TT subjects who were H. pylori –positive also 
demonstrated a significant difference in their P-glycoprotein expression compared to 
those who were H.pylori – negative (p = 0.029). In the resistance group, the subjects 
also demonstrated higher relative antral P-glycoprotein expression levels compared 
to those in H.pylori – negative group (p = 0.036). Most subjects who had failed 
eradication therapy demonstrated resistance to clarithromycin (72%), metronidazole 
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(63.6%) or both (54.5%). About 90% of the resistance subjects were cured after 
being treated with a second-line regimen consisting of rifabutin, amoxicillin and 
rabeprazole. 
 
In the second phase of the study, Caco-2 and LS174T cell lines were used to assess 
bacterial attachment. Two strains of H. pylori causing gastric cancer, namely G27 
and J99 were used to see how well they attached to the gastrointestinal cell lines 
within certain incubation periods. Escherichia coli W and Staphylococcus aureus 
were used as positive controls in this study. A potent P-glycoprotein inhibitor, 
valspodar (PSC-833) was used to evaluate whether inhibition of P-glycoprotein 
would have any influence on bacterial attachment. Additionally, the level of P-
glycoprotein expression in the LS174T cell lines was induced with rifampicin for the 
bacterial attachment study. 
 
Generally, all bacteria used in the study showed an increasing pattern of attachment 
to the Caco-2 cells over a 4 hour study period. H. pylori G27 demonstrated 
significantly higher bacterial attachment to Caco-2 cells at 30, 90, 180 and 240 
minutes when PSC-833 was introduced compared to the control cells (p < 0.05).  H. 
pylori J99 was also observed to have higher bacterial attachment to Caco-2 cells, 
significantly at 90 and 180 minutes in the presence of the P-glycoprotein inhibitor 
compared to the control Caco-2 cells (p < 0.05). Increased bacterial attachment to 
Caco-2 cells over a 4 hour study period was also observed with E. coli and S. aureus.  
 
On the other hand, the bacterial attachment of both H. pylori G27 and J99 strains to 
LS174T cell lines were found to be unaffected by the levels of P-glycoprotein 
expression. In contrast, E. coli W demonstrated significantly more bacterial 
attachment to the LS174T cells that had been pre-incubated with PSC-833 at 90, 
120, 180 and 240 minutes than the control cell line (p < 0.001). S. aureus showed 
significantly less bacterial attachment to the LS174T cells that had been pre-
incubated with rifampicin than the control cell lines at 90, 120, 180 and 240 minutes 
(p < 0.001). S.aureus also demonstrated higher bacterial attachment to the LS174T 
cells that had been pre-incubated with PSC-833 than the control cell line at all time 




Phase 1 of this study provides evidence that increased P-glycoprotein expression in 
the upper gastrointestinal tract is associated with H. pylori infection. Further to that, 
the 3435TT homozygotes have the capacity to increase P-glycoprotein expression to 
a greater extent than 3435CC and 3435CT homozygotes when being exposed to H. 
pylori which may explain of why 3435TT subjects have lower risk of gastric cancer. 
It is postulated that this potential protective mechanism of P-glycoprotein in the 
human intestinal tract may be exploited through the use of P-glycoprotein inducers, 
such as rifabutin as part of the eradication regimen.  
 
The second phase of this study demonstrated that manipulating P-glycoprotein 
expression by the use of inducers and inhibitors may influence the bacterial 
attachment to gastrointestinal cell lines of H. pylori and other bacterial pathogens. 
Based on these findings, the role of P-glycoprotein expression in H. pylori infection 
may not be dismissed. H. pylori infection induces P-glycoprotein in the 
gastrointestinal tract and genetic polymorphism does influence its protein 
expression. With high P-glycoprotein expression, H. pylori attachment to the 
gastrointestinal cell lines may be limited, subsequently reducing the risk of the 







I would like to express my deepest gratitude to my supervisor, Professor Jeffery 
Hughes, who has provided me with guidance, encouragement and advice to 
complete my doctoral programme. At many stages in the course of this programme I 
benefited from his advice, particularly so when exploring new ideas. I would also 
like to thank my co-supervisor, Dr Andrew Crowe, whose helpful guidance enabled 
me to complete my laboratory work and provided constructive criticism in writing 
my thesis.  
 
Special thanks to Dr. Hooi Ee and his helpful staff from Department of 
Gastroenterology/Hepatology, Sir Charles Gairdner Hospital, Nedlands without 
which I would not be able to collect the needed samples for my project. I would like 
to thank Professor Barry Marshall and his staff, particularly Dr Chin Yen Tay and 
Ms Fanny Thirriot from Helicobacter pylori Research Laboratory, University of 
Western Australia, Nedlands for the training and permission to utilize their facilities 
during my research.   
 
I would like to acknowledge Dr. Richard Parsons who provided me with statistics 
consultation. I would also like to express my thanks to Dr. Simon Fox and Erin 
Bolitho who facilitated my laboratory work in the first phase of my study. Staff from 
School of Pharmacy, Curtin University also deserves my sincere thanks, their 
assistance has meant more to me that I could not express.  
 
I thank Ministry of Higher Education, Malaysia and National University of Malaysia 
for the generous sponsorship and support for my study. Finally, I would like to thank 
my husband, my parents and family for all the support and encouragement that they 








 P-glycoprotein expression in Helicobacter pylori-positive patients: The 
influence of MDR1 C3435T polymorphism. Omar M, Crowe A, Parsons 
R, Ee H, Tay CY, Hughes J. J Dig Dis 2012;13;414–420 
 
2. Manuscript (under review) 
 
 Potential exploitation of P-glycoprotein expression levels in treatment - 




 Oral presentation “P-glycoprotein expression in Helicobacter pylori-
positive patients”. 7
th
 conference on New Frontiers in Microbiology and 
Infection on Helicobacter pylori - from basic science to clinical issues. 
Villars sur Ollon, Switzerland (2- 6 October 2011) 
 
 Poster presentation “ Do Helicobacter pylori and MDR1 [C3435T] 
polymorphism influence P-glycoprotein expression in human ?”. 
 Keystone Symposia on Proteomics, Interactomes, Stockholm, Sweden 
(7-12 May 2012) 
 
 Poster presentation “P-glycoprotein expression level in treatment - 
resistant Helicobacter pylori patients”. Joint ASCEPT-APSA 2012 




 Poster presentation “P-glycoprotein expression in Helicobacter 
pylori-positive patients”. Mark Liveris Health Science Research 
xviii 
 
Student Seminar, Faculty of Health Sciences, Curtin University 
Western Australia (14 November 2011) 
 
 Poster presentation “P-glycoprotein expression in Helicobacter 
pylori-positive patients”. The Inaugural Curtin Health Innovation 
Research Institute [CHIRI] Conference, Curtin University Western 
Australia (24 November 2011) 
 
 Oral presentation “P-glycoprotein expression level in treatment - 
resistant Helicobacter pylori patients”. Mark Liveris Health Science 
Research Student Seminar, Faculty of Health Sciences, Curtin 





















Helicobacter pylori has been reported to be associated with a number of 
gastrointestinal diseases in humans and this bacterial infection may occur in up to 15 
to 20% of the population [1]. The combination of a proton pump inhibitor and 
antibiotics successfully treats up to 90% of H. pylori-positive cases. However, there 
have been numerous reports worldwide observing an increasing incidence of 
antibiotic resistance which is linked to failed H. pylori eradication [2]. Among the 
common reasons for therapy resistance are poor patient compliance [3], molecular 
bacteria resistance [4], low gastric pH [5] and a high bacterial load [6]. Other 
mechanisms have also been proposed for multidrug resistance associated with H. 
pylori eradication failure including reduced permeability of the cell membrane to 
certain drugs, active efflux of the drug from resistant cells and reduced binding of the 
drugs to their intracellular targets [7].  
 
P-glycoprotein (also known as multidrug resistance protein 1, MDR1 or ATP-binding 
cassette sub-family B member 1, ABCB1) is a large transmembrane glycoprotein 
(170kDa) that belongs to a large super family of highly conserved ATP-binding 
cassette (ABC) transporters [8]. In humans, P-glycoprotein is expressed on the 
luminal surface of the intestinal epithelial, the renal proximal tubule, bile canalicular 
membrane of the hepatocytes, the placenta and the blood brain barrier where it acts 
as a defence mechanism towards harmful xenobiotics [9]. Proton pump inhibitors 
such as omeprazole, pantoprazole and lansoprazole are P-glycoprotein substrate and 
their absorption from gastrointestinal tract might be affected by alterations of P-
glycoprotein expression.  The variability of P-glycoprotein gene polymorphism, such 
as MDR1 C3435T has been proposed in the literature as one of the reasons for 
different treatment outcomes in various diseases [10]. However, little literature exists 
pertaining to H. pylori infection and its eradication therapy and MDR1 C3435T 
polymorphisms. Assuming that P-glycoprotein expression will vary depending on its 
polymorphism and H. pylori as Class 1 carcinogen could lead to gastric cancer, there 
has been discussions as to whether a particular allele may have an effect on the risk 
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of gastric cancer [11-12]. There are also other genetic polymorphisms that have been 
linked to different outcomes in H. pylori eradication therapy, for example in 
CYP2C19 and CYP3A4. The inter-individual differences in those genes activity 
could produce changes in drug pharmacokinetics and pharmacodynamics, thus they 
may potentially affect the success of treatment given.  
 
Meanwhile, the attachment of H. pylori to the human gastric epithelium is a crucial 
step in its carcinogenicity [13]. H. pylori can penetrate the protective gastric mucosa 
lining, producing urease that damages the mucus layer which neutralises gastric acid 
[14]. The gastric tissue is thus prone to the damaging effects of acid and pepsin, 
leading to the ulcer formation in the stomach or duodenum. If then, increases in P-
glycoprotein expression levels in gastric mucosa tissue influences the extent of  H. 
pylori binding and manipulation of these levels could potentially prevent the 
development of H. pylori-associated gastrointestinal disease, such as gastric cancer. 
 
1.1 Research questions 
 
Does P-glycoprotein expression influences the outcome of H. pylori eradication 
therapy and is H. pylori attachment to the gastrointestinal mucosa influenced by P-
glycoprotein expression levels? 
 
1.2 Research hypotheses 
 
a) H. pylori induces P-glycoprotein expression in the human gastrointestinal tract, 
contributing to the eradication therapy failure. 
 
b) P-glycoprotein polymorphism influences the H. pylori eradication therapy 
outcomes.  
 
c) P-glycoprotein expression influences H. pylori attachment gastrointestinal 






1.3 Focus of dissertation 
 
There are plentiful studies on influence of drug efflux transport protein, P-
glycoprotein on the drug-drug interactions, yet little is known about the effect of P-
glycoprotein in H. pylori eradication therapy. The main goal of this dissertation was 
to study the effect of H. pylori on P-glycoprotein expression and to determine 
whether P-glycoprotein expression plays a role in H. pylori eradication therapy 
outcomes.  
 
1.4 Research objectives 
 
a) To evaluate the level of P-glycoprotein expressions in human antral and duodenal 
tissues in relation to the H. pylori infection status.  
 
b) To examine the relationship between P-glycoprotein expressions and its genetic 
variant, particularly MDR1 C3435T.  
 
c) To assess the level of P-glycoprotein expression and the potential influence of 
CYP2C19 polymorphism in subjects who experienced resistance towards H. 
pylori eradication therapy. 
 
d) To investigate the extent of H. pylori attachment to the human gastrointestinal 
cell lines, namely LS174T and Caco-2, in the presence of a P-glycoprotein potent 
inducer or inhibitor.  
 
1.5 Research significances 
 
This study demonstrated the changes in P-glycoprotein expression levels in human 
gastrointestinal tract in the presence of H. pylori. This study also highlighted the 
association between P-glycoprotein expression and the prevalence of MDR1 C3435T 
and is the first to illustrate the prevalence of MDR1 C3435T polymorphisms in the 
Australian population. In this study, subjects who experienced resistance towards H. 
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pylori eradication therapy showed elevated P-glycoprotein levels in the presence of 
H. pylori irrespective of their MDR1 C3435T polymorphism. Finally, this study also 
demonstrated the extent of H. pylori attachment to the human gastrointestinal cell 

























The adenosine triphosphate (ATP)-binding cassette (ABC) transporter super family 
is the biggest transporter gene family that is essential to transport specific substances 
including amino acids, sugars, inorganic ions, polysaccharides and peptides across 
the extra and intracellular lipid membranes [15]. ABC transporters employ the 
energy released from ATP hydrolysis to pump substrate across the membrane against 
a concentration gradient [16]. Classic ABC transporters usually consist of two 
transmembrane domains (TMD) and two nucleotide-binding domains (NBD) 
encoded by a single polypeptide [17].  
 
ABC transporters are found in bacteria, yeast, protozoa, insects and animals [18]. In 
humans, there are 48 members of the ABC super family that are grouped into seven 
families based on their structure, namely ABCA, ABCB, ABCC, ABCD, ABCE, ABCF 
and ABCG [19] as shown in Table 2-1. The ABC transporters play significant roles 
in human, from bile acid homeostasis to the protection of tissue from cytotoxic 
substances [79]. Impairment of this mechanism has been associated with certain 
diseases. For instance, cystic fibrosis which occurs due to a mutation in the encoding 
gene on chromosome 7 that impairs cystic fibrosis transmembrane regulator protein 
(CFTR) synthesis, a member of the multidrug-resistance-associated-protein (MRP) 
subfamily [80].  
 
Only a few human ABC transporters are known to be involved in xenobiotic 
transport. For example, ABC1 which are located in the intestine, liver, kidney and 
blood brain barrier have their substrates such drugs as digoxin, cyclosporine and 




Table 2-1: List of ABC transporters, location, function and disease associated with the genes 
 
Subfamily Member Function Associated Disease Reference 
ABCA ABCA1 Cholesterol and phospholipids transport Tangier Disease [20-21] 
 Dementia [22] 
 Alzheimer’s Disease [23] 
 Atherosclerosis [24] 
 ABCA2 Drug resistance Small cell lung cancer [25] 
 Cholesterol and phospholipids transport Alzheimer`s Disease [26-28] 
 ABCA3 Drug resistance Childhood acute myeloid 
leukemia 
[29] 
 ABCA4 Transport prorogated N-retinylide- phosphotidylethanolamine Stargardt macular dystrophy [30-31] 
 Lipid transporter in myelination process Unknown [32] 
 ABCA7 Peripheral phospholipids metabolism Unknown [33] 
 ABCA12 
 
Transport glucosyl-ceramides Lamellar ichthyosis [34] 




ABCB ABCB1 Drug resistance Parkinsonism [36] 




Subfamily Member Function Associated Disease Reference 
 ABCB3 Peptide transport Immune deficiency [38] 




 ABCB5 Drug resistance Unknown [41] 
 ABCB6 Iron transport Unknown [42] 
 ABCB7 Hematopoiesis X-linked sideroblastic anemia 
with ataxia 
[43] 
 ABCB8 Drug resistance Unknown [44] 
 ABCB9 Drug resistance Unknown [45] 
 ABCB10 Drug resistance Unknown [46] 
 ABCB11 Bile-acid transport Hypercholesterolemia [47] 
ABCC ABCC1 Drug resistance Unknown [48] 
 ABCC2 Drug resistance Unknown [49] 
 Bile-acid transport Dubin-Johnson Syndrome [50] 
 Non-alcoholic fatty liver [51] 
 ABCC3 Bile-acid transport Hepatotoxicity [52] 
 ABCC4 Platelet adenine nucleotide storage Unknown [53] 
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Subfamily Member Function Associated Disease Reference 
 ABCC5 Fetus protection Abnormal placenta development [54] 
 ABCC6 Unknown Pseudoxanthome elasticum [55] 
 ABCC7 Chloride ion channel Cystic fibrosis [56-57] 
 
 ABCC8 Insulin receptor Persistent infancy 
hypoglycemia 
[58] 
 ABCC9 Chloride ion channel Heart disease [59] 
 ABCC10 Drug resistance Unknown [60] 
 ABCC11 Drug resistance Abnormal axillary odor [61] 
 ABCC12 Drug resistance Unknown [62] 
ABCD ABCD1 Fatty acid transport X-linked adrenoleukodystrophy [63] 
 ABCD2 Fatty acid transport Unknown [64] 
 ABCD3 Fatty acid transport Unknown [65] 
 ABCD4 Fatty acid transport X-linked adrenoleukodystrophy [66] 
ABCE ABCE1 Eukaryotic post-termination ribosomal recycling Unknown [67] 
ABCF ABCF1 Cellular immunity Unknown [68] 
 ABCF2 Drug resistance Breast cancer [69] 
 ABCF3 Tumorigenesis Melanoma [70] 
ABCG ABCG1 Apoptosis in macrophage Unknown [71] 
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Subfamily Member Function Associated Disease Reference 
  Cholesterol transport Unknown [72] 
 ABCG2 Drug resistance Unknown [73] 
 ABCG4 Cholesterol transport Changes in metabolic pathway [74] 
 ABCG5 Sterol transport  Sitosterolemia [75-76] 
 ABCG8 Sterol transport Sitosterolemia [77-78] 
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Table 2-2: List of ABC transporters, primary tissues distribution and substrates 
 
Gene Protein Primary tissue distribution Substrate 
ABCB1 MDR1, 
P-glycoprotein 
Kidney, liver, intestine, brain, 
lymphocytes 
Digoxin, cyclosporine, paclitaxel, vinca alkaloids,  
loperamide, erythromycin 
ABCB11 BSEP Liver Vinblastine, tamoxifen citrate 
ABCC1 MRP1 Ubiquitous Vinca alkaloids, methotrexate, etoposides 
ABCC2 MRP2 Liver Vinca alkaloids, methotrexate, pravastin, irinotecan, cisplatin 
ABCC3 MRP3 Liver, kidney, small intestine Doxorubicin, vincristine, methotrexate, cisplatin 
ABCC4 MRP4 Prostate, liver, brain, kidney Nucleoside analogues (9-(2-phosphonylmethoxyethyl) adenine), 
nucleobase analogues (6-mercaptopurine, methotrexate) 
ABCC5 MRP5 Brain, heart, placenta Nucleoside analogues (cladribine, gemcitabine),  
nucleobase analogs (5-fluorouracil, 6-mercaptopurine) 
ABCC6 MRP6, 
MOAT-E 













The most widely studied human ABC transporter is ABCB1, which encodes P-
glycoprotein. P-glycoprotein is a 170-180 kDa adenosine triphosphate (ATP)-dependent 
efflux protein that was first identified by Juliano and Ling in 1976 in Chinese hamster 
ovary cells which exhibited colchicine resistance [84]. P-glycoprotein belongs to a large 
super-family of ATP- binding cassette (ABC) transporter proteins that is composed of 
two homologous halves; each consists of a nucleotide binding domain and a 
transmembrane domain separated by a flexible linker region (Figure 2-1) which is 
important for the proper interaction of the two halves or ATP sites [85, 86]. P-
glycoprotein has a large hydrophobic area in the transmembrane domain and drug 
binding domain located within the membrane.  
 
Although the mechanism of P-glycoprotein transport is not well understood, it is 
believed that mediated action is energy dependent [87]. It has been hypothesized that the 
transport pathway of P-glycoprotein is initiated by the binding of drug and ATP. The 
drug binds to the protein membrane on the inward facing high-affinity site (cytoplasmic) 
and is pushed out through a conformational change that transforms the protein 
membrane to a low-affinity outward facing site (extracellular). P-glycoprotein is 
believed to have more than one binding sites not including that two ATP-binding 
domains. During the catalytic cycle, ATP binding is stimulated by P-glycoprotein 
substrates causing dimerization in the nucleotide binding domain leading to large 
structural changes [88]. This results in an outward facing conformation that allows drug 
movement to the extra-cellular space. Thus, inhibition of P-glycoprotein transport of a 
drug can be triggered by either competition for drug binding and ATP-hydrolysis 






Figure 2-1: Schematic structural organization of P-glycoprotein. Each half contains 
a highly hydrophobic domain with six transmembrane-α – helices and a 
hydrophilic domain located at the cytoplasmic face of the membrane, nucleotide 
binding domain 1 (NBD1) and 2 (NBD2), containing an ATP-binding site. (adapted 





Paine et al [89] reported there were no difference between healthy men and women 
found for P-glycoprotein expression. However, changes in P-glycoprotein expression 
according to the age group have been seen. According to Pilarski et al [90], the efflux of 
R123 in B-cells increased in early childhood and reached maximum levels in adulthood 
before decreasing with age. This finding was supported by Machando et al [91] who 
measured the R123 efflux from CD4
+
 and CD8+ T cells in subjects aged between 0 to 
80 years. The P-glycoprotein function in both cells were highest in cord blood, then 
markedly decreased with age and reached the lowest levels in the 70 - 80 years age 
group.  
 
In another study, the elderly group (i.e. those aged between 70 to 90 years old) tended to 
show a higher expression of ABCB1 gene from CD4
+
 and CD8+ T cells and lower 
intracellular concentration of R123 compared to the young group age between 22 to 26 
years old [92]. A progressive increase in P-glycoprotein activity as a function of age was 
also observed in the 35 to 50 years age group based on R123 efflux from normal human 
bone marrow CD34+/CD45+ stem cells [93]. The activity of P-glycoprotein in the 50-
82 years age group was lower, however not significantly lower than the other age 
groups. In another study using a group of kidney transplant recipients, Lown et al [94] 
found that P-glycoprotein expressions in the intestinal cells were not significantly 
correlated with age. The differences between the various studies` findings might be 
contributed by the differences in methodologies, types of cell studied, sample size and 
age group distribution.  
 
2.1.2 Location of P-glycoprotein 
 
P-glycoprotein is present in various locations in the human body including 
gastrointestinal tract epithelium, renal proximal tubule, bile canalicular membrane of the 
hepatocytes, adrenal gland, testes, placenta and blood-brain barrier [95]. Figure 2-2 
illustrates the organ distribution of P-glycoprotein found in human tissues. In the liver, 
P-glycoprotein has been detected in a highly polarized fashion on the biliary canalicular 
surface of hepatocytes and on the apical surface of small biliary ducts [96]. High 
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polarized P-glycoprotein has also been found on the apical surface of columnar 
epithelial cells of the colon and jejunum. Similarly, the apical surface of small pancreatic 
ducts also expressed high polarized P-glycoprotein levels. As opposed to other tissues, 
P-glycoprotein in the adrenal gland was not present in a polarized distribution but being 
detected in both the adrenal cortex and medulla.  
 
It has been reported that P-glycoprotein expression is not uniform along the 
gastrointestinal tract. The MDR1 mRNA expression has been found to progressively 
increase from stomach to the colon when measured in normal tissues which supports P-
glycoprotein`s role as access barrier in the gastrointestinal tract [97].  Mouly and Paine 
[98] reported that “among individuals, the relative P-glycoprotein levels varied 2.1 fold 
in the duodenal /proximal jejunal region, 1.5- to 2.0- fold in the middle/distal jejuna 
region and 1.2-fold to 1.9-fold in the ileal region” which indicated that the differences 
between P-glycoprotein expression in the intestine may influence bioavailability of 
drugs in human. Similarly, mRNA expression has also been found to increase from 
stomach and duodenum with the highest level was recorded in left descending colon 
[99]. The increased of P-glycoprotein seen in that study occurred without influence of 
gender, age or medication taken by the subjects. On the other hand, Ueda et al [100] 
demonstrated that over expression of P-glycoprotein is associated with an increase in 
transcripts of a gene called MDR1 (Multi Drug Resistance) which has been shown to be 
the gene product of MDR1. Another member of the P-glycoprotein gene family that 
exists in humans  is MDR3; the other three members of the family are present in mice 
(mdr1a, mdr1b and mdr2). Mice have two genes encoding P-glycoprotein namely the 
mdr1a gene which is predominantly expressed in the intestine, liver and brain as well as 
testis, and the mdr1b gene that is be abundantly found in the adrenals, placenta and 
ovaries [101]. In mice, mdr1a is expressed at relatively high levels in the intestines, 
intermediate levels in the brain and testes and at lower levels in the kidney but not in the 
adrenal gland, pregnant uterus or placenta [102]. In contrast, mouse mdr1b is expressed 
at high level in the adrenals, pregnant uterus, placenta and kidney and at a relatively 











2.1.3 Role of P-glycoprotein 
 
Both human MDR1 and mouse mdr1a/1b genes act as drug transporter by pushing 
out substrates of the cells [101]. P-glycoprotein is also involved in active transport of 
drugs back to the lumen after passive absorption into the enterocytes. Because of its 
localization, P-glycoprotein appears to have a greater impact on limiting 
cellular uptake of drugs from the blood circulation into the brain and from the 
intestinal lumen into epithelial cells than on enhancing the excretion of drugs out of 
hepatocytes or the renal tubules into the adjacent luminal space [102].  
 
Due to the abundant expression of P-glycoprotein in gastrointestinal tract, it is 
believed that the protein acts as a body defence mechanism against toxic xenobiotics 
and drugs in humans by excreting those compounds into the intestine lumen [103-
104]. P-glycoprotein also acts to excrete those compounds into the bile and urine, as 
well as preventing their accumulation in brain and testes. Further, over expression of 
P-glycoprotein has often been associated with drug resistant in cancer patients where 
it acts as xenobiotic pump which makes certain cancer cell resistant to selected 
chemotherapeutic agents. 
 
P-glycoprotein expression has also been associated with altered secretion of 
cytokines and progressive T cell-mediated immune deficiency when tested in T-
lympocytes in mice, human T –lympocytes and liver, intestine, kidney, lymphocytes 
and epithelium in mice [105-107]. There are various P-glycoprotein substrates 
ranging from small organic cations, carbohydrates, amino acids and antibiotics to 
macromolecules such as polysaccharides and proteins [108]. There is also a broad 
range of overlapping substrate specificities and tissue distribution for CYP3A and P-
glycoprotein where both proteins act synergistically as a protective barrier to the 
orally administered drugs [109].  
 
P-glycoprotein plays a major role as a drug efflux transporter and influences the 
regulation of drug absorption, distribution and elimination [110]. In addition to anti-
neoplastic agents, P-glycoprotein also transports saquinavir, colchicines, 
dexamethasone, cortisol, rhodamine 123, digoxin, cimetidine, morphine and 
cimetidine [111]. A list of common P-glycoprotein substrates as well as inducers and 
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inhibitors is shown in Appendix I [112-116]. The P-glycoprotein inhibition will 
result in an increase of substrate plasma levels and tissue distribution. On the other 
hand, induction of P-glycoprotein will cause lower drug plasma levels, which may 
lead to therapy failure. Both inhibition and induction of P-glycoprotein may lead to 
drug interactions in human, particularly for drugs with a narrow therapeutic index 
[112].  
 
It is difficult to assess the mechanism of P-glycoprotein inhibition when its substrates 
and inhibitors are given simultaneously. For instance, a daily dose of 160 mg 
verapamil caused a 40% increased in digoxin plasma concentration while 240 mg 
verapamil caused a 60 to 80% increase; suggesting a dose-dependent P-glycoprotein 
inhibition [117]. The interaction resulting in increased digoxin absorption and 
decreased elimination which in turn leads to accumulation of digoxin in cardiac 
tissue. Interestingly, Fenner et al [118] found only four co-medications namely 
valspodar, quinidine, amiodarone and cyclosporin A significantly increased levels of 
digoxin. The dissimilarities of the findings could be explained by the different 
mechanisms that are responsible for P-glycoprotein inhibition. For example, 
verapamil inhibits the transport function in a competitive manner without 
interrupting the cyclic activity of ATP hydrolysis of P-glycoprotein while 
cyclosporin A, on other hand, inhibits transport function by interfering with both 
substrate recognition and ATP hydrolysis [119-120]. 
 
Additionally, some herbal ingredients commonly used in complementary and 
alternative medicines and dietary phytochemicals have been reported to vary P-
glycoprotein expression and/or activity [112]. Constituents such as piperine, 
ginsenosides, silymarin found in milk thistle has been reported to inhibit P-
glycoprotein activity in vitro, whereas curcumin, curcuminoids and several catechins 
from green tea are reported to reduce P-glycoprotein expression and activity in vitro. 
Similarly, constituents of grapefruit and orange juice were also found to inhibit P-
glycoprotein expression and/or activity. 
 
Although it is difficult to prove directly the effect of P-glycoprotein in humans, a 
clinical study has shown that quinidine, a brain and intestinal P-glycoprotein 
inhibitor significantly increased oral morphine maximum plasma concentrations up 
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to two-fold but had no influence its elimination rate [121]. In cancer patients, the oral 
bioavailability of paclitaxel has been found to be increased by 50% when cyclosporin 
A was co-administered [122]. Similarly, another study reported that the 
bioavailability of docetaxel increased up to 88% when given in combination with 
cyclosporin A [123]. These results suggested that there is involvement of P-
glycoprotein as barrier to the absorption of anti-cancer drugs.  
 
P-glycoprotein expression can be up-regulate by certain drugs, hence reducing the 
intracellular concentration of co-administered P-glycoprotein substrate as well as 
limiting their pharmacological efficacy. For example, using a Caco-2 cell line, Silva 
et al [124] demonstrated that P-glycoprotein expression and activity was significantly 
increased after doxorubicin exposure which subsequently reduced paraquat 
cytotoxicity. Antiretroviral agents such as non-nucleoside HIV-1 reverse 
transcriptase inhibitors (NNRTIs) have been shown to increase P-glycoprotein 
expression [125-126]. Further, the chronic morphine administration has been found 
to induce P-glycoprotein expression in the brain and proposed as one of the 
mechanisms of morphine tolerance as more morphine is required as more is effluxed 
out from the brain [127].  
 
Apart from drugs, certain diseases have been reported to increase P-glycoprotein 
expression. Tsujimura et al [128] observed that P-glycoprotein was over-expressed 
on rheumatoid arthritis lymphocytes compared with normal lymphocytes. P-
glycoprotein over-expression on lymphocytes therefore may cause efflux of 
corticosteroids and disease-modifying antirheumatic drugs from lymphocytes, 
resulting in drug resistance in patients with highly active rheumatoid arthritis. 
Likewise, P-glycoprotein expressions in the peripheral lymphocytes of the 
systemic lupus erythematosus patients were observed to be significantly higher 
compared with that of the healthy controls [129]. In that study, there was a positive 
correlation observed between disease activity and P-glycoprotein expression levels 
among systemic lupus erythematosus patients suggesting that the high expression 
levels of P-glycoprotein in the peripheral lymphocytes in this group of patients may 





2.1.3.1    Role of P-glycoprotein in drug pharmacokinetics 
 
2.1.3.1.1  Role of P-glycoprotein in drug absorption and 
distribution 
 
Most orally administered drugs will be absorbed in the small intestine where the 
presence of CYP3A4 and P-glycoprotein may reduce the intracellular concentration 
of drug substrates by metabolism and transmembrane efflux, respectively [130]. 
Figure 2-3 illustrates the intestinal disposition of substrate by P-glycoprotein. 
 
The colon carcinoma cell line, Caco-2 is often used as an in vitro model for 
absorption studies since it expresses abundant P-glycoprotein but less oxidizing 
cytochrome P450, particularly the isoform CYP3A4 [131]. When this model is used, 
the study drugs are added to one side of the monolayer and the rate of transport or 
diffusion to or from either media compartment is measured. Functional P-
glycoprotein is expressed along the apical surface of Caco-2 cell monolayers and has 
been shown to mediate efflux from the basolateral to apical media compartment. 
Hunter et al [133] first demonstrated by using the Caco-2 cell line that the transport 
of vinblastine and docetaxel were higher when measured from basolateral-to-apical 
compared to apical-to-basolateral. This indicated that drug-efflux at the apical 
surface renders the epithelium relatively impermeable to the substrate. However, 
apical-to-basolateral transport was enhanced significantly in presence of verapamil 
that blocked P-glycoprotein efflux function, suggesting P-glycoprotein plays 
significant role in drug absorption. Drug absorption after oral administration was 
found to increase by P-glycoprotein inhibition and be further enhanced when 
CYP3A4 was suppressed [134]. The efflux function of intestinal P-glycoprotein was 
further demonstrated by Hochman et al [135] who showed that indinavir metabolites 
were selectively secreted into the apical compartment in the absence of cyclosporin 
A in the Caco-2 cell lines. The metabolites then were released into both basolateral 






Figure 2-3: Intestinal disposition of substrates by P-glycoprotein. (A) P-glycoprotein substrates are absorbed from the 
intestinal lumen into enterocytes. (B) Absorption of substrates from enterocytes into the circulation. (C) Substrates are 
metabolized in the enterocytes. (D) Substrates are secreted back into the intestinal lumen facilitated by P-glycoprotein. (E) 




Fricker et al [136] reported that cyclosporin A permeation basolateral to apical was 
greater than apical to basolateral. Further, the authors found the P-glycoprotein-
mediated transport in vitro was inhibited in the presence of vinblastine and 
daunomycin.  When they administered cyclosporin A enterally to a group of healthy 
volunteers, they found that the absorption of cyclosporin A was dependent on the 
location of drug absorption, greatest from stomach, then the jejunum/ileum and 
finally the colon. This decrease in absorption exhibited a marked correlation (r = 
0.994) to the expression of mRNA for P-glycoprotein over the gastrointestinal tract 
(stomach < jejunum < colon). This finding did support the fact that difference in 
intestinal P-glycoprotein expression influence the rate of drug`s bioavailability. 
Similarly, the absorption of talinolol, a P-glycoprotein substrate was found to be 
lower at the distal site of the small intestine compared to the proximal site [137]. The 
drug bioavailability after distal administration was only half of that proximal 
intestinal site. This site-dependent characterization absorption provides strong 
support that difference levels of P-glycoprotein expression may contribute to the 
variability of drug absorption.  
 
Meanwhile, Greiner et al [138] demonstrated that concomitant rifampin therapy 
affects digoxin disposition in humans by induction of P-glycoprotein in a group of 
eight healthy volunteers who received a single-dose of 1 mg orally and intravenously 
of digoxin before and after co-administration of rifampin (600 mg/day for 10 days). 
The plasma concentration of oral digoxin was significantly lower during rifampin 
treatment which was accompanied by an increased in intestinal P-glycoprotein of 3.5 
± 2.1–fold. However, that effect was less observed when subjects received digoxin 
intravenously. This lead to the idea that P-glycoprotein may act as a drug efflux 
protein transporter that forced out foreign compounds from enterocytes into the 
intestinal lumen when they begin to be absorbed across the epithelial cells. This 
process will be repeated along the intestinal tract and since those discarded 
xenobiotics can be reabsorbed into the enterocytes before another cycle of extrusion 






Ito et al [134] found that drug absorption after oral administration was increase by P-
glycoprotein inhibition and further enhanced when CYP3A4 was suppressed. This 
demonstrated the importance of both drug efflux and metabolism in drug oral 
bioavailability. P-glycoprotein as mentioned above prolongs drug absorption time 
due to repeated cycles of absorption and efflux, and in doing so it increases the 
parent drug’s exposure to CYP3A4. P-glycoprotein may also remove CYP3A4 
metabolites from inside cells further enhancing the extent of CYP3A4 metabolism 
[134,140].   
 
2.1.3.1.2 Role of P-glycoprotein in drug metabolism and excretion 
 
P-glycoprotein in the liver has been suggested to be critical to the metabolism and 
elimination of certain drugs which are P-glycoprotein substrates, such as tacrolimus. 
As demonstrated by Chiou et al [141], the mean hepatic intrinsic clearance of 
tacrolimus was reduced by 10-fold in P-glycoprotein knockout mice compared to the 
normal mice, suggesting that P-glycoprotein influences the access of substrates to the 
site of elimination.  
 
Interestingly, Sparreboom et al [143] found that P-glycoprotein could limit the oral 
uptake of paclitaxel and mediates direct excretion of the drug from the systemic 




) mice intestinal lumen. The drug plasma concentration 
was higher in that group compared to wild-type mice after drug administration, both 
oral and intravenous. The oral bioavailability of paclitaxel was increased from 11% 





) mice was significantly lower compared to wild-type mice although no 









2.1.3.2    Role of P-glycoprotein in drug pharmacodynamics 
 
There is growing evidence indicating that P-glycoprotein also contributes to the 
biochemical or physiological effects of drugs in the human body. P-glycoprotein 
does influence the distribution of drugs and metabolites to the site of action but not in 
the relationship between substrate concentration and effect. For example, Sadeque et 
al [144] found that loperamide produced no respiratory depression when 
administered alone, but respiratory depression occurred when the drug was co-
administered with quinidine, a known inhibitor of P-glycoprotein. Loperamide is a 
substrate for P-glycoprotein and is not associated with central opiate effects such as 
respiratory depression at usual or even high clinical doses, reflecting the fact that 
loperamide can not gain access to the brain in the present of P-glycoprotein.  
 
Furthermore, using Visual Analogue Scales (VAS), subjective self-assessment of 
feelings or mood states was measured by Kharasch et al [145] in 12 subjects who 
received methadone after a dose of quinidine. Although the quinidine increased the 
plasma concentrations of oral methadone, the study found that quinidine had no 
effect on methadone pharmacodynamics, suggesting that P-glycoprotein did not 
appear to be a determinant of the access of methadone to the brain.  
 
In a study involving 10 healthy volunteers, pre-treatment with rifampicin (600mg 
daily for 5 days) was found to significantly reduce both the total absorption and peak 
concentration of glyburide and to shorten its elimination half-life [146]. These 
changes in the pharmacokinetics of the glyburide were accompanied by a reduction 
in its blood glucose lowering effects. In the case of glipizide, the rifampicin pre-
treatment was found to reduce the its overall absorption, although to a less extent 
than glyburide (AUC reduction 22% vs. 39% for glyburide) and its elimination half-
life by over an hour (3.0 hours to 1.9 hours). These changes were however not 
accompanied by significant changes in blood glucose concentrations.  In the case of 
glyburide, the interaction is probably due to induction of either CYP2C9 or P-
glycoprotein or both. The increased systemic elimination of glipizide is likely to be 




2.1.4 P-glycoprotein (ABCB1) polymorphisms  
 
ABCB1 was among the first genes to be fully sequenced in the coding and regulatory 
regions [147-148]. Majority of the single nucleotide polymorphisms (SNPs) involved 
in non-coding regions and do not affect the P-glycoprotein amino acid sequence. The 
SNPs can be linked to altered oral bioavailability, drug resistance and susceptibility 
to human disease. As for C3435T SNPs, the Japanese demonstrated similar C-allele 
frequency to the other Asian populations while higher frequency of the C-allele was 
found in the African population [149]. 
 
2.1.4.1 P-glycoprotein polymorphisms and diseases 
predisposition 
 
Polymorphism in P-glycoprotein has been associated with predisposition to certain 
clinical conditions although there were contradicting results reported, for example in 
inflammatory bowel disease. Inflammatory bowel disease constitutes of chronic 
diseases of the gastrointestinal tract in which ulcerative colitis and Crohn’s disease 
are the two main diseases [150]. Genome-wide association studies have been 
performed to identify genetic
 
factors that may contribute to these disorders.  
 
Schwab et al [151] reported a strong association between MDR1 C3435T 
polymorphisms and ulcerative colitis in a group of German subjects although no 
effect for that particular gene polymorphism was observed in Crohn`s disease. 
Similarly, Ho et al [152] reported that in Scottish subjects, the 3435TT genotype was 
found more commonly in subjects with ulcerative colitis, however there was no 
association seen with G2677T and inflammatory bowel disease. In another study, 
Iranian subjects with ulcerative colitis also showed higher frequency of the 3435T 
allele [153]. On the other hand, an association between MDR1 C3435T with Crohn`s 
disease was observed in a group of Spanish subjects, suggesting that the MDR1 gene 
may be a risk factor for inflammatory bowel disease [154].  
 
In contrast, there was no association reported for neither MDR1 C3435T nor 
G2677T/A with overall disease susceptibility although C3435T polymorphism was 
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found significantly increased in subjects with ileoclonic Crohn`s disease [155]. 
Another genotyping study conducted amongst Hungarian subjects also showed that 
the MDR1 C3435T and G2677T/A alleles were not associated with the inflammatory 
bowel disease [156]. Dudarewick et al [157] reported that although the 3435CC 
genotype was present more frequently among Polish patients with inflammatory 
bowel disease than matched controls, there was no indication that C3435T gene is a 
risk factor for inflammatory bowel diseases such as ulcerative colitis and Crohn’s 
disease. Similarly, although the 3435CT allele was the most frequently found in 
Greek subjects with ulcerative colitis, there was no association found with the 
C3435T polymorphism and ulcerative colitis [158].   
 
Other examples of P-glycoprotein (ABCB1) gene polymorphisms and diseases 
disposition are shown in Table 2-3. Of all ABCB1 genes, 3435C/T, G2677T/A and 
C1236T have been the most studied single-nucleotide polymorphisms. Overall, it 
does appear that ABCB1 gene polymorphisms may predispose people to certain 
diseases such as mental and behavioral disorders. Variability in findings between 
disease predisposition and gene polymorphisms, especially in carcinoma 
however suggest that the genetic polymorphism may be influenced by other factors 










Study Population Disease Finding Reference 
G2677 A/T 
 
French subjects (207 cases and 482 
controls) 






288 Swedish patients and 313 control 
subjects 
Parkinson`s disease 1336 C >T associated with Parkinson`s 
disease 
[160] 
3435 C/T 599 European patients and controls Parkinson`s disease Significant association with disease risk due 
to pesticide exposure 
[161] 
G2677 A/T 182 Spanish white men, 86 cancer-free 
controls and 96 lung cancer patients 
Lung cancer 3435 TT allele has significant association 
with lung cancer risk 
[162] 
3435C/T Turkish subjects (79 non-small cell lung 
cancer patients) 
Non-small cell lung 
cancer 






Caucasian subjects (177 small cell lung 
cancer patients) 
Small cell lung 
cancer 
G2677T>A, 3435CT, 3435TT and 2677T/A-
3435T haplotype had a longer progression-





102 osteosarcoma patients Osteosarcoma Significant association between ABCB1 






Study Population Disease Finding Reference 
3435 C/T Epidemiological studies (3,829 cases and 
6,193 controls) 
Breast cancer 3435 TT allele has significant association 
with high risk of breast cancer 
[166] 
3435C/T 39 samples of breast cancer tissues Breast cancer No association between disease and gene 
polymorphism 
[167] 






Chinese subjects (1173 breast carcinoma 
patients and 1244 controls) 
Breast carcinoma C3435T, G2677T/A variations and haplotype 
3435T-1236T-2677T related to the risk and 





309 patients from the Australian Ovarian 
Cancer Study 





Brazilian population (109 patients) Acute myeloid  
leukemia 
CC allele associated with better prognostic [171] 
rs3789243 Norwegian population (167 carcinomas, 
990 adenomas, 400 controls) 
Colorectal adenoma 
and colorectal cancer 





3,662 German subjects (1809 colorectal 
cancer cases and 1853 controls) 
Colorectal cancer rs1202168T and rs868755T carriers had an 







Study Population Disease Finding Reference 
2677G/T Iranian subjects (60 cancer patients and 60 
controls) 
Colorectal cancer 2677GG  associated with high P-
glycoprotein expression in cancerous region 
[174] 
3435C/T Iranian population (118 patients and 137 
controls) 
Colorectal cancer C allele associated in decreased susceptibility 
to colorectal cancer 
[175] 










Japanese subjects (150 H. pylori- positive 
gastritis, 292 gastric cancer, 215 gastric 
ulcer and 163 duodenal ulcer patients) 
 
Gastric cancer and 
peptic ulcer disease 
 




3435 C/T 102 patients with surgically resected 
gastric cancers 
Gastric cancer 3435TT and 3435CT were significantly 
associated with a shorter progression-free 
survival and overall survival 
[178] 
3435C/T 48 gastric cancer patients Gastric cancer 3435TT  allele associated with high 
incidence of gastric cancer 
[179] 
3435 C/T Chinese subjects (284 controls and 244  
patients with end stage renal disease) 
End stage renal 
disease  
3435TT allele has significant association 
with progression of end stage renal disease 
 
[180] 









116 Swedish subjects Psychosis 3435TT allele has significant association 




Iranian subjects (200 healthy controls and 
332 epileptic patients) 






Chinese children's population (91 patients 
and 368 controls) 
Epilepsy 3435TT associated with increased risk of 






Japanese subjects (631 major depressive 
disorders patients and 1100 controls) 
Major depressive 
disorders 
3435TT allele was significantly more 
common in patients than in the controls 
[184] 
3435C/T Caucasian subjects  
(40  cases, 40 controls) 
Cannabis dependence 3435 CC allele is independently associated 
with cannabis dependence 
[185] 
3435 C/T 97 patients with Behçet’s disease Behcet`s disease No association between disease and gene 
polymorphism 
[186] 
3435 C/T 104 patients with Behcet`s disease Behcet`s disease 3435 TT allele has significant association 




2.1.4.2 P-glycoprotein polymorphism affecting drug 
pharmacokinetics  
 
Digoxin is a well-known probe for the activity of P-glycoprotein in vivo and in vitro 
[188]. Several variants in the ABCB1 have been found to influence P-glycoprotein 
expression in subjects who taking cardiac glycosides. For example, the relationship 
between the ABCB1 gene with digoxin pharmacokinetic was first reported by 
Hoffmeyer et al [189] where a significant correlation was found between 
polymorphism in exon 26 (C3435T) with P-glycoprotein expression and function in 
duodenum. The homozygous TT subjects were associated with lower P-glycoprotein 
expression levels compared with homozygous CC and recorded the highest digoxin 
plasma levels. In a subsequent study, Johne et al [190] reported that homozygous TT 
showed faster and more complete absorption of digoxin as compared to CC genotype 
carriers. In addition, C3435T was found to significantly affect digoxin concentrations 
with homozygous TT subjects presenting with higher digoxin plasma concentrations 
than CC and CT subjects [191]. Similarly, Sakaeda et al [192] reported that the 
serum concentrations of digoxin was higher in the Japanese subjects whom carried 
T-allele at exon 26 of the MDR1 gene after single oral of drug administration as 
compared to CC and CT subjects. Kurata et al [193] also reported that after a single 
oral dose of 0.5 mg digoxin in healthy Japanese subjects, a 70% higher digoxin 
exposure was detected in TT subjects compared to CC subjects. However, Gerloff et 
al [194] using 1 mg of digoxin dose, demonstrated that saturation of the transport 
capacity of intestinal P-glycoprotein, and suggested this would lead to the lack of 
effect of MDR1 on digoxin absorption.  
 
Chowbay et al [195] reported that in Caucasian and Japanese subjects, there was no 
major influence of the C3435T on levels of digoxin although maximum 
concentration for digoxin were lower in 3435CC subjects compared with 3435TT 
genotypes and the oral availability of digoxin appeared to be lower in wild-type (CC) 
Caucasian populations compared with wild-type Japanese subjects. However, it is 
not only digoxin which demonstrates pharmacokinetic variations in association with 
ABCB1 polymorphisms, the pharmacogenetic studies of cyclosporine also showed 
conflicting results. The cyclosporine intracellular and blood concentration in the 
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3435T carriers were found to be increased up to 1.7-fold and 1.2-fold respectively in 
64 stable organ transplant recipients suggesting that ABCB1 polymorphisms could 
influence drug immunosuppressive activity [196]. The homozygous TT carriers also 
tend to develop more cyclosporine nephrotoxicity as compared to the CC genotype 
[197-198]. On the other hand, no association was demonstrated between ABCB1 
polymorphisms and cyclosporine absorption in Japanese kidney transplant recipients 
[199]. In addition, Haufroid et al [200] reported that no association was found 
between trough cyclosporine blood concentrations or dose requirement with 
ABCB1 genotype in stable renal transplants subjects. The variations discussed have 
implications for the therapeutic efficacy of many drugs especially for P-glycoprotein 
substrates that could explain inter-individual variability in dosing requirements and 
pharmacological response. Other examples of the influence of polymorphism in 
ABCB1 on number of drug pharmacokinetics are shown in Table 2.4. 
 
2.1.4.3 P-glycoprotein polymorphism affecting drug 
pharmacodynamics 
 
Most studies on MDR1 genotype focused more on pharmacokinetics; however there 
have been few studies conducted aimed at determining the influence of MDR1 
genotype on drug pharmacodynamics, particularly on P-glycoprotein substrates. 
Among different MDR1 variants, the C3435T genotype has been extensively studied 
to determine any association with pharmacodynamic effect of certain drugs (Table 
2.5). For instance, the inhibition of P-glycoprotein may allow loperamide to cross the 
blood-brain barrier and subsequently exerts the central opioid effects which could be 
contributed by a particular genotype [225]. The authors also demonstrated that TT 
genotype was associated with the significant increased of the miotic effects of 
loperamide when quinidine was co-administered. On the other hand, another study 
reported that there was no association found between MDR1 C3435T and the 
respiratory response in a group of healthy subjects who received 16 mg of 
loperamide alone, although minimal respiratory response was recorded [226]. 
Nevertheless, the different observations in those clinical responses could be 
attributed by pharmacokinetic changes which alter the dose-response relationship 
rather than involving the pharmacodynamic pathway. 
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Table 2-4: ABCB1 (C3435T) polymorphism associated with drug pharmacokinetics 
 
Polymorphism Study drug Population Parameter Outcome Reference 
3435 C> T Fluvoxamine 62 psychiatric patients Fluvoxamine Css CC had significantly higher 
concentration to dose ratio at the 
200 mg/dose 
[201] 




No significant association [202] 




TT carriers had association with 
lower cyclosporine dose 
[203] 
3435 C> T Sirolimus 105 healthy volunteers 





No significant association [204] 




12) and dnC(max) 
No significant association [205] 
3435 C> T Efavirenz 67 HIV-positive subjects Efavirenz Cp No significant association [206] 
3435 C> T Tacrolimus 103 Chinese renal 
transplant recipients 
Tacrolimus AUC ABCB1 had significant 




Polymorphism Study drug Population Parameter Outcome Reference 
3435 C> T Lopinavir 113 HIV-infected men Lopinavir Cp No significant association [209] 
3435 C> T Tacrolimus 104 full liver transplant 
patients 
Tacrolimus Cp No significant association [210] 







No significant association [211] 





No significant association [212] 
3435 C> T Prednisolone 95 renal transplant 
recipients 




3435 C> T Atazanavir 118 Caucasians HIV-
infection subjects 









Polymorphism Study drug Population Parameter Outcome Reference 





CC carriers had significantly low 
ratio 
[215] 
3435 C> T Tacrolimus 44 renal transplant 
recipients 
Tacrolimus Cp TT carrier had significant lower 
drug blood concentrations 
[216] 
3435 C> T      
3435 C> T Tacrolimus 106 renal transplant 
Chinese recipients 
Tacrolimus C0 TT carriers required lower dose 
compared to CC subjects 
[217] 
3435 C> T      
3435 C> T Carbamazepine 84 epilepsy subjects Carbamazepine Css TT carriers had a significantly 
lower drug plasma concentration 
[218] 
3435 C> T Efavirenz 121 healthy subjects Efavirenz CL Higher drug bioavailability in CC 
carriers 
[219] 
3435 C> T Phenytoin 96 healthy Turkish 
subjects 
Phenytoin Cp CC carriers had significant lower 
drug level 
[220] 
3435 C> T Paclitaxel 10 prostate cancer 
subjects 
Paclitaxel CL No significant association [221] 
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Polymorphism Study drug Population Parameter Outcome Reference 
3435 C> T Tipifarnib 28 Caucasians with 
advanced solid tumors 
subjects 
Tipifarnib AUC TT allele associated with high 
AUC 
[222] 
3435 C> T Amlodipine 26 healthy subjects Amlodipine Cp CC carriers had higher drug 
levels 
[223] 
3435 C> T Vincristine 52 childhood acute 
lymphoblastic leukemia 
Vincristine AUC No significant association [224] 
Abbreviations: 
 dose-normalized trough levels (dnC[0]) 
 dose-normalized area under the curve (dnAUC[0-12]) 
 dose-normalized maximum concentration (dnC[max])
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Table 2-5: ABCB1 (C3435T) polymorphism associated with drug pharmacodynamics 
 
Polymorphism Study drug Population Tested Parameter Outcome Reference 
3435 C> T Morphine 145 Italian subjects Pain relief response TT carriers had best response 
towards morphine 
[227] 
3435 C> T Nelfinavir and 
efavirenz 
67 subjects on long 
term HIV treatment 
Rise in CD4-cell 
count 
TT carriers had higher rise 
after 6 month of therapy 
[228] 
3435 C> T Nelfinavir and 
efavirenz 
504 subjects on HIV 
treatment 
Decrease in plasma 
HIV-1 RNA level 
TT genotype was associated 
with decreased likelihood of 
virologic failure 
[229] 
3435 C> T Vincristine 34 survivors of acute 
lymphoblastic leukemia 
Motor performance No association [230] 
3435 C> T Paclitaxel 10 prostate cancer and 6 
advanced transitional 
cell carcinoma subjects 
Level of neutrophils 
and platelets after 
drug administration 
No association [231] 
3435 C> T Etoposide and 
cisplatin 




CC carrier had better  
response to chemotherapy 
[232] 
3435 C> T Morphine 194 subjects underwent 
abdominal surgery 
Clinical analgesia and 
side effects 





Polymorphism Study drug Population Tested Parameter Outcome Reference 
3435 C> T Carbamazepine 210 Japanese epileptics Presence of seizure TT carriers had higher number 
of drug-resistance cases 
[234] 
3435 C> T Clopidogrel 60 subjects Platelet function No association [235] 




Increased HDL-cholesterol in 
CC carriers 
[236] 
3435 C> T Phenobarbital 60 subjects with 
idiopathic epilepsy 




3435 C> T Risperidone 59 subjects with 
schizophrenia 
Akathisa and dystonia 
occurrence 
No association [238] 




persistence pain post 
surgery 
TT carrier had higher 
incidence of chronic pain after 
surgery 
[239] 
3435 C> T First line 
antiepileptic 
329 epileptic subjects Drug response No association [240] 










2.2  Helicobacter pylori and P-glycoprotein expression 
 
2.2.1  Helicobacter pylori 
 
Helicobacter pylori is a Gram-negative microaerophilic non invasive spiral bacillus 
(Figure 2-4) that colonizes the gastric mucosa [242]. H. pylori has urease activity 
that catalyze the hydrolysis of urea to ammonia in order to survive in the surrounding 
gastric acid [243]. This bacteria was initially known as Campylobacter pylori before 
being included in a new genus, Helicobacter and renamed as Helicobacter pylori in 
1989 [244].
 
The principal reservoir for H. pylori infection appears to be the human 
stomach, especially the antrum [245].  H. pylori colonizes the gastric antrum of more 
that 95% of patients with duodenal ulcer disease. The overall seroprevalance of H. 
pylori infection was reported to be 15.1% in 2002 with seropositively rates 
increasing progressively with age. These range between 4% in the 1 to 4 years old to 
about 23.3% in 50 to 59 years old. H. pylori infection and use of non-steroidal anti-
inflammatory drugs are the predominant causes of peptic ulcer disease, accounting to 
48% and 24% of the cases respectively.  
 
Peptic ulcer disease is characterized by mucosal damage secondary to pepsin and 
gastric acid secretion which usually occurs in the stomach and proximal duodenum 
[246]. The necrotic mucosa defects that extend through the muscular mucosa into the 
submucosa will occur when the epithelial cells are damaged by acid and pepsin 
[247]. Worldwide ulcer prevalence differs according the region with duodenal ulcers 
dominating in Western populations and gastric ulcers being more frequent in Asian 
populations [248]. H. pylori infection is mainly acquired during childhood and is 
usually asymptomatic [249]. Around 15 to 20% of people infected will progress to 
develop peptic ulcer disease or gastric ulcer usually in later life.  Modes and risk 
factors of transmission vary between developing and developed countries [250]. As 
such, low socioeconomic status constitutes the main risk factor for asymptomatic 
infection amongst children in developing countries. Whereas the prevalence of H. 
pylori infection in developed countries varies considerably with ethnic background 
and within each population with age. Table 2-6 illustrates the prevalence of H. pylori 












Table 2-6: Prevalence of H. pylori infection in selected populations in Australia and New Zealand 
 
Country Number of 
subject 
Population Age range 
(years) 
Diagnostic test Percentage of 
positive test 
Reference 
Australia 1355 Australian adults 18–79 Serology
 
15.5% [251] 
520 Indigenous Australian 2-90 
13
C-Urea breath test 76% [252] 
273 Random population 20-80 Serology 38% [253] 





273 Caucasian (controls) 23% 










190 European 36% 
195 Maori 57% 




Previous studies have shown that H. pylori is present in more than 90% of patients 
with duodenal ulcer and in 60 to 90% of patients with gastric ulcer [257-259]. The 
infection is acquired by oral ingestion of the bacterium and is mainly transmitted 
within families who become the main source of transmission [260]. Once acquired, 
H. pylori evades the host immune system and causes chronic inflammation by 
reducing the thickness of the mucus gel layer as well as diminishing mucosal blood 
flow and interacting with the gastric epithelium throughout all stages of the infection 
[261]. Urease protects the H. pylori from the bactericidal effects of gastric acid and 
helps to enhance the bacterial adherence [262]. Further, gastric acid secretion is 
increased due to antigens produced, virulence factors and soluble mediators. Chronic 
gastritis induced by H. pylori increases the risk for gastric and duodenal ulcer, distal 
adenocarcinoma and gastric mucosal lymphoproliferative diseases such as non-
Hodgkin’s lymphoma.  
 
There is no single test that can be considered the gold standard for the diagnosis and 
the sensitivity of all endoscopic and non-endoscopic tests that identify active H. 
pylori infection can be reduced by the recent consumption of proton pump inhibitors, 
bismuth or antibiotics [263]. A ‘test and treat’ approach is recommended in adult 
patients under the age of 45 years presenting in primary care with persistent 
dyspepsia [264]. However, the prevalence of H. pylori infection in the elderly is 
higher than younger patients, accounted about 70% of people with H. pylori 
pathologies and over 50% in asymptomatic patients [265]. It has been reported that 
only 40 to 60% of elderly patients who were hospitalized for peptic ulcer disease 
were tested for H. pylori infection and that eradication therapy was given to only 50 
to 73% of infected patients [266].  
 
The most severe clinical outcome after H. pylori infection is gastric cancer which 
usually occurs in the elderly and for this reason, eradication of the anaerobe in high 
risk patients is requisite [267]. For elderly patients with dyspepsia, the ‘test and treat’ 
strategy may be misleading and potentially dangerous [268-269]. Upper 
gastrointestinal endoscopy is always indicated for elderly patients with new 
abdominal symptoms because of the high prevalence of advanced gastric diseases. It 
is recommended to obtain gastric biopsies at least from both the antrum and the body 
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of the stomach. A second test for H. pylori should be performed in high risk elderly 
patients if a urease-based or histological test is negative [268].  
 
Therapy with bismuth subsalicylate tablets, 525 mg four times a day; metronidazole, 
250 mg or 500 mg three times a day and either tetracycline or amoxicillin, 500 mg 
four times a day for two weeks has been found to eradicate H. pylori in up to 65% to 
90% of peptic ulcer disease`s patients [270]. Use of standard triple therapy 
containing of proton pump inhibitor, clarithromycin and amoxicillin or 
metronidazole is more successful if extended to more than 7 days [271]. The proton 
pump inhibitor-clarithromycin-amoxicillin or metronidazole is the first choice 
treatment in populations with less than 15 to 20% clarithromycin resistance. In 
populations with less than 40% metronidazole resistance, proton pump inhibitor-
clarithromycin-metronidazole is preferable. A sequential treatment consisting of 5 
days of a proton pump inhibitor plus amoxicillin followed by 5 additional days of a 
proton pump inhibitor plus clarithromycin plus tinidazole has been shown to be 
better than the combination of a proton pump inhibitor plus amoxicillin and 
clarithromycin for 7 days. H. pylori infection is successfully treated in about 90% of 
all cases with the remaining 10% continuing to harbor gastrointestinal H. pylori 
[272]. Figure 2-5 summarizes the suggested H. pylori eradication regimens.  
 
The common causes of treatment failure in H. pylori eradication therapy are patients’ 
non-compliance and antimicrobial resistance of the infecting bacterial strain [273]. 
Resistance to clarithromycin and metronidazole is one of the major reasons for 
treatment failure [274].  The prevalence rate of metronidazole resistance among H. 
pylori strains has been reported as high as 30% in North America, in Australia it is 
around 17% and varies from 5 to 50% in European countries [275]. Resistance to 
clarithromycin will reduce treatment efficacy by an average of 55.4% [276]. For 
adults in Northern Europe, the global prevalence of clarithromycin resistance is less 
that 5% while in Southern Europe it is as high as 20%. Overall, resistance to 




First line therapy 
Proton pump inhibitor (standard 
dose, twice daily), clarithromycin 
(500 mg, twice daily) and 
amoxicillin (1000 mg, twice 
daily) for 1 week 
 
or 
Proton pump inhibitor (standard 
dose, twice daily), clarithromycin 
(500 mg, twice daily) and 
metronidazole (400 or 500 mg, 
twice daily) for 2 weeks 
     
Second line therapy 
Proton pump inhibitor 
(standard dose, twice 
daily), bismuth (120 mg, 
four times daily) 
metronidazole (500 mg, 
three times daily) and 
tetracycline (500 mg, 







dose, twice daily), 
metronidazole 
(500 mg, two 
times daily) and 
tetracycline  
(500 mg, four 







dose, twice daily) 
metronidazole  
(500 mg, two 
times daily) 
and amoxicillin  
(1 g, two times 
daily) for 1 week 




Third line therapy 
 
Empiric rescue therapy 
 
or 
Treatment tailored to individual antibiotic 
sensitivity 
     
 
Figure 2-5: Summary of the suggested Helicobacter pylori eradication regimens 








 In Australia, Grove and Koutsouridis [277] reported a 4-fold increase in proportion 
of isolates of H. pylori that were resistant to clarithromycin over 5 year period. 
Strong associations between H. pylori infection and gastric lymphoma as well as 
gastric ulcer have been reported [278]. The risk of ulceration is higher with more 
virulent strains with expression of active forms of vacuolating cytotoxin (VacA) and 
possession of cytotoxin associated gene, cagA that stimulates the host inflammatory 
response. The VacA gene is present in all H. pylori strains where its subtype s1, m1 
genotype may produce higher levels of cytotoxin activity than other genotypes. 
Meanwhile, cagA gene
 
is a marker for a pathogenicity island
 
which is not present in 
every H. pylori strain but is associated with more severe clinical outcomes [279].  
 
2.2.2 Helicobacter pylori eradication therapy resistance 
  
The aim of H. pylori eradication is to cure peptic ulcer disease and reduce the 
lifetime risk of gastric cancer [280].  In Australia, the first-line standard regimen for 
the H. pylori eradication is a 7 day course consisting of two antibiotics namely 
amoxicillin (1 g twice daily) and clarithromycin (500 mg twice daily) together with 
proton pump inhibitor to increase antibiotic efficacy [281]. The standard eradication 
regimen is useful in preventing gastric ulcer and may eradicate H. pylori in up to 70 
% of the infected people. It has been recommended to increase the dose of proton 
pump inhibitor if the first treatment regimen fails and patients should be given 
second attempt with longer therapy duration, for example 10 to 14 days followed by 
an antimicrobial sensitivity test if two eradication attempts have failed [282].  
 
The Maastricht III Consensus Report in 2007 also recommended that the Triple 
Therapy using a proton pump inhibitor with clarithromycin and amoxicillin or 
metronidazole should remain as the first choice therapy to eradicate H. pylori [283]. 
The bismuth-containing quadruple regimen would be the best second choice if 
available. Whereas the combination of proton pump inhibitor-amoxicillin or 
tetracycline and metronidazole are recommended if bismuth is not available. There is 
geographic variability in the efficacy of proton-pump inhibitors in the treatment of 
peptic ulcer disease, due to differences in body weight, CYP2C19 genetic 




With the wide use of antibiotics among patients for various other conditions such as 
pulmonary infections, there are increasing reports worldwide of increased antibiotic 
resistance and subsequent failure of H. pylori eradication therapy [284]. Antibiotic 
resistance is a key factor in the failure of eradication therapy and recurrence of H. 
pylori infection [283]. Fischbach and Evans [285] have reported that standard proton 
pump inhibitor-based therapy fail in up to 30% of patients and that eradication rates 
have fallen to 70% over the last few years, mostly contributed by resistance towards 
clarithromycin. The prevalences of clarithromycin, metronidazole and levofloxacin 
resistance have been significantly increased in Europe, Asia, America and Africa 
since 2006 [286]. Among the main reasons for resistance to H. pylori therapy are 
poor patient compliance [287], molecular bacteria resistance [288-290], low gastric 
pH [291-292] and a high bacterial load [293-294]. 
 
Overall, in populations with less than 15 to 20% of clarithromycin resistance, proton 
pump inhibitor-clarithromycin-amoxicillin or metronidazole treatment is the 
recommended first choice [282]. Whereas, in populations with less than 40% 
metronidazole resistance, proton pump inhibitor-clarithromycin-metronidazole 
regimens are preferred. As for second choice treatment, bismuth based quadruple 
therapy remains the preferred option (if available) and if rescue treatment is needed, 
patients should be treated based on antimicrobial susceptibility testing.  
 
The use of fluoroquinolones, furazolidone or rifabutin as an alternative to the 
standard eradication therapy also have been studied, however their efficacy has been 
limited by the increased incidence of fluoroquinolone resistance over the years [295]. 
Several other possible mechanisms for multidrug resistance associated with H. pylori 
eradication have been proposed such as reduced permeability of the cell membrane 
to the certain drugs, active efflux of the drug from resistant cells and reduced binding 




2.2.3 Role of P-glycoprotein in Helicobacter pylori eradication 
therapy 
 
The induction of P-glycoprotein expression in the gastrointestinal tract as part of the 
xenobiotic defence has been demonstrated by Helicobacter spp. as these bacteria has 
been used in various studies to examine the pathogenenesis of bacteria-induced 
intestinal disorders [297-298]. It is believed that H. pylori plays a significant role in 
pathogenic mechanisms such as damage to the intestinal mucosa [299] and abnormal 
activation of immune competent cell [300].   
 




) mice have been shown to be more 
susceptible to develop inflammatory bowel disease. However, the high incidence of 
colitis in these knockout mice could be prevented by treatment with antibiotics. 
Therefore, it has been suggested that P-glycoprotein could prevent the accumulation 
of inflammation-inducing bacteria and bacterial products. Helicobacter bilis and H. 
hepaticus are commonly found in the rodent liver and intestine [302]. H. hepaticus 
has been shown to induce hepatocellular carcinomas in susceptible strains of mice 
that are not associated with mutation in p53 or Ras genes while colorectal cancer has 
been induced in RAD2-deficient mice by infection with H. hepaticus.  
 
Meanwhile, H. bilis has been shown to induce the development of inflammatory 




) mice infected by H. bilis was 
found to develop severe diarrhoea, weight loss and inflammatory bowel disease. 




) mice did not accelerate the 
development of colitis rather it delayed it and lessened it severity. These authors 
suggested that “Helicobacter spp. may provide a useful tool to explore the 
pathogenesis of microbial-induced inflammatory bowel disease in a model with a 
presumed epithelial cell “barrier” defect.” Subsequently Maggio-Price et al [302] 
reported that Helicobacter spp. infection results in increase of c-myc, IL-1 and COX-




] mice. As a result, the increased inflammation that is 
associated with Helicobacter infection further elevates oxidative damage, leading to 




P-glycoprotein is generally undetectable in normal gastric mucosal tissues but it is 
over-expressed in up to 50 % of gastric cancer patients [303]. H. pylori- dependent 
induction of COX-2 is associated with enhanced production of P-glycoprotein and 
Bcl-xL that may contribute to gastric tumorigenesis and resistance to the drug 
therapy. Preliminary data from Babic et al [305] suggested that H. pylori might 
stimulate P-glycoprotein expression in patients with peptic ulcer disease. The author 
assessed P-glycoprotein activity in gastric mucosa biopsies from H. pylori - positive 
subjects who were treated with antibiotics plus a proton pump inhibitor and 
compared these with control subjects with normal endoscopic findings. In their 
study, stronger gastric biopsies extrusion of rhodamine dye was recorded in most 
patients who were H. pylori positive. The patients were then randomly chosen to 
assess their pre- and post-therapeutic P-glycoprotein activity regardless of 
therapeutic success. The intensity of rhodamine dye extrusion by gastric biopsies 
from patients who were H. pylori positive was found to be higher than the control 
group.  
 
2.2.4 P-glycoprotein polymorphisms (MDR1 C3435T) and Helicobacter 
pylori eradication therapy  
 
P-glycoprotein (MDR1) polymorphism has been studied to evaluate the association 
between this polymorphism and the risk of gastric cancer and its influence on H. 
pylori eradication therapy outcomes. Tahara et al [306] examined the influences of 
MDR1 gene polymorphism on the risk of gastric cancer in the Japanese populations. 
The frequency of MDR1 3435TT genotype was found to be significantly higher in the 
control group compared to gastric cancer patients. There was no significant 
difference in the CT and CC genotype frequencies between gastric cancer patients 
and control group. Their study suggested that 3435TT polymorphism of MDR1 was 
associated with a reduced risk of gastric cancer in the Japanese population. 
 
Nevertheless, Sugimoto et al [307] found that no significant difference existed in 
frequencies of MDR1 C3435T polymorphisms between H. pylori-negative controls 
and H. pylori-positive gastritis patients and that the MDR1 3435T allele carriage did 
not affect the risk of gastric cancer or peptic ulcer development. The age- and sex-
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adjusted odds ratios of MDR1 3435T allele carriers relative to the 3435CC genotype 
group for gastric cancer, gastric ulcer and duodenal ulcer risk were 0.96 (95%CI: 
0.56–1.66), 1.16 (95%CI: 0.72–1.84) and 1.00 (95%CI: 0.61–1.62), respectively.  
 
Recently, Salagacka et al [308] suggested that having the 3435CT and 3435TT 
genotype increased the likelihood of H. pylori infection compared to the 3435CC 
genotype. In their study, a trend towards a higher incidence of the 3435TT genotype 
in a subgroup of men with peptic ulcer was also observed. Additionally, Gawronska-
Szklarz et al [309] reported that there was a significantly higher prevalence of 
subjects with 3435TT genotype in Caucasian group of patients who has successful H. 
pylori eradication after the first cycle of the therapy. Interestingly, higher eradication 
rate was observed in the subjects who received the combination of pantoprazole, 
amoxicillin and metronidazole compared to omeprazole, amoxicillin and 
metronidazole, supporting to the fact that pantoprazole has lowest potential for 
metabolic interaction among other proton pump inhibitors [310].   
 
On the other hand, Kodaira et al [311] reported that in 15 healthy Japanese 
volunteers who received oral lansoprazole 30 mg for 15 days, the drug plasma 
concentrations were higher in subjects with the 3435TT genotype compared to 
3435CC and 3435CT, respectively. The impact of MDR1 C3435T polymorphism on 
the lansoprazole pharmacokinetics was observed to be smaller after subjects received 
repeated doses; implying that in long term therapy such as that used for 
gastroesophageal reflux disease, lansoprazole pharmacokinetic could be less affected 
by this polymorphism.  
 
Gawronska-Szklarz et al [312] reported that there was no significant association 
between MDR1 C3435T and the H. pylori eradication rate among Polish Caucasian 
peptic ulcer subjects whom received combination of pantoprazole, amoxicillin and 
metronidazole. This finding was different to what had been observed in other studies 
[313-314] where MDR1 C3435T polymorphism was significantly associated with 
successful eradication in clarithromycin-resistance H. pylori- positive subjects.  
 
Oh et al [315] also failed to demonstrate an association between MDR1 C3435T 
polymorphism and the outcome of H. pylori eradication therapy amongst a group of 
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Korean subjects treated with the combination of pantoprazole 40 mg, clarithromycin 
500 mg and amoxicillin 1000 mg twice daily for 7 days. The dissimilarities reported 
regarding MDR1 C3435T polymorphism and H. pylori treatment outcomes or 
infection risk may be contributed to by differences in protein analysis techniques, the 
various antibodies used and/or patient demographics. 
 
2.3  Helicobacter pylori adherence in disease development 
 
2.3.1 Principles of bacteria pathogenesis  
 
A bacterial pathogen must first enter a host, find a unique niche, avoid other 
competing microbes and host defence barriers before multiplying sufficiently to 
establish itself or to be transmitted to a new susceptible host [316]. The bacterial 
pathogenesis comprises two major mechanisms, first is the invasiveness which 
include the ability to adhere and colonize the tissue; production of extracellular 
substances to facilitate the invasion and ability to overcome any host defence 
mechanism. The second mechanism is the ability of the bacteria to produce toxins, 
either exotoxins or endotoxins.  
 
An important step in the host-pathogen interaction is adherence of the pathogen to 
host surfaces [317]. Adherence also involves internalization, deeper tissue 
penetration and possible systemic distribution. Once pathogens adhere to a specific 
host cell surface such as mucous membranes or endothelial tissues, they initiate 
specific biochemical pathways including proliferation, toxin secretion, host cell 
invasion and activation of host cell signaling cascades resulting in disease 
development [318]. Bacterial invasion can be divided into two different types, 
namely extracellular and intracellular. Extracellular invasion is when the pathogens 
break down the tissue barrier to disseminate in the host while they remain outside the 
host cells.  
 
For example, Pseudomonas aeruginosa is an opportunistic pathogen that exploits any 
compromised host defences to initiate an infection [319]. This pathogen secretes an 
enzyme to aid the lung tissue invasion in individuals with cystic fibrosis. P. 
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aeruginosa then has access to the tissues and can proliferate before disseminating to 
other sites in the body to express toxins and later initiate inflammatory responses. On 
the other hand, a number of Gram negative and positive bacteria demonstrate the 
ability to cause the invasion intracellularly [318]. H. pylori exhibits this type of 
invasion and is able to form large vacuolar compartments for the bacteria to persist 
for long periods and evade the host immunological defenses [320].  
 
Fundamentally, the ability of pathogenic bacteria to cause disease in a susceptible 
host is determined by multiple virulence factors acting individually or together at 
different stages of the infection [321]. Virulence factors are the molecules that are 
produced by a microorganism to evoke disease [322]. Bacterial virulence factors may 
be encoded on chromosomal, plasmid, or bacteriophage DNA. They can be divided 
into several groups based on their mechanism of virulence and function. For 
example, some bacteria such as Salmonella spp. and Escherichia coli will produce 
pili (fimbriae), cell wall adhesion proteins or biofilm-producing capsules in order to 
adhere to host cells and avoid any physical removal.  
 
Colonization, with or without subsequent invasion, is the consequence of bacterial 
adhesion [323]. Bacteria will later produce endotoxins or exotoxins which are vital to 
their ongoing viability. For example, Listeria monocytogenes avoids phagosomal 
killing by producing a toxin known as lysteriolysin that allows them to escape into 
the cytosol before further replicating and spreading through other cells through their 
actin-tail-based motility [324]. Many bacterial pathogens also produce a specialized 
secretory system that resembles a syringe and use it as effectors to inject toxins into 
the host cell [325]. These effectors will mimic the function of host proteins and 
substantially alter mammalian signaling pathways, subsequently contributing to the 
disease process. Additionally, cells of the innate immune system such as dendritic 
cells and macrophages also provide an innate protection against microorganisms that 
are newly encountered by the host [326].  
 
The ability to avoid detection by either the innate or acquired host immune system is 
important for bacterial pathogens to survive [327]. One strategy is to disguise the 
surface of the microbe or the infected cell such that it is not recognized by host 
surveillance systems. Since the host's immune system rapidly develops specific 
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responses to an invading pathogen, microbial mechanisms for phase and antigenic 
variation can reduce the restrictive effect of host immune responses [328]. This is 
often accomplished by bacterial genetic mechanisms which involve DNA 
rearrangement. In order to promote their life cycle, bacterial pathogens may also use 
host cells to aid their own adherence, replication or dissemination [329]. After entry 
to host cells, invasive pathogens are either localized in the cytosol or sequestered in 
vesicular structures. Bacterial pathogens could further manipulate the cytoskeleton 
by interacting with actin filaments and modulating G proteins to help invade a host 
cell or to gain motility in the cell. Many bacterial pathogens also manipulate actin-
filament dynamics so that they can move within the infected host cell after the 
invasion and escape from membrane-enclosed vesicles into the cytosol.  
 
Another crucial step in the development of infection and disease progression is the 
ability of intracellular pathogens to exit the host cell once replication has ceased, 
thereby allowing infection of new host cells [330]. Listeria for example, promote 
their escape from phagosomes through the action of pore-forming cytolysins [331]. 
Cellular release then occurs as these bacteria use actin polymerization to protrude out 
of the cell. Meanwhile, intracellular bacteria that reside within a vacuole have the 
additional challenge of needing to traverse two membranes to successfully escape the 
host cell. One example is the merozoite-stage rupture of erythrocytes by the malaria 
parasite Plasmodium falciparum where cysteine proteases have been shown to be 
essential for sequential rupture of the vacuole and cell.  
 
A comprehensive understanding of the mechanisms underlying the bacteria 
pathogenesis is a must in order to design an effective drug therapy while avoiding 
any risk of bacterial resistance. The increasing prevalence of bacterial strains that are 
resistant to available antibiotics demands the discovery of new therapeutic 
approaches [332]. As some elements of virulence are fundamental for many 
pathogens, the new combination therapy may be designed so that bacterial clearance 
is mediated by standard antibiotics and the symptoms of virulence are suppressed by 
the anti-virulence drugs. The principle behind this combination therapy is to disarm 




2.3.2 Helicobacter pylori pathogenesis  
 
H. pylori is mainly found attached to the gastric mucous layer [334]. While in a small 
number of the population, H. pylori has been observed to invade the lamina propria 
of antrum, causing more severe mucosa inflammation [335]. H. pylori-induced 
gastric epithelial damage allows the bacteria to translocate to the gastric lymph nodes 
and chronically stimulate the host immune system. H. pylori adherence to gastric 
epithelial cells facilitating access to nutrients and delivery of effector molecules has 
been considered essential for development of disease [336].  
 
Peristalsis and gastric acidity are the fundamental barriers to successful colonization 
of H. pylori in the stomach, hence the bacteria has to establish several mechanisms to 
escape from those primary host defences [337]. Upon colonization, H. pylori 
penetrates the mucus layer to multiply near to the surface epithelium. H. pylori uses 
their flagella in order to facilitate their motility within gastric mucus and to overcome 
peristalsis [338]. Each flagellum is about 3 μm long and exhibits a typical bulb-like 
structure at its distal end that represents a dilation of the flagellar sheath. The 
flagellar sheath is an extension of the bacterial outer membrane that is important in 
protecting the acid-labile flagellar structure from the attack of the stomach acid. 
Interestingly, H. pylori also uses the flagella to mediate chemotaxis to promote 
infection [339]. 
 
H. pylori uses a variety of strategies to undermine the innate and adaptive immune 
systems of the host, therefore represents a remarkable medical challenge [340]. H. 
pylori biofilm formation has been reported to be involved in the colonization of the 
human stomach [341]. The biofilm is likely to provide greater protection for H. 
pylori under stressful conditions. In antral biopsies from patients with peptic ulcer 
disease and urease positive, almost the entire mucosal surface was covered with 
mature biofilms, while coverage was less than 2% in urease-negative patients [342]. 
To adhere to gastric epithelial cells, H. pylori also can assume either a spiral or 
coccoid form, passing through an intermediate U-shape during the conversion from 
one form to another [343]. H. pylori is known to mainly present in a spiral shape but 
it converts into a coccoid shape when exposed to detrimental environmental 
circumstances [344]. Coccoid H. pylori is found attached to severely damaged gastric 
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epithelial cells and can be identified in up to 93% of biopsy specimens from patients 
with H. pylori-associated adenocarcinoma [345]. 
 
H. pylori not only survives the low pH of the stomach, but thrives in it [346]. To 
overcome acid stress, H. pylori produces urease, which catalyses the hydrolysis of 
urea to carbon dioxide and ammonia. Urease also helps the bacterium to maintain a 
proton motive force that is essential for their metabolism and survival. Meanwhile, 
ammonia molecule helps to buffer the H. pylori cytoplasm and the microenvironment 
as it is secreted from the bacterial cell. Urease is important to the pathogenesis of H. 
pylori infection and urease-negative mutants have been demonstrated to fail in 
colonizing various animal models [347]. Urease protein activity is elevated under 
acidic condition. H. pylori may then modulate the urease activity in vivo through 
activation of nickel transporters such as NixA.  
 
During colonization, the gastric epithelium lining will respond to the infection by 
degenerative changes such as mucin depletion, cellular exfoliation and compensatory 
regenerative changes and production of cytokines such as interleukins and tumor 
necrosis factor alpha [348]. Host innate immunity functions as a pathogen sensor also 
begin to induce the pathogen eradication and establish the adaptive immunity [349]. 
The innate toll-like receptor (TLR) system is usually recognizes bacterial 
lipopolysaccharides before triggering the pro-inflammatory response. There is 
evidence showing that H. pylori is able to bypass the TLR as the latter does not react 
towards lipopolysaccharides from the bacteria cell wall. H. pylori flagellum function 
was also shown to not signal through TLR and stimulate any innate immune 
response. In addition, H. pylori also modulates the adaptive immune system by 
blocking the antigen dependent proliferation of T cells partially by delivery of the 
vacuolating cytotoxin, VacA, which blocks T-cell receptor signaling events that 
normally lead to the production of cytokines, important mediators of the immune 
response [350]. The risk of ulceration is higher with more virulent strains which 
express active forms of VacA and posses the cytotoxin associated gene (cagA) that 
stimulates the host inflammatory response [351].  
 
These virulence factors of H. pylori play important roles in gastric mucosal injury, 
such as gastric inflammation, peptic ulceration, atrophy, intestinal metaplasia, 
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dysplasia, and malignancy [352]. The VacA gene is present in all H. pylori strains 
where the subtype s1, m1 genotype produces higher levels of cytotoxin activity than 
other genotypes. CagA is a marker for a pathogenicity island which is not present in 
every H. pylori strain but is associated with more severe clinical outcomes [353]. The 
cagA gene which encodes a family of high-molecular-mass protein (120 to 140 kDa) 
is present in approximately 60% of H. pylori isolates. The cagA is directly secreted 
from bacterial cells into epithelial cells via the cag-encoded type IV translocation 
apparatus and disturbs the physiological signal transduction [354]. This causes 
pathological cellular responses such as increased cell proliferation, motility, 
apoptosis and morphological changes.  
 
While H. pylori has also been shown to produce reactive oxygen species (ROS) in 
infected gastric mucosa, cagA itself can induce ROS production in gastric epithelial 
cells [355]. Serologic response to cagA has been detected in H. pylori-infected 
patients with peptic ulcer disease more frequently than in the infected patients with 
gastritis alone. Serum IgG cagA antibodies were present in 44.1% of healthy H. 
pylori infected volunteers, 58.8% of those peptic ulcer disease, 57.7% of those with 
duodenal ulcer and in 63.3% of those with gastric ulcer [295]. Infection with a cagA-
positive H. pylori strain increases the risk of development of gastric ulcer and 
presence of cagA-positive isolates has been proven to contribute to difficulties in 
bacterial eradication [356]. 
 
One final mechanism that may be crucial for H. pylori to escape from the host 
immune response is the ability to undergo genetic rearrangement that either 
eliminates particular immunostimulatory gene products or causes variation in 
potentially immunostimulatory molecules [357]. Additionally, H. pylori may also 
hide from the cell host defences through intracellular invasion of the epithelial cell 
lines [358]. H. pylori needs to establish adherence with the epithelial cells before 
gain the entry into a cell. H. pylori attachment to cell lines is associated with protein 
phosphorylation and cytoskeleton rearrangement leading to formation of 
pseudopodia [359]. H. pylori adhesins may be involved in this process, for instance 
SabA is involved by mediating the binding to gangliosides and stimulation of G-
proteins, and the activation of phagocytosis and oxidative burst reactions of 
neutrophils [360]. Additionally, the cagA mediated reorganization of the host cell 
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membrane and signaling is probably fundamental in bacterial adhesin accumulation 
in the bacterial–host cell interface.  
 
H. pylori may colonize the human gastric mucosa for long periods, rather than just 
days or weeks as occurs with other gastrointestinal pathogens [361]. Gastric 
inflammation always leads the development of peptic ulceration and is a critical 
component in initiating the progression towards gastric carcinogenesis [362]. 
Although all H. pylori strains induce gastritis, strains that contain the cag PAI (cag+) 
enhance the severity of gastritis and atrophic gastritis and distal gastric cancer risks 
compared to those with strains which lack the cag island (cag-deficient mutants) 
[363]. Chronic gastritis induced by H. pylori further increases the risk for various 
gastrointestinal diseases including peptic ulcer disease, distal gastric adenocarcinoma 
and gastric mucosal lymphoproliferative diseases such as non-Hodgkin's lymphoma 
[364].  
 
2.3.3 Helicobacter pylori adherence to gastric tissues 
 
H. pylori internalization starts from cell surface through the gastric epithelial cells 
during the early phase of the infectious process [365]. The adherence and adhesion of 
the bacteria to the gastric mucosa are key steps in the establishment of a successful 
infection [366].  Bacterial adhesion to a material surface can be described as a two-
phase process; Phase 1 which is an initial, instantaneous and physically reversible 
and Phase 2 which is a time-dependent and irreversible molecular and cellular phase 
[367]. On the other hand, adherence is a general description of bacterial adhesion 
which is the initial process of bacteria directly binding to the surface. H. pylori 
adhere specifically to epithelial cells in the antral and fundal mucosa of human 
stomach [368]. The close association of H. pylori with gastric epithelial cells 
stimulates not only morphological but also physiological changes within gastric 
epithelial cells [369]. This in vitro study has confirmed the specificity of H. pylori 
for human gastric epithelial cells and its lack of binding to human esophageal 
epithelial cells and human fibroblasts.  
 
H. pylori adherence has been demonstrated in vitro using human tissue culture lines 
such as KATO-III and AGS that are derived from gastric cancer patients [370]. In 
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their study, AGS human gastric carcinoma tissue culture cell monolayers were 
infected with H. pylori. The authors found that only 0.6-2.0% of the inoculums were 
actually internalized by the host cells. H. pylori were also seen within coated pits and 
appeared to be taken into the host cell by endocytosis. Once taken into the cell, 
bacteria were seen within vacuoles in the epithelial cells. Some of the H. pylori that 
were not internalized made their way into the tight junctions and were seen between 
cells. Earlier, Hemalatha and colleagues [371] examined the adherence of H. pylori 
to KATO-III cells, an epithelial cell line derived from a human gastric 
adenocarcinoma. The author demonstrated in vitro that adherence of H. pylori to 
gastric epithelial cells involved attachment and effacement mechanisms. Some H. 
pylori were shown to adhere to the intact microvillus, while others closely adhere to 
the plasma membrane in regions where microvilli were effaced. Interestingly, their 
adherence assays also showed that binding of H. pylori was temperature- and gastric 
pH-dependent.  
 
In another study, Nilius et al [372] compared attachment of five H. pylori strains 
taken from patients with gastritis (4 strains) and duodenal ulcer (1 strain) to three 
different gastric cell lines namely human surface mucous cells (HSMC), tumour 
surface mucous cells (TSMS) and bovine surface mucous cells (BSMC). All strains 
consistently showed adhesion to human epithelial mucous cells (HSMC and TSMS) 
with one strain additionally adhering to BSMC. The single H. pylori strain which 
adhered to bovine stomach had been isolated from a patient with duodenal ulcer, 
whereas the remaining four strains came from patients with gastritis. As the adhesion 
of this H. pylori strain to BSMC is apparently in contradiction to earlier reports of a 
selective affinity of H. pylori for human gastric surface mucous cells in vivo, the 
authors suggested that some bacteria may adhere because of different adherence 
factors, possibly related to their virulence potential. 
 
There was an assumption that infection can be prevented by inhibiting the pathogens 
adherence to a cells surface [373]. For instance, the pathogens adherence inhibition 
could be achieved by using commensal bacteria to interfere with microbial 
pathogenesis at certain mucosal sites to compete for nutrients and host-cell-binding 
sites. If bacteria cannot adhere to the mucosal layer, they will be removed rapidly by 
the local, nonspecific host-defence mechanisms such as peristalsis, ciliary activity 
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and turnover of the epithelial cell populations and mucous layer [374]. The 
carbohydrate compositions of natural glycoconjugates that are genetically regulated 
in individuals may also act as natural antimicrobial clearance factors. It is an 
interesting concept that the initial adherence of bacteria to cell surface receptors 
might play such an important role in pathogenesis and any changes to the adherence 
process could subsequently affect the infectious diseases predisposition. 
 
In a preliminary study, Crowe and Bebawy [375] proposed that P-glycoprotein 
expression in the gastrointestinal tract may prevent the bacterial toxicity by inhibiting 
the bacterial adherence to the human enterocytes cells. Three human cell lines (Caco-
2, RKO and MCF7) and six species of bacteria (Staphylococcus aureus, Salmonella 
typhimurium, Klebsiella pneumoniae, Clostridium sporogenes and Pseudomonas 
aeruginosa) were used. These authors found that the P-glycoprotein inhibition did 
lead to a significant increase in the adherence of all bacteria species studied to the 
Caco-2 cells but this was not the case with RKO and MCF7 cells. As Caco-2 cells 
that originated from human colon adenocarcinoma is known to express P-
glycoprotein and has been extensively used as a model for the intestinal barrier, the 
study by Crowe and Bebawy demonstrated the role of P-glycoprotein in preventing 
the bacterial adherence and its potential in protecting gastrointestinal mucosa tissue. 
Their study may be expanded to determine the influence P-glycoprotein on the 
adherence of other bacteria species, such as H. pylori adherence and to determine 
whether manipulating its expression can influence to the occurrence and severity of 
bacteria-related gastrointestinal diseases. P-glycoprotein has been reported to 
increase stem cell proliferation and regulate apoptosis and whilst its absence results 
in decreased repair of intestinal epithelial cells after chemical injury [376]. Microbial 
and host factors that determine the outcome of H. pylori colonization have been 
difficult to define, in part because both H. pylori and humans are genetically diverse 
[377]. H. pylori ability to establish physical contact with the gastric epithelium is an 
important factor for their pathogenesis, therefore affecting its ability to influence 


























This study was divided into two – Phase 1 (Helicobacter pylori and P-glycoprotein 
expression) and Phase 2 (Helicobacter pylori attachment to gastrointestinal cell 
lines). 
 
3.1 Phase 1 : Helicobacter pylori and P-glycoprotein expression 
 
3.1.1 Patient recruitment 
 
All patients who attended the Endoscopy Unit, Department of 
Gastroenterology/Hepatology, Sir Charles Gairdner Hospital, Nedlands, Western 
Australia from October 2010 to July 2011 for an upper gastroendoscopy were invited 
to participate in the study. On the day of the procedure, the doctor obtaining consent 
for the upper gastrointestinal endoscopy had assessed the patient eligibility for the 
study. Patients who were unable to converse in English, were unwilling to participate 
or deemed too unwell by the doctor had been considered ineligible for study. Patients 
who were on any antibiotics upon the endoscopy also had been excluded from this 
study.  
 
When the patient was deemed eligible, the study had been explained and the signed 
consent form was obtained from patients who agree to participate. Participants also 
required to fill-in a set of questionnaire (comprehended of four questions) attached 
with the informed consent. The information regarding participant`s medical and 
medication history also had been taken before proceeded to the endoscopy 
procedure. On the day of recruitment, all the participants underwent an upper 
gastroendoscopy as scheduled by their doctor where four additional biopsies were 
collected for the research purpose. Whole blood samples (10 mL) also were collected 
by jugular venipuncture into vacutainer tubes with anticoagulant, Ethylene diamine 




3.1.2 Sample size calculation 
 
It is reported that 48% of patients diagnosed with peptic ulcer disease are caused by 
Helicobacter pylori [245]. Previous study had shown that about 15 to 20% of 
patients diagnosed with H. pylori were expected to have an increased in P-
glycoprotein levels [305]. While the majority (80% to 85%) of patients having 
normal or lower P-glycoprotein levels. 
 
Based on the number of endoscopy procedure performed which was 1818 for the 
year 2009 at Department of Gastroenterology/Hepatology at Sir Charles Gairdner 
Hospital, Nedlands, the prevalence of P-glycoprotein expression in H. pylori–
positive patients had been estimated along with its 95% confidence interval (CI). The 
sample size has been selected to give adequate precision to this prevalence estimate. 
Allowing for failure to obtain some data, about 200 participants was expected to be 












20% ± 8% 96 
± 7% 125 
± 6% 170 
15% ± 8% 76 






3.1.3 Ethics approval 
 
This study was approved by ethics committee at Sir Charles Gairdner Hospital, 
Nedlands which conforms to the provisions of the World Medical Association’s 
Declaration of Helsinki in 1995 (as revised in Tokyo 2004) followed by human 
ethics clearance granted by Curtin University Ethics Committee in September 2010. 
The copy of ethic approval is attached in Appendix II and Appendix III along with 




All the participants were required to fill in the questionnaire before the endoscopy 
procedure. Participants also were required to submit additional information in the set 
of questions regarding their past medical and medication history. The questionnaire 
contained the following four questions: 
 
A. Have you ever been tested for bacteria named Helicobacter pylori? 
 Yes 
 No 
 Don`t know 
B. If yes, do you know the result of the test? 
 Positive 
 Negative 
 Don`t know 
C. Have you ever been treated for Helicobacter pylori infection? 
 Yes 
 No 
 Don`t know 
D. If yes, was the therapy successful in eliminating the infection? 
 Yes 
 No 





3.1.5 Endoscopy procedure 
 
All the participants underwent upper gastroendoscopy as planned by their doctors. 
The participants were required to be in fasting condition and some pre-medications 
were prescribed to assist the procedure such as intravenous Fentanyl 100 mcg and 
Midazolam 5 mg. The gastroscopy video system (GIF-H180) had been used to assist 
endoscopist in obtaining best upper gastrointestinal image and collecting the 
biopsies. All the endoscopy procedures were conducted in sterile environment.  
 
All our participants have been informed that antibiotic therapy, bismuth or proton 
pump inhibitors should be ceased a few weeks before biopsies needed to be taken. 
Four additional biopsies have been collected for the purpose of this study (two 
samples from antrum and two samples from duodenum). All biopsies had been 
labelled with participant`s identification number, date, time and site of biopsy. Upon 
the upper gastroendoscopy procedure, one antral biopsy that would be used to 
determine H. pylori status was immediately placed in transport media (brain heart 
infusion broth 2% with 20% glycerol, PathWest Media, Western Australia). For 
other antral and duodenal biopsies, there were immediately kept on dry ice before 
being transferred to the laboratory for storage.   
 
In addition, a 10 mL blood was collected by jugular venipuncture into vacutainer 
tubes with anticoagulant, Ethylene diamine tetra-acetic acid (EDTA) and placed on 
the dry ice together with the biopsies in a closed container. All the specimens 
obtained on that particular day were then transported back to the laboratory within 
four hours and kept in the freezer for -80 °C storage before any further analysis. 
 
3.1.6 Helicobacter pylori infection status 
 
The H. pylori infection status was determined based on culture or polymerase chain 
reaction (PCR) results using antral biopsies. Samples were considered positive for H. 
pylori if one of the methods (culture or PCR) yielded positive results. The rapid 
urease test (CLOtest) and antibiotic sensitivity test was only performed on 
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participants that had been diagnosed with failure towards H. pylori eradication 




In this current study, all bacterial culture work has been conducted in a special 
laboratory that only dedicated for Helicobacter work. The antral biopsy was removed 
from the transport media and crushed using a sterile blade before being transferred to 
two different blood agar bases (Columbia Blood Agar Base, Oxoid, Australia) with 
and without H. pylori-selective supplement.  Supplemental antibiotic (H. pylori-
selective supplement, Dent, Oxoid, Australia) was introduced to our Columbia blood 
agar base to inhibit growth of other organisms, maintain the H. pylori viability and 
optimize the survival conditions. The supplement consists of vancomycin, 
trimethoprim, cefsulodin and amphotericin B. Another blood agar base without 
antibiotic supplement was also used to culture the H. pylori from each sample.  
 
All the blood agar plates were incubated at 37 °C under microaerobic conditions 
(90% CO2, 4% N2, 2% H2) for five to seven days. After the first 48 hours, each plate 
was examined and any colony that resembled H. pylori was transferred to a new 
blood agar for further incubation periods. About 48 hours later, the colonies were re-
suspended with a cotton swab in 1 mL of sterile saline. A 90 µL of bacteria 
suspension then was added to the surface of a new blood agar and incubated for 
another 48 hours. As expected, the conventional media without the antibiotic 
supplement did allow growth of few other bacteria; however H. pylori could be 
differentiated based on its shape under microscope, pattern of colonization on the 
blood agar as well as urease and catalase tests. 
 
Isolates were identified based on colony morphology, gram staining, oxidase, 
catalase and urease tests [378]. For Gram staining, crystal violet was used to flood 
the glass slide for about one minute. The stain was washed off with deionised water 
before been flooded again with Gram iodine solution for another minute before been 
removed again by deionised water. Alcohol 95% was used for 10 seconds to cover 
the glass slide and drained. The glass slide was then flooded with carbol fushin for 
two to three times before been drained and blot dried with clean paper towel. The 
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glass slide was then immersed with oil immersion lens before been examined under 
the microscope.  
 
To confirm the H. pylori infection status, sterile inoculating loops aseptically 
transferred colonies of pure H. pylori to two separate curvetttes containing catalase 
and urease reagents. After a few minutes, a positive urease test of H. pylori resulted 
in changes of orange to pink solution. Meanwhile, a positive catalase test was 
indicated by rapid bubbling of the peroxide solution. On the other hand, an oxidase 
strip was directly placed on the bacteria colony on a blood agar where positive result 
for H. pylori was shown by rapid development of blue colour. 
 
3.1.6.2 Polymerase chain reaction  
 
Polymerase chain reaction (PCR) was used to determine presence of H. pylori in 
antral biopsies. Earlier, the boiling method was used to obtain bacteria DNA from the 
biopsies as adapted from Holmes & Quigley [379]. The specimen was placed in 50 
µL of Tris buffer and boiled in a dry bath at 90 °C for about 15 minutes. This was 
followed by vortexing and centrifugation at 12,000rpm for 5 minutes. A supernatant 
containing the DNA was transferred to a new tube and kept at -20°C storage. The 
PCR analysis was performed in a 50 µL of reaction volume that consisted of 1 µL of 
genomic DNA, 25 µL of MasterMix, 2µL of each oligonucleotide primers and 22 µL 
of pure water. The PCR cycle was performed using PTC-100™ Programmable 
Thermal Controller (MJ Research, Minnesota) for 95 
o
C, 30 seconds; 95 
o
C, 18 
seconds ; 55 
o
C,  30 seconds (30 cycles); 68 
o
C ,90 seconds; 68 
o
C, 5 min. About 5 
µL of amplified samples with 1 µL of loading dye were electrophoresed on 1.5% 
agarose gel in tris-borate-EDTA (TBE) buffer for 85 minute at 85 volt and the 
amplified bands were visualised under ultraviolet light. All the primer sequences and 
PCR conditions used were listed in Table 3-2. 
 
With availability of commercial bacteria DNA purification kits, our specimen DNA 
was then purified using EDNA Hispex™ Kit (Saturn Biotech, Western Australia) 
and quantified using Biospec-Nano (Shimadzu Biotech, New South Wales). The 
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genomic DNA and 24 µL of reaction mixture containing 10x PCR buffer, 25mM 
MgCl2, 5mM dNTPs, 25 pmol/µL of each oligonucleotide primers and thermo-stat 
Taq DNA polymerase in PTC-100™ Programmable Thermal Controller (MJ 
Research, Minnesota).As such DNA sequences encoding rRNA are highly 
ubiquitous, there is a possible risk of nonspecific products, particularly when 
analyzing DNA extracted from mammalian tissue (380). Therefore, vacA gene, a 
species-specific and highly conserved locus in H. pylori was also targeted in our 
PCR. H. pylori 26695 was used as positive control and sterile water was used as 
negative control. About 10 µL of amplified samples were electrophoresed on 2% 
agarose gel in tris-acetate-EDTA (TAE) buffer for 60 minute at 80 volts. The gel was 
stained with 30 µL gel red in 100 µL of TAE buffer and the amplified bands were 
visualised under ultraviolet light 
 
3.1.6.2 Rapid urease test (CLOtest) 
 
For a few participants, their H. pylori infection status also was confirmed by 
incubating the antrum biopsy in CLOtest (Kimberly Clark, Sydney) at the time of 
gastroendoscopy. A biopsy of gastric mucosa was taken from the antrum and placed 
into a medium containing urea while phenol red acted as indicator. H. pylori then 
produced urease which transformed the urea to ammonia and the increased pH of the 
medium would change the colour from yellow (negative) to red (positive). 
 
3.1.6.3 Antibiotic sensitivity test 
 
Antibiotic sensitivity test was performed in the resistance group by E-test (Biodisk, 
BioMérieux France) for amoxicillin (AC), clarithromycin (CH), metronidazole (MZ), 
tetracycline (TC), rifampicin (RI) and ciprofloxacin (CI). A strip that had been 
impregnated with the respective antibiotic was laid on a blood agar plate where the 
H. pylori had already been spread.  
 
After 24 hours of incubation, an elliptical zone of inhibition (if any) would be seen 
and reading for minimal inhibitory concentration was obtained. Resistance was 
69 
 
defined according to National Committee for Clinical Laboratory Standards [382] for 
antibiotic minimal inhibitory concentration (MIC) : AC, MIC ≥ 2 μg/ml ; CH, MIC ≥ 
1 μg/ml ; MZ, MIC ≥ 8 μg/ml ; TC, MIC ≥ 1 μg/ml ; RI, MIC ≥ 4 μg/ml and CI, MIC 
≥ 1 μg/ml. 
 
3.1.7 Protein analysis  
 
The protein analysis involved protein concentration determination by the Micro-
Lowry Method for total protein and Western Blot Analysis for P-glycoprotein 
expression.  
 
3.1.7.1 Sample preparation 
 
In sample preparation for Western Blot Analysis, proteolysis degradation is the main 
concern during fractionation of cell extracts [383]. SIGMAFAST™ protease 
inhibitor tablet (Sigma-Aldrich, St Louis MO) and Phenylmethylsulfonyl fluoride 
(Sigma-Aldrich, St Louis MO) were added to tissue lysis buffer to ensure stable 
protein collection. Tris was added to permeabilize the cell membrane by releasing the 
lipopolysaccharides of the lipid bilayer. In this study, biopsies prepared for protein 
analysis were placed in 300 µL of an ice-cold tissue lysis buffer (0.05 M Tris 
Hydrochloride, 20% glycerol, 2 mM Ethylenediaminetetraacetic acid, 0.2 mM 
Phenylmethanesulfonyl and one protease inhibitor tablet) and homogenized.  
 
3.1.7.2 Protein concentration 
 
Protein concentration were estimated using a Micro-Lowry Method [384] adapted for 
use with multi well plates on a TECAN Sunrise™ (TECAN Group Ltd, Switzerland) 
96- well plate spectrophotometer with a 750 nm filter using Magellan 3 software for 
Windows 2000. For about 1 to 30 µg protein in reaction, a CTC reagent was 
prepared consisting CuSO4.5[H2O], Na-K-Tartrate and Na2CO3 that had been 
dissolved in nanopure water to make 100 mL of total solution. A solution of 0.8M 
NaOH was then prepared by dissolving the NaOH pellets in nanopure water to make 
100 mL of total solution. A Lowry reagent was prepared by adding one part of CTC 
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reagent to 2 parts of nanopure water and 1 part of 0.8M NaOH solution. To prepare a 
Folin reagent, 2N Folin was added to nanopure water. 
 
A bovine serum albumin (BSA) stock solution of 2 mg/mL was prepared from 
analytical grade BSA (Sigma-Aldrich, St Louis MO) and a concentration range of 10 
to 1500 µg/mL was used as our protein standard. All the protein samples, standard 
and stock solution were transferred by pipettes into a 96- well plate accordingly. 
Lowry reagent was added to each well using a multi-channel pipettor and incubated 
for 15 minutes at room temperature. At the end of 15 minute-incubation period 
diluted Folin reagent (1:4) was added into each well. The 96- well plate was then 
incubated again for another 30 minutes.  
 
Using a spectrophotometer set to 750 nm, the absorbance value was measured by 
Magellan 3 software. A standard curve was generated by plotting the average blank-
corrected 750 nm values for each BSA standard versus its concentration in μg/mL. 
The standard curve was used to determine the protein concentration of each sample.   
 
3.1.7.3 Western Blot Analysis 
 
Western Blot Analysis was used to quantify expression of P-glycoprotein from 
biopsies with B-actin as a loading control in a NuPage® Novex 3-8 % Tris-Acetate 
gels with fifteen 1.5 mm x 25 uL wells (Invitrogen, Victoria). The X-cell apparatus 
(Xcell Sure Lock™, Invitrogen, Victoria) were set up and 20 µL of solution prepared 
previously were loaded to each well. The Novex Sharp
®
 Standard was loaded to the 
last well of the gel as molecular weight marker proteins. The X-cell apparatus was 
run using 150 V for 67 minute. 
 
A Immun-Blot® PVDF cut 8 x 9 cm membrane was used to electrophoretically 
transfer proteins from polyacrylamide gel using the Xcell II™ Blot Module. The 
Xcell II blot module was run for 105 minute and 33 V. By using a clean forceps, the 
Immun-Blot® PVDF membranes were collected and washed with Tris-Buffered 
Saline with 0.5% Tween-20 (TBST) twice. SimplyBlue™ SafeStain (Invitrogen, 
Victoria) was used to detect protein transfer by visualizing protein bands on 
polyacrylamide gels. The mini gels were rinsed with double deionised water three 
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times for five minute each before the stain solution was poured to each gel and left 
for about one hour. The gels were washed again with double deionised water and 
were rocked for one hour to remove the blue stain. Any visible band on the gel was 
then examined. 
 
Meanwhile, Ponceau S method was used to determine protein transfer on the PVDF 
membranes using the commercially available Ponceau S solution (0.1% in 5% acetic 
acid, Sigma-Aldrich, St Louis MO). The blots were removed from the transferring 
sandwich in Xcell II™ Blot Module and rinsed three times with distilled water. 
100% methanol was used to saturate the PVDF membrane for a minute before the 
staining solution was poured to the blots for another minute. Any visible band on the 
gel was then examined and the stain could be removed by rinsing it in 0.1 M NaOH 
for a few minutes. Both membranes were washed for once in TBST and left sitting 
the TBST for another 10 minute before being rinsed off. Blocking agents from 
Western Breeze
®
, (Invitrogen, Victoria) consisting of 20 % blocker A, 30% blocker 
B and 50% double deionised water were added and membranes were left blocked 
overnight at 4 °C.  
 
On day 2, the membranes were washed twice in TBST for 5 minute each on a 
rocking platform to remove blocking agents. TBST was rinsed off and 10 mL 
antibody solution from Western Breeze
®
 (Invitrogen, Victoria) containing 40 µL of 
PgP Sc13131 Mdr [G-1] mouse monoclonal IgG2b (200 µg/ml; Santa Cruz 
Biotechnology) and 2 µL of mouse anti-B-actin (42kDa protein; Sigma-Aldrich, St 
Louis MO) were added to each membranes. B-actin, a cytoskeletal protein is very 
abundant in mammalian and act as a housekeeping protein on the same blot. 
Membranes were left on rocking tray at room temperature for two hours. After 2 
hours, primary antibodies were removed by washing the membranes four times in 
antibody wash solution with 5 minute for each wash. 10 mL diluted secondary 
antibody (Goat anti mouse IgG AP Pre-diluted, Western Breeze
®
, Invitrogen, 
Victoria) was added to each membrane and incubated for 1.5 hour on room 
temperature. Both membranes were washed four times for five minute each in 
antibody wash solution (Western Breeze, Invitrogen, Victoria) and rinsed once with 
double deionised water.  A 2 ml of the Chemiluminescent substrate were applied 




An AlphaInnotech-ChemiImager 4400 (Alpha Innotech, San Leandro, CA) with a 
CoolSnap HQ charge-coupled device camera (Roper Scientific, Trenton, NJ) was 
used to capture chemiluminescence of any p-glycoprotein expression and recorded as 
a image after 10 to 15 minutes of exposure. The intensity of P-glycoprotein band was 
quantified based on the corresponding pixel intensity values designated as IDV 
(Integrated Density Value) in Spot Density Tools from the AlphaImager 4400 which 
represent p-glycoprotein expression level. With the chemiluminescence intensity 
mentioned in its raw form, simple intensity numbers that relevance is in its 
comparative nature to other bands measured in the same image and other plots using 
the same exposure time and equipment i.e. what is important is how many fold 
higher or lower these photon intensity plots are to each other.  
 
3.1.8 MDR1 (C3435T) polymorphisms 
 
The genotyping for MDR1 (C3435T) involved blood DNA preparation from frozen 
sample, PCR for determining P-glycoprotein band, followed by enzyme digestion 
with Mbo-1 to obtain particular band for 3435CC,3435 TT and 3435CT genotype.  
 
3.1.8.1 Blood DNA preparation 
 
DNA could be extracted from whole EDTA-treated blood, buffy coat or lymphocyte 
preparations using a commercial kit or home-made lysis buffer (red cell and nuclei) 
followed by precipitation with ammonium acetate and ethanol. In this study, genomic 
DNA was extracted from venous blood using home-made lysis buffer. The frozen 
blood had been thawed in the room temperature upon the laboratory work. The 
thawed blood then was decanted into a sterile conical centrifuge tube and red cell 
lysis buffer was added. The mixture was mixed gently by inversion for several times 
at room temperature before being centrifuged at 2000 x g for 10 minutes. The 
supernatant was discarded and a fresh red cell lysis buffer was added again to the 
conical centrifuge tube followed by inversion and centrifuging. That step was 
repeated three to four times. Following the final centrifugation step, the supernatant 
was discarded and remaining pellet was vortexed. White cell lysis buffer was added 
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to the dispersed pellet. The lysis buffer and pellet were mixed gently by repeated 
aspiration with a pipette, before being transferred to a fresh sterile conical centrifuge 
tube and incubated for 10 minutes at 40 
o
C. A Proteinase K 10 mg/ml was added to 
each conical centrifuge tube and the incubation continued at 55 
o
C for 60 minutes. A 
10M ammonium acetate solution was added to each conical centrifuge tube, followed 
by vortex then centrifuging process at 2000 x g for 10 minutes.  The supernatant was 
then decanted into an amount of absolute ethanol in a fresh small conical tube. The 
solution was mixed by gentle inversion until the DNA becomes visible as white 




All the conical tubes containing the DNA strands were then centrifuged at 2000 x g 
for 10 minutes. The supernatant was discarded and the pellet was washed with small 
amount of 70% ethanol before being transferred to an eppendorf tube. The eppendorf 
tube was then centrifuged at 12 000 RPM for 10 minutes. The 70% ethanol was 
discarded carefully by inverting the eppendorf tubes on an absorbent paper and each 
sample was rehydrated with Tris-EDTA buffer. The DNA quantification was read by 
using Biospec-Nano (Shimadzu Biotech, New South Wales) with Tris-EDTA buffer 
as blank solution. All the DNA samples were stored at -20 
0
C before further analysis. 
 
3.1.8.2 Polymerase chain reaction  
 
The PCR analysis for determining P-glycoprotein band was carried out in 25 uL of 
reaction volume consisting of 1 µL of genomic DNA and 24 µL of reaction mixture 
containing 10× PCR buffer, 25mM MgCl2, 5mM dNTPs and 25 pmol/µL of each 
oligonucleotide primers (forward 5`-TCTTTTCAGCTGCTTGATGG-3` and reverse 
5`-AAGGCATGTATGTTGGCCTC-3`) in PTC-100™ Programmable Thermal 
Controller (MJ Research, Minnesota) [385]. Thermo-stat Taq DNA polymerase was 
added to each reaction volume. The Caco-2 cell line was used as a positive control 
and sterile water was used as negative control. The amplification cycles consisted of 
95 
o
C for 3 minutes, 35 cycles of 95 
o
C for 20 seconds, 60 
o
C for 20 seconds and 72 
o
C for 1 minute with final extension at 72 
o
C for 5 minute. To determine P-
glycoprotein band, about 10 µL of amplified samples were electrophoresed on 2% 
agarose gel in TAE buffer for 60 minute at 80 volt. The gel was stained with 30 µL 
74 
 
gel red in 100 µL of TAE buffer and the amplified bands were visualised under 
ultraviolet light.   
 
3.1.8.3 Enzymatic digestion for C3435T polymorphisms 
 
A 20 µL of reaction consisted of 10x buffer, 2 units of Mbo-1 enzyme (New England 
BioLabs Inc, Ipswich MA), pure water and 10 µL of PCR product obtained from 
previous step was set on ice. After incubation overnight at 37
o
C, the amplification of 
DNA was analysed by agarose gel electrophoresis using standard procedures where 
10 µL of amplified samples were electrophoresed on 2.5% agarose gel in TAE buffer 
for about 60 minute at 80 volt. The gel was stained with gel red (30 µL in 100 µL 
TAE buffer) and the amplified bands were visualised under ultraviolet light. The 
final genotype bands were examined by two independent investigators. Enzymatic 
digestion with 2 units of Mbo-1 that had been performed to analyse C3435T 
polymorphism would be yielded products of one band (197 bp) for homozygous 
3435TT, 158 bp (3435CC) and two bands (197 and 158 bp) for heterozygous 3435CT 
genotype [386].  
 
3.1.9 CYP2C19 polymorphisms 
 
An additional work of CYP2C19 genotyping was undertaken for a group of 
participants who were referred as “failure towards H. pylori eradication therapy”. 
Basically, a 25 µL of reaction volume consists of 1 µL of genomic DNA and 24 µL 
of reaction mixture containing Taq 2x MasterMix (New England BioLabs Inc, 
Ipswich MA), PCR grade water and oligonucleotide primers (Table 3-3) was 
prepared for CYP2C19*2 or CYP2C19*3 analysis and run in PTC-100™ 
Programmable Thermal Controller (MJ Research, Minnesota). Similar to the PCR 
work in determining MDR1 C3435T band, the amplification cycles consisted of 95 
o
C for 3 minutes, 35 cycles of 95 
o
C for 20 seconds, 60 
o
C for 20 seconds and 72 
o
C 
for 1 minute with final extension at 72 
o
C for 5 minute. About 10 µL of amplified 
samples were electrophoresed on 2.5% agarose gel in TAE buffer for 60 minute at 80 

















  Reference : [387]
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amplified CYP2C19*2 (300 bp) or CYP2C19*3 (247 bp) bands were visualised 
under ultraviolet light. To determine whether the CYP2C19*2 band was present,  a 
20 µL of reaction consisted of 10x buffer, 2 units of restriction enzymes (SmaI, New 
England BioLabs Inc, Ipswich MA), pure water and 10 µL of the amplified PCR 
product of 300 bp was prepared and left for incubation overnight at 25
o
C. For 
CYP2C19*3, the enzymatic digestion was performed with 2 units of BamHI (New 
England BioLabs Inc, Ipswich MA) and incubated overnight at 37
 o
C. The reaction 
was electrophoresed on 2.5% agarose gel in TAE buffer for about 60 minute at 80 
volt, followed by the gel red staining before the amplified bands were visualised 
under ultraviolet light. As the restriction site is absent in the mutant alleles for both 
CYP2C19*2 and CYP2C19*3, the 300 or 247 bp of PCR product would not digested 
by the restriction enzymes [387]. The subjects were then classified into three 
different genotypes groups as follows: homozygous extensive metabolizer 
(CYP2C19*1/*1), heterozygous extensive metabolizer (CYP2C19*1/*2 or 
CYP2C19*1/*3) and passive metabolizes (CYP2C19*2/*2 or CYP2C19*3/*3). 
 
3.1.10 Statistical analysis 
 
Standard descriptive statistics (frequencies and percentages for categorical variables, 
median, means, standard deviations and ranges for variables measured on a 
continuous scale) were used to summarise the demographic data for the study 
participants. SAS® software version 9.2 (SAS Institute Inc. Carry North Carolina 
USA) was used in this study and in all analyses, p-value less than 0.05 was taken to 
indicate a statistically significant association. Differences in these variables between 
subjects who were H. pylori – positive and H. pylori – negative were examined and 
p-values calculated.  Similarly, differences in distribution of demographic variables 
across MDR1 C3435T polymorphisms were compared using Chi-square statistic. P-
glycoprotein expressions according to the MDR1 C3435T polymorphisms were 
compared between antrum and duodenum using a paired t-test. A regression model 
was used to identify any association of antrum and duodenum P-glycoprotein values 
with Helicobacter infection status and MDR1 genotype. The tables quoted raw 
medians of the P-glycoprotein expression but p-values (including the paired t-test) 




3.2 Phase 2: Helicobacter pylori attachment to gastrointestinal cell 
lines 
 
3.2.1 Caco-2 cell culture  
 
Originally, the human adenocarcinoma cell line (Caco-2) is supplied by American 
Type Culture Collection (ATCC; Manassas, VA, USA) in liquid nitrogen. Caco-2 
cell cultures are routinely maintained in Nunc 25 cm
2
 tissue culture flasks 
in Dulbecco's Modified Eagle's Medium (DMEM; Sigma-Aldrich New South Wales) 
supplemented with 10% foetal calf serum (FCS), 2 mM L-glutamine, 1 mM non-
essential amino acids and 100 U/mL penicillin/streptomycin antibiotic solution. The 
cell cultures were maintained in CO2 incubator at 37°C (5% CO2, 95% air 
atmosphere) with the culture media replaced every 2 days. 
 
Once the cell cultures reached around 90% confluence, the old culture medium was 
removed and cell lines were washed with PBS or saline. The solution then was 
aspirated out and trypsin-EDTA was added to detach cells from flask surface. The 
cell flask was then returned to the CO2 incubator for about eight minutes. Any 
floating cells that lifted from the bottom of the flask were viewed under the 
microscope. When most of the cells had lifted and were seen floating, a serological 
pipette was used to mix the solution in the flask. The clumping of any remaining 
cells was reduced by forcefully pipetting the mixture against side of flask for few 
times. After the final mixing of saline, trypsin and cells, the solution was transferred 
to a fresh conical tube containing of fresh DMEM growth medium to inactivate the 
trypsin. The conical tube was capped tightly and centrifuged at 1600 RPM for seven 
minutes. The supernatant was aspirated out after the centrifuging and a new DMEM 
growth medium was added to the remaining pellet. The pellet and growth medium 
were mixed using a sterile transfer pipette a number of times to attempt to dissociate 
clumping cells prior to seeding in few plates and flasks. To determining the number 
of cells in the suspension, a haemocytometer was used. A mixture consisting 25 µL 
of saline, 25 µL of 0.4% trypan blue and 25 µL of cell suspension was prepared. A 
heavy coverslip was placed over the counting surface and the hemocytometer 
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counting chamber was then placed on the microscope stage and viewed under 100 x 
magnifications for the total cells calculation. After cell counting by haemocytometer, 
about three to four drops of cells suspension was transferred into a new 25 cm
2
 tissue 
culture flask for passage maintenance. A 3.5 mL DMEM growth medium was added 
and the flask was returned to the CO2 incubator. Cells in the flask were fed again by 
changing growth media approximately once every two days and passaged once it 
reaches the 90% confluence. For the purpose of this study, a 96-well plate (black) 
was fed with 2000 cells per well. The 96-well plate was feed for every other day for 
19 to 21 days before it was ready for the bacterial adherence experiment. 
 
3.2.2 LS174T cell culture 
 
LS174T cells are also human adenocarcinoma cells and are used as another human 
gut cell line for our bacterial attachment study. LS174T cells were acquired from 
ATCC and grown in 25 cm
2
 flasks in growth media containing 10% foetal calf serum 
(FCS), 2 mM L-glutamine, 1 mM non-essential amino acids and 100 U/mL 
penicillin/streptomycin antibiotic solution.  LS174T cells also were seeded into 96-
well plates at 2000 cells per well and incubated for 9 days. All cell cultures were 
maintained in CO2 incubator at 37°C (5% CO2, 95% air atmosphere) with the growth 
media replaced every 2 days. A 96- well plate and 25 cm
2
 flasks were seeded with 
LS174T cells. 
 
3.2.3 Bacterial cultures 
 
Two strains of H. pylori causing gastric cancer, namely G27 (NCBI 563041) and J99 
(ATCC 700824) were donated by the Helicobacter pylori Research Laboratory, 
University of Western Australia. H. pylori strain G27 has been used extensively in H. 
pylori research [388]. Each strain was grown on a blood agar plate enriched with H. 
pylori-selective supplement (Dent, Oxoid, Australia). All the blood agar plates were 
incubated at 37 °C under microaerobic conditions (90% CO2, 4% N2, 2% H2) for five 
to seven days upon the experiment. The aerobic bacteria (Escherichia coli W (ATCC 
9637) and Staphylococcus aureus (ATCC 6538) were stored in nutrient broth at 4 °C. 
Upon the experiment, all aerobic bacteria were inoculated onto nutrient agar plates 
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and incubated for 24 to 48 hours at 37 °C. All nutrient agar and nutrient broth used in 
this study were obtained from Oxoid (Adelaide). 
 
3.2.4 BacLight green preparation 
 
All bacteria colonies were scraped from their agar plates and suspended in 10 mL of 
cold sterile phosphate buffered saline (PBS, Sigma-Aldrich, New South Wales). The 
bacteria suspension was then centrifuged at 4000g for 10 minutes. Each bacterial 
pellet was re-suspended in 1000 µl cold PBS and pipette tips were used to resuspend 
the pellet before being transferred to microcentrifuge tubes. A 9 µl of a 100 µM 
BacLight Green solution in DMSO Molecular Probes (Eudene, Oregon USA) was 
added to each of the bacterial suspensions in each centrifuge tube to give a final dye 
concentration of 900 nM. The BacLight Green bacterial stain is a fluorescent labeling 
reagent for detecting and monitoring live bacteria. Bacteria stained with the BacLight 
Green will exhibit bright green fluorescence (absorption/emission about 480/516 
nm). These tubes were incubated for 1 hour at 37 °C in a rotating incubator at 650 
RPM.  The samples were subsequently centrifuged at 11 000g for 5 minutes, 
aspirated and washed with multiple times of cold PBS. After the final wash, the 
pellets were re-suspended in PBS to the final volume of 1 mL.   
 
For the bacterial attachment study with the presence of P-glycoprotein inhibitor, 
Hepes Balanced Salt Solution (HBSS) was prepared. A tube containing 30 mL of 
HBSS and 10%  foetal calf serum (FCS) and a combination of HBSS, FCS and 4 µM 
PSC-833 (valspodar) were also prepared. To make up bacterial solution, two 
eppendorf tubes were prepared for each bacteria strain. One eppendorf tube 
contained HBSS, FCS and bacterial solution while the other eppendorf tube 
contained HBSS, FCS, bacterial solution and PSC-833.  
 
3.2.5 Rapid bacteria count 
 
A new 96- well plate was used for rapid bacteria count. 100 µL of cold PBS was put 
to the beginning of each row followed by 100 µL of each bacterial solution. 
Doubling dilution was conducted along each well of the row where the bacteria 
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solution was added. The absorbance measurement was read at 415 nm wave length 
using a TECAN Sunrise™ (TECAN Group Ltd, Switzerland) 96-well plate reader 
using the Magellan 3 software for Windows 2000. Bacterial cell count was 
determined from the absorbance of 400 nm. 
 
3.2.6  Bacterial attachment study 
 
3.2.6.1  Caco-2 cells and P-glycoprotein expression inhibition 
 
A potent P-glycoprotein inhibitor, PSC-833 (valspodar) was used in this study. 21 
day old Caco-2 cells grown in black 96-well plates were used for bacterial 
attachment study. Medium was replaced with HEPES Balanced Salt Solution at pH 
7.4. The P-glycoprotein inhibitor, PSC833 was incubated with Caco2 cells for only 
30 minutes prior to the first bacterial incubation period to allow P-glycoprotein 
transport sites to be blocked prior to exposure to bacteria [389]. S. aureus and E.coli 
W were used as the positive controls as both bacteria may also colonize the 
gastrointestinal tract. 
 
One 96- well plate was used for one bacterial strain. The bacterial solutions were 
loaded into the black 96-well plates accordingly. Quadruplicate wells were each 
incubated with bacteria in growth medium for 30, 60, 90, 120, 180 and 240 minutes 
and incubated at 37 °C during this time period. Concurrently with bacterial 
attachment studies done at these time points, additional wells of the plate were 
incubated with PSC-833 to block P-glycoprotein function (Figure 3-1). Bacteria 
were also incubated at 30, 60, 90, 120, 180 and 240 minutes in here. Once the 
addition of bacterial solution to the cell lines at the required times had been 
completed, loosely associated bacteria were washed off from the well with at least 
three washes of cold PBS. Finally, a 96-well fluorescence plate reader (Fluostar 
Optima) from BMG LabTech (Mornington, Victoria) was used to detect fluorescent 
bacteria in these black 96-well plates. A 485 nm excitation filter and 520 nm 






Figure 3-1: The arrangement of bacteria solution in a 96- well plate seeded with Caco-2 cells with incubation period 





To check the bacteria stickiness to the well, another black 96-well plates was filled 
with each bacteria solution (with and without PSC-833) and incubated at 37 °C for 
about 60 minutes. After end of incubation period, the plate had its fluorescence 
measured using the Fluostar Optima before and after aspiration of the fluorescence 
bacteria. 
 
3.2.6.2 LS174T cells and P-glycoprotein expression inhibition 
 
Black 96- well plate was seeded with LS174T cells and grown up to ten days upon 
the experiment in a CO2 incubator at 37°C (5% CO2, 95% air atmosphere) with the 
growth media replaced every two days [375]. Similar method as in Chapter 3.2.6.1 
was utilized for bacterial attachment study in LS174T cells with the presence of P-
glycoprotein inhibitor, PSC-833. 
 
3.2.6.3 LS174T and P-glycoprotein expression induction  
 
In this current study, P-glycoprotein expression of LST174T cells was induced with 
rifampicin. After four days of seeding, growth media containing 10 µM rifampicin 
was given to the LST174T cells in black 96- well plate and parallel 25 cm
2
 flasks 
that had been used for collecting protein for Western Blot Analysis. The growth 
media containing rifampicin was replaced every 2 days. The LST174T cells were 
used after 6 days of exposure to rifampicin. For bacterial attachment study in 
LS174T cells with the presence of P-glycoprotein inhibitor (PSC-833), the method 
used was similar to Chapter 3.2.6.1. One 96-well plates was used for each bacteria 
strain and quadruplicate wells were used for each incubation period as the 
arrangement illustrated in Figure 3-2.  
 
In order to determine the influence of P-glycoprotein induction by rifampicin, P-
glycoprotein expression in 10 days old LS174T was measured by Western Blot 
Analysis. Each 25 cm
2
 flasks containing LS147T was feed either with rifampicin 
enriched growth media or normal growth medium. For protein collection, the growth 




Figure 3-2: The arrangement of bacteria solution in a 96- well plate seeded with LS174T cells with incubation period of 
30, 60, 90, 120, 180 and 240 minute.  Rifampicin was added into second half of the 96-well plates to induce P-






tissue cell lysis buffer was added into each flask to over the cells surfaces. After 10 
minutes, the cells were extracted out from the flasks and transferred into new 
centrifuge tubes. The tubes were sonicated for 10 minutes in sonicating water. After 
final centrifugation, the supernatant were collected from each tube and kept at -20 °C 
until the protein determination and Western Blot Analysis could be done. The 
Western Blot Analysis was performed based on the method outlined in Chapter 
3.1.7.3. ChemiDoc™ MP programme was used to determine the P-glycoprotein 
expression from Western Blotting 
 
3.2.7 Statistical analysis 
 
For bacterial attachment studies using Caco-2 cells, the fluorescence intensity for 
cells that has been incubated with 4 µM PSC-833 were compared to its control cells 
using student t-test. Results were presented as the mean ± standard deviation of 
quadruplicate well at each incubation period. SAS
®
 software (SAS Institute Inc.) was 
used in this study and in all analyses, p-values less than 0.05 were taken to indicate a 
statistically significant difference.  
 
For bacterial attachment studies using LS174T cells, the fluorescence intensity for 
cells that has been incubated with 4 µM PSC-833, 10 µM rifampicin or 4 µM PSC-
833 plus 10 µM rifampicin were compared to its control cells using student t-test. 
Results were presented as the mean ± standard deviation of quadruplicate well at 
each incubation period. SAS
®
 software (SAS Institute Inc.) was used in this study 



























This study was divided into two phases: Phase 1 (Helicobacter pylori and P-
glycoprotein expressions) and Phase 2 (Helicobacter pylori attachment to 
gastrointestinal cell lines).  
 
4.1 Phase 1: Helicobacter pylori and P-glycoprotein expression 
 
4.1.1 Participant`s demographic 
 
In this phase of study, a total of 91 participants had been recruited. A total of 33 
participants have been classified as H. pylori –positive including 11 whom had been 
diagnosed with failure towards H. pylori eradication therapy. Another 58 participants 
were H. pylori – negative. Participant`s demographic based on their Helicobacter 
infection status has been summarized in Table 4-1. Table 4-2 demonstrates the 
indication for endoscopy.  
 
The distribution of endoscopy findings is illustrated in Figure 4-1. Most of study 
subjects demonstrated spectrum of normal upper gastrointestinal tract anatomy 
during their endoscopy (normal endoscopy, n = 34, 37%). In relation to the age 
group, most subjects with normal endoscopy came from 40-49 years old (n = 9, 
26.5%) followed by 60-69 years old (n = 8, 23.5%) and 50-59 years old (n = 7, 
20.6%) as opposed to younger subjects (20-39, n = 4, 11.8%) and older age group 






Table 4-1: Demographic characteristic of study subjects according to H. pylori 
infection status 
 




n = 33 (36.3%) 
H. pylori-negative 
n = 58 (63.7%) 
Gender Male 14 (42.4%) 28 (48.28%) 0.48 
Female 19 (57.6%) 30 (51.72%) 
Age 20-29 3 (9.09%) 4 (6.89%) 0.78 
30-39 4 (12.12%) 5 (8.62%) 
40-49 8 (24.24%) 13 (22.41%) 
50-59 4 (12.12%) 12 (17.24%) 
60-69 6 (18.18%) 14 (24.14%) 
70-79 5 (15.15%) 6 (10.34%) 





9 (27.27%) 6 (10.34%) 0.025 




CC 9 (27.27%) 11 (18.96%) 0.334 
CT 12 (36.36%) 31 (53.45%) 
TT 12 (36.36%) 16 (27.58%) 
Use of proton 
pump 
inhibitor 
Yes 10 (30.30%) 27 (46.55%) 0.034 














Abdominal pain 66 2 (2.19%) 
Epigastric pain 56.5 8 (8.79%) 
Anaemia 58.7 10 (10%) 
Dyspepsia 50.2 13 (14.28%) 
Dysphagia 58.3 7 (7.69%) 
Varices 58.9 9 (9.89%) 
Bleeding 51.7 3 (3.3%) 
Malignancy 45.1 11 (12.09%) 
Ulcer 63 5 (5.49%) 
Abdominal imaging 68.6 7 (7.69%) 
Others Anorexia 53.7 1 (1.1%) 
Atypical chest pain 1 (1.1%) 
Barret`s syndrome 1 (1.1%) 
Cough 1 (1.1%) 
Diarrhoea 3 (3.3%) 
Duodenal biopsy 1 (1.1%) 
Gastroparesis 1 (1.1%) 
Heartburn 1 (1.1%) 
Reflux syndrome 1 (1.1%) 
Stricture 1 (1.1%) 
Vomiting 1 (1.1%) 




















































Participants were required to answer two questions upon the endoscopy procedure. 
The answer for the questionnaire was populated in Table 4-3. Overall, most of the 
participants did not know whether they were ever tested for H. pylori (41.76%, n = 
38). Only 32.97% of the participants (n = 30) stated that they were tested for the 
bacterial infection while the remaining 25.27% of the participants (n = 23) have not 
received any test for H. pylori. On the other hand, nearly quarter of the participants 
(24.17%, n = 22) acknowledged to receive treatment for H. pylori infection. About 
34.1% of the participants (n  = 23) stated that have not received any treatment for H. 
pylori before the recruitment. Again, most of the participants did not know whether 
they were ever treated for H. pylori (41.76%, n = 38). 
 
 
Table 4-3: Distribution of answer for all questionnaires 
 








  (n = 33) (n = 58)  





Yes 13 (39.39)] 17 (29.31%) 0.4474 
No 9 (27.27%) 14 (24.14%) 
I don`t know 11 (33.33%) 27 (46.55%) 
 








  (n = 33) (n = 58)  





Yes 12 (36.36%) 10 (17.24%) 0.0757 
No 10 (30.30%) 21 (36.21%) 






4.1.3 Helicobacter pylori infection status 
 
All the antral biopsies collected upon the endoscopy were sent to the laboratory to 
determine H. pylori infection status based on culture and polymerase chain reaction 
(PCR). In addition, few antral biopsies have been sent off to the pathology laboratory 
for histology and the result was obtained from participant`s medical record. For those 
H. pylori - resistance subjects, the gastroenterologist also had performed additional 
test (CLOtest) in the endoscopy suite, however their antral biopsies still went to the 
laboratory for culture and PCR.  
 
Figure 4-2 shows the positive growth of H. pylori on blood agar after been cultured 
for four days. The example of PCR positive results using two different primers could 
be seen in Figure 4-3 and Figure 4-4. Overall, 33 of our subjects were diagnosed as 
H. pylori-positive. The total positive cases came from the combination of various 
tests conducted here in our laboratory as well as in the recruitment site. In our 
laboratory, 23% (n = 21) of our subjects were detected positive based on bacteria 
culture. By using PCR, the percentage of positive subjects was increased to 30.76% 
(n = 28). In addition, 10 antral biopsies were sent to the hospital laboratory for 
histology and only one was confirmed positive for H. pylori infection. A number of 
subjects (n = 14) also underwent CLOtest during their endoscopy procedure and all 








Figure 4-2: Example of positive growths of Helicobacter pylori on blood agar after been cultured for four 
days at 37 °C under microaerobic conditions (90% CO2, 4% N2, 2% H2).  (Picture courtesy of Chin Yen 











Figure 4-3: Example of primary amplication of vacA gene of Helicobacter pylori specific sequences using vacA 1 and 
vacA 2 primers in antral biopsies with 100 bp ladder as molecular marker. Lane 1, 3 were negative; lane 2, 4, 5, 6 








Figure 4-4: Example of primary amplication of 16S rRNA gene of H. pylori specific sequences using 16S rRNA primers in 
antral biopsy specimens with 100 bp ladder as molecular marker. Lane 1 was negative and lane 2, 3, 4 and 5 were 





4.1.4 Protein analysis 
  
The protein concentration was determined using a Micro-Lowry Method using 
TECAN Sunrise 96 well plate spectrophotometer and Magellan 3 software before 
been used running protein analysis on Western Blot. The example of Western Blot 
gel and its P-glycoprotein expression is illustrated in Figure 4.5.  
 
The statistical analysis was divided into two parts; the first one was for the first 76 
participants recruited in this study. While the second part of the data analysis only 
concentrated on the group of participants (n = 15) who were recruited from the 
referral list due to resistance to H. pylori eradication therapy. 
 
4.1.4.1 P-glycoprotein expression in antrum and duodenum 
 
In the 76 subjects recruited in the first part of this study, there was a significant 
difference between P-glycoprotein expression in antrum and duodenum (medians 
218 vs. 797, p < 0.0001) as illustrated in Figure 4.6. The P-glycoprotein expression 
in the duodenum was found to be higher than that in the antrum.  
 
4.1.4.2 P-glycoprotein expression and Helicobacter pylori 
infection status  
 
In 76 subjects, a significant difference in P-glycoprotein expression between H. 
pylori positive and H. pylori negative subjects (means ratio of antrum to duodenum: 
0.38 ± 0.19 vs. 0.29 ± 0.15, p = 0.028) was detected [Figure 4.7]. The P-glycoprotein 
expression in H. pylori positive was found to be higher than that in the H. pylori 
negative subjects. That ratio of P-glycoprotein expression was not influenced by the 
proton pump inhibitor taken by the subjects prior to the endoscopy (p = 0.171). 
Gender or age also had no influence on P-glycoprotein expression in the antrum or 










Figure 4-5: Expression of P-glycoprotein in subject 1 to subject 6. 
Representative western blot gel showing P-glycoprotein expression in antral (A) 
and duodenal (D) biopsies with two different Caco-2 passages as positive 
controls (upper figure). The expression of P-glycoprotein was detected by 
incubating the blot membranes with PgP Sc13131 Mdr [G-1] mouse monoclonal 
IgG2b antibodies. The mouse anti-B-actin was used as control to normalize the 
gel loading and western blot transfer (middle figure). Relative P-glycoprotein 
expression level in antrum and duodenum according to the each subject (1 to 6) 











































Figure 4-6: The distribution of P-glycoprotein expression in antrum and 
duodenum from overall subjects (n = 76). Antrum: medians (218), mean (452), 










































Figure 4-7: Comparison of P-glycoprotein expression (log antrum / duodenum) 







4.1.5 Influence of MDR1 C3435T polymorphisms 
 
The blood DNA quantification was obtained using a Biospec-Nano 
spectrophotometer (Shimadzu Biotech New South Wales) at 712 nm with TE buffer 
as blank solution for all samples. Using the blood DNA, the C3435T polymorphism 
band was yielded followed by the enzymatic digestion with 2 units of Mbo-1 enzyme 
to produce one band (197 bp) for homozygous TT, 158 bp for homozygous CC and 
two bands (197 and 158 bp) for heterozygous CT genotype (Figure 4-8).  
 
A regression model was used to identify if there was any difference between MDR1 
genotype and P-glycoprotein levels from antrum (Table 4-4). The heterozygous 
subjects demonstrated to have an intermediate level of P-glycoprotein expression 
when compared to the homozygous (CC and TT) although the different was not 
statistically significant (p = 0.1049). However, based on the paired t-test, the 3435TT 
genotype appeared to have a significantly lower P-glycoprotein expression than 
3435CC subjects (p = 0.041). 
 
Figure 4-9 illustrates the distribution of homozygous (CC and TT) and heterozygous 
(CT) subjects with H. pylori-positive and H. pylori-negative in relation to P-
glycoprotein expression (antrum to duodenum ratio). There was an increasing trend 
in P-glycoprotein expression linked to the presence of H. pylori for all the genotypes, 
however only the homozygous TT subjects demonstrated a statistically significant 
difference in their P-glycoprotein when compared between H. pylori –positive and – 








Figure 4-8: MDR1 C3435T bands determined by PCR-RFLP using blood DNA of subjects 1 to 9 (upper figure). MDR1 C3435T SNPs 
after Mbo-1 incubation as determined by PCR-RFLP using blood DNA of subjects 1 to 9 (lower figure) where two bands indicated 








Table 4-4: P-glycoprotein expression in antrum and MDR1 C3435T genotype 
 




Pair wise p-values 
     CT TT 
Antrum CC 15 383.4 (61.4) 0.1049 0.075  
 CT 38 274.3 (31.6)    





























Figure 4-9: Comparison of P-glycoprotein ratio (antrum/ duodenum) according to MDR1 genotype (CC, CT and TT) and Helicobacter 





4.1.6 Helicobacter pylori treatment resistance and CYP2C19 
polymorphisms 
 
Out of 91 participants that had been recruited, 15 of them had been referred as 
“failure towards H. pylori eradication therapy”. Those 15 patients were treated with 
either Nexium HP7 or Klacid HP7 regimen previously. Among them, only 11 were 
tested positive for H. pylori upon referral based on CLOtest and culture.  
 
Table 4-5 shows the demographic characteristic of resistance subjects in comparison 
to the H. pylori-negative subjects. Antibiotic sensitivity profile for 11 participants 
with H. pylori positive and had failed their eradication therapy is given in Table 4-6. 
Details of their medication regimens taken pre- and post-referral are listed in Table 
4-7. Their P-glycoprotein levels were determined using Western Blot Analysis 
(Figure 4-10). Most of the subjects demonstrated resistance to clarithromycin (72%) 
and metronidazole (63.6%). No resistance to amoxicillin, tetracycline or 
ciprofloxacin was observed in any of our subjects and rifampicin resistance was 
limited to one subject. Six of our subjects (54.5%) demonstrated resistance to both 
metronidazole and clarithromycin. Interestingly, two subjects demonstrated no 
antimicrobial resistance despite a history of repeated treatment failure. 
 
Based on the enzymatic digestion with SmaHI (Figure 4-11) or BamHI (Figure 4-
12), the study subjects were classified into five different allelic patterns as follows: 
homozygous for wild type alleles (*1) in exons 4 and 5 (*1/*1), heterozygous 
extensive metabolizers for the CYP2C19*2 polymorphism without the CYP2C19*3 
polymorphism (*1/*2), heterozygous extensive metabolizers the CYP2C19*3 
polymorphism without the CYP2C19*2 polymorphism (*1/*3), homozygous passive 
metabolizers for the CYP2C19*2 polymorphism without the CYP2C19*3 
polymorphism (*2/*2) and homozygous passive metabolizers for the CYP2C19*3 











Variable Helicobacter pylori status p-value 
H. pylori- 
treatment 
resistant (n = 11) 
H. pylori – 
negative 
(n =  54) 
Gender Male (%) 3 (27 %) 25 (46%) 0.44 
Female (%) 8 (73%) 29 (54%) 
Age Mean (SD) 46.8 (10.4) 55.7 (16.1) 0.09 











Table 4-6: Resistance profile for participants with H. pylori - positive whom failed their eradication therapy 
 
Participant CLOtest Culture Antibiotic minimal inhibitory concentration 
MZ AC TC CI RI CH 
1 Positive Positive R S S S R R 
2 Positive Positive S S S S S S 
3 Positive Positive R S S S S R 
4 Positive Positive R S S S S S 
5 Positive Positive R S S S S R 
6 Positive Positive R S S S S R 
7 Positive Positive S S S S S S 
8 Positive Positive R S S S S R 
9 Positive Positive R S S S S R 
10 Positive Positive S S S S S R 
11 Positive Positive S    S S S S R 
 Antibiotic sensitivity testing was performed by E-test (Biodisk) for amoxicillin (AC), clarithromycin (CH), metronidazole (MZ), tetracycline (TC), 
rifampicin (RI) and ciprofloxacin (CI).  
 R for resistance and S for sensitive strains 
 Resistance was defined according to National Committee for Clinical Laboratory Standards for antibiotic minimal inhibitory concentration (MIC) : AC, 











1  Nexium HP7 + Regimen A++ 
2  Nexium HP7 + Regimen A++ 
3           Nexium HP7 + Regimen A++ 
4              Nexium HP7 + + Metronidazole Regimen A++ 
5            Metronidazole Regimen B+++ 
6           Nexium HP7 + Regimen A++ 
7 Nexium HP7 + Regimen B+++ 
8 Nexium HP7 + Regimen A++ 
9 Nexium HP7 + Regimen A++ 
10 Nexium HP7 + Regimen A++ 
11 Nexium HP7 +                             Regimen C++++ 
+ Nexium HP7 consists of esomeprazole, amoxicillin and clarithromycin, Klacid HP7 consists of clarithromycin, amoxicillin and omeprazole 
++ Regimen A consists of rabeprazole 20 mg (3 times daily for 10 days), amoxicillin 1000 mg (3 times daily for 10 days), ciprofloxacin 500 mg 
(starting from day 6, 2 times daily for  5 days) and rifabutin 150  mg (starting from day 6, 2 times daily for 5 days) 
+++ Regimen B consists of rabeprazole 20 mg (3 times daily for 10 days), bismuth subcitrate 240 mg (4 times daily for 10 days), ciprofloxacin 500 
mg (2 times daily for 10 days) and rifabutin 150 mg (2 times daily for 10 days) 
++++ Regimen C are consists of rabeprazole 20 mg (3 times daily for 10 days), amoxicillin 1000 mg (3 times daily for 10 days) and metronidazole 







Figure 4-10: Western blot showing P-glycoprotein expression from antrum (A) and duodenum (D) of study subject 1 to 6 (upper 
figure) with B-actin as a loading control. The relative quantities was determined using densitometry from CoolSnap HQ charge-
coupled device camera and presented as P-glycoprotein expression (antrum over duodenum ratio) (bottom figure). Subject 1-4 








Figure 4-11: Gel electrophoresis for the CYP2C19*2 analysis. The PCR-RFLP of exon 5 digested overnight with 








Figure 4-12: Gel electrophoresis for the CYP2C19*3 analysis. The PCR-RFLP of exon 4 digested overnight with BamHI for 









Figure 4-13: The distribution of resistant subjects according to five different allelic patterns of CYP2C19 genotypes. 
(A) Homozygous for wild type (Wt) alleles (*1) in exons 4 and 5 (*1/*1). (B) Heterozygous extensive metabolizers 
(EM) for the CYP2C19*2 polymorphism without the CYP2C19*3 polymorphism (*1/*2). (C) Heterozygous extensive 
metabolizers the CYP2C19*3 polymorphism without the CYP2C19*2 polymorphism (*1/*3). (D) Homozygous passive 
metabolizers (PM) for the CYP2C19*2 polymorphism without the CYP2C19*3 polymorphism (*2/*2).(E) Homozygous 
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4.1.7 Helicobacter pylori treatment resistance: P-glycoprotein 
expression and MDR1 C3435T polymorphisms 
 
A total number of 15 subjects were referred due to H. pylori eradication therapy 
failure. Only 11 participants were confirmed positive for H. pylori and subsequently 
resistant towards H. pylori therapy (H. pylori- treatment resistant). Table 4-8 and 
Figure 4-14 show the demographic characteristic and P-glycoprotein expression 
levels in antrum of resistant and H. pylori-negative groups, respectively. For both H. 
pylori- treatment resistant and H. pylori-negative groups, the P-glycoprotein 
expression was higher in the duodenum rather than in antrum (p = 0.027).  
 
The mean of P-glycoprotein expression (antrum over duodenum) among H. pylori- 
treatment resistant subjects was found higher when compared to the H. pylori-
negative group (mean P-glycoprotein expression 0.37 vs. 0.29, p = 0.0361) 
suggesting that the P-glycoprotein increases with presence of H. pylori. The P-
glycoprotein expression in H. pylori- treatment resistant subjects was compared to 
the subjects that were also H. pylori- positive but yet to receive any eradication 
therapy (H. pylori – positive - treatment naïve, n = 22). There was no difference of P-
glycoprotein expression observed between the H. pylori-positive- treatment naïve (n 
= 22) and H. pylori- treatment resistant (n = 11) groups (p = 0.319).  
 
In the H. pylori- treatment resistant group, all the MDR1 C3435T genotypes showed 
an increasing trend of P-glycoprotein expression with the presence of H. pylori 






Table 4-8: Demographic characteristic of H. pylori-treatment resistant and H. pylori-negative groups 
 
Variable Helicobacter pylori status p-value 
H. pylori- treatment resistant 
(n = 11) 
H. pylori – negative 
(n = 54) 
Gender Male (%) 3 (27 %) 25 (46%) 0.44 
Female (%) 8 (73%) 29 (54%) 
Age Mean (SD) 46.8 (10.4) 55.7 (16.1%) 0.088 
Range 35-68 23-88 
MDR1  
3435 C>T genotype 
3435CC 5 (45.45%) 11 (20.37%) 0.138 
3435CT 3 (27.27%) 29 (53.7%) 














Figure 4-14: The differences in P-glycoprotein expression (antrum over 
duodenum) between the H. pylori- treatment resistant subjects (n = 11, mean P-
glycoprotein = 0.37) and H. pylori - negative subjects (n = 54, mean P-









Figure 4-15: The differences in P-glycoprotein expression (antrum over duodenum) according MDR1 C3435T genotypes (CC, CT 






4.2 Phase 2:  Helicobacter pylori attachment to gastrointestinal cell 
lines 
 
4.2.1 Caco-2 cells and bacterial attachment study  
 
All the Caco-2 cells used in this study were grown in a 25 cm
2
 flask and fed every other 
day with DMEM + 10% FCS. Once the cells achieved 90% confluence, the cells were 
split and seeded onto 96-well plates and fed with growth medium up to 21 days. In this 
study, potent P-glycoprotein inhibitor (PSC-833) was used to assess the influence of P-
glycoprotein expression towards attachment of two different strains of H. pylori. The 
intensity of bacterial fluorescence represented the bacteria remaining associated with the 
human cell monolayers after the washing steps. 
 
Overall, both strains of H. pylori showed an increasing bacterial attachment to Caco-2 
cells over the 4 hour study period (Figure 4-16 and Figure 4-17). H. pylori G27 
demonstrated significantly higher bacterial attachment to Caco-2 cells at 30, 90, 180 and 
240 minute when PSC-833 was introduced compared to the control cells (p < 0.05). 
While H. pylori J99 was also observed to have higher bacterial attachment to Caco-2 
cells, significantly at 90 and 180 minute in the presence of P-glycoprotein inhibitor 
compared to the control Caco-2 cells (p < 0.05). Increase bacterial attachment to Caco-2 
cells over 4 hour study period was also observed with E. coli and S. aureus (Figure 4-18 
and Figure 4-19). For E. coli, the differences between bacterial attachment to Caco-2 
cells with and without PSC-833 were significant at 60, 90, 180 and 240 minute (p < 
0.05). Whilst S. aureus demonstrated marked high bacterial attachment to Caco-2 cells 








Figure 4-16: 4 hour study of BacLight Green labelled H. pylori G27 attachment to 
the Caco-2 cells grown for 21 days in a 96-well plate. Control Caco-2 cells (filled 
diamond) was compared to the Caco-2 cells that was incubated with 4 µM of PSC-
833 (filled square) the 30, 60, 90, 120, 180 and 240 minute incubation period. 
Results shown are the mean ± standard deviation of quadruplicate wells (minus 
blank) at each time point. * p < 0.05 illustrates significantly higher fluorescence for 
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Figure 4-17: 4 hour study of BacLight Green labelled H. pylori J99 attachment to 
the Caco-2 cells grown for 21 days in a 96-well plates. Control Caco-2 cells (filled 
diamond) was compared to the Caco-2 cells that was incubated with 4 µM of PSC-
833 (filled square) the 30, 60, 90, 120, 180 and 240 minute incubation period. 
Results shown are the mean ± standard deviation of quadruplicate wells (minus 
blank) at each time point.  p < 0.05 illustrates significantly higher fluorescence for 
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Figure 4-18: 4 hour study of BacLight Green labelled E .coli W attachment to the 
Caco-2 cells grown for 21 days in a 96-well plates. Control Caco-2 cells (filled 
diamond) was compared to the Caco-2 cells that was incubated with 4 µM of PSC-
833 (filled square) the 30, 60, 90, 120, 180 and 240 minute incubation period. 
Results shown are the mean ± standard deviation of quadruplicate wells (minus 
blank) at each time point. p < 0.05 illustrates significantly higher fluorescence for 
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Figure 4-19: 4 hour study of BacLight Green labelled S. aureus attachment to the 
Caco-2 cells grown for 21 days in a 96-well plate. Control Caco-2 cells (filled 
diamond) was compared to the Caco-2 cells that had been incubated with 4 µM of 
PSC-833 (filled square) during the 30, 60, 90, 120, 180 and 240 minute incubation 
period. Results shown are the mean ± standard deviation of quadruplicate wells 
(minus blank) at each time point. * p < 0.05 illustrates significantly higher 
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4.2.2  LS174T cells and bacterial attachment study  
 
All the LS174T cells used in this study were grown in a 25 cm
2
 flask and fed every other 
day with DMEM + 10% FCS. Once the cells achieved the 90% confluence, the cells 
were split and seeded onto 96-well plates and fed with growth medium up to 10 days. 10 
µM rifampicin was given to half of LS174T cell lines in the 96-well plates to induce P-
glycoprotein expression. Similar to the Caco-2 cells and bacterial attachment study, 
potent P-glycoprotein inhibitor (PSC-833) was also used to assess the influence of P-
glycoprotein expression towards attachment of two different strains of H. pylori. S. 
aureus and E. coli W were used as positive controls in this study.  
 
The bacterial attachment of both H. pylori G27 and J99 strains to LS174T cell lines 
were found to be unaffected by the levels of P-glycoprotein expression (Figure 4-20 and 
Figure 4-21). There was no difference found between three treatment conditions and the 
control cells for H. pylori G27 and J99 strains. Initially, binding of H. pylori G27 and H. 
pylori J99 to the control LS174T cell lines were reduced at the 60 minute of incubation 
period. After that, both H. pylori G27 and J99 strains managed to overcome the P-
glycoprotein barrier formed in LS174T cells. In contrast, E. coli W demonstrated 
significantly more bacterial attachment to the LS174T cells that have been pre-incubated 
with PSC-833 at 90, 120, 180 and 240 minutes than the control cell lines (p < 0.001).  
There was no significant difference found between bacterial attachment to the LS174T 
cells that have been pre-incubated with rifampicin and the control cells at all time points 
except for 180 minutes as shown in Figure 4-22. Additionally, the pre-incubated 
rifampicin treated LS174T cells with PSC-833 showed significant difference of the E. 
coli W attachment when compared to the control cells at all time points except for 30 
and 60 minutes.  
 
In this study, S. aureus showed significantly less bacterial attachment to the LS174T 
cells that have been pre-incubated with rifampicin than the control cell lines at 90, 120, 
180 and 240 minutes (p < 0.001).  S. aureus also demonstrated significantly more 





than the control cell lines at all time points (p < 0.001) as shown in Figure 4-23. Further, 
the pre-incubated rifampicin treated LS174T cells with PSC-833 showed significant 
difference of the S. aureus attachment when compared to the control cells at all time 









Figure 4-20: 4 hour study of BacLight Green labelled H. pylori G27 attachment to 
the LS174T cells grown up to 10 days in a 96-well plate. Control LS174T cells 
(filled diamond) was compared to the LS174T cells that was incubated with 4 µM 
of PSC-833 only (filled triangle), LS174T cells that was incubated with 10 µM of 
rifampicin only (filled square) and similar pre-incubated rifampicin treated 
LS174T cells with 4 µM PSC-833 (cross) during the 30, 60, 90, 120, 180 and 240 
minute incubation period. Results shown are the mean ± standard deviation of 
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Figure 4-21: 4 hour study of BacLight Green labelled H. pylori J99 attachment to 
the LS174T cells grown up to 10 days in a 96-well plate. Control LS174T cells 
(filled diamond) was compared to the LS174T cells that was incubated with 4 µM 
of PSC-833 only (filled triangle), LS174T cells that was incubated with 10 µM of 
rifampicin only (filled square) and similar pre-incubated rifampicin treated 
LS174T cells with 4 µM of PSC-833 (cross) during the 30, 60, 90, 120, 180 and 240 
minute incubation period. Results shown are the mean ± standard deviation of 
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Figure 4-22: 4 hour study of BacLight Green labelled E. coli W attachment to the 
LS174T cells grown up to 10 days in a 96-well plate. Control LS174T cells (filled 
diamond) was compared to the LS174T cells that was incubated with 4 µM of PSC-
833 only (filled triangle), LS174T cells that was incubated with 10 µM of rifampicin 
only (filled square) and similar pre-incubated rifampicin treated LS174T cells with 
4 µM of PSC-833 (cross) during the 30, 60, 90, 120, 180 and 240 minute incubation 
period. Results shown are the mean ± standard deviation of quadruplicate wells 
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Figure 4-23: 4 hour study of BacLight Green labelled S. aureus attachment to the 
LS174T cells grown up to 10 days in a 96-well plate. Control LS174T cells (filled 
diamond) was compared to the LS174T cells that was incubated with 4 µM of PSC-
833 only (filled triangle), LS174T cells that was incubated with 10 µM of rifampicin 
only (filled square) and similar pre-incubated rifampicin treated LS174T cells with 
4 µM of PSC-833 (cross) during the 30, 60, 90, 120, 180 and 240 minute incubation 
period. Results shown are the mean ± standard deviation of quadruplicate wells 
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4.2.3 Induction of P-glycoprotein expression in LS174T cell lines 
 
Although it has been confirmed in two separate publications [389, 582] that rifampicin 
at 10 µM for a week exposure can vastly increase P-glycoprotein expression, still it was 
considered important to confirm P-glycoprotein expression in paired control cells and 
parallel to the bacterial attachment study. P-glycoprotein over-expression test would 
prove that the cells in the bacterial attachment experiment did indeed have high P-
glycoprotein levels. Thus to confirm the induction of MDR1 gene by rifampicin, 
LS174T cells were treated with rifampicin in this study. The P-glycoprotein expression 
was determined by western blotting. The relative expression of P-glycoprotein in 10 
days old LS174T cells and in 10 days old LS174T cells following 6 days exposure to 10 
µM rifampicin were measured.  
 
The data from both LS174T cell lines were compared to 21 days old Caco-2 cells as 
illustrated in Figure 4-24. It was clear that based on the densitometry, the 10 days old 
LS174T cells (sample 1) have shown the lowest P-glycoprotein level as compared to the 
10 days old LS174T cells following 6 days exposure to 10 µM rifampicin (sample 2) 
and Caco-2 cells (sample 3). The control LS174T cells had a relatively low expression 
of P-glycoprotein when grown without any P-glycoprotein inducer. It was found that the 
P-glycoprotein expression in LS174T cells that was induced by rifampicin became 
nearly 3.7- fold higher than the control LS174T cells. Nevertheless, pre-incubation of 
LS174T cells with rifampicin did not increase P-glycoprotein levels beyond that of the 
Caco-2 cells. Caco-2 cells proved to have significant quantities of P-glycoprotein 
expression, about 20-30% higher than LS174T cells induced by rifampicin and 5–fold 









Figure 4-24: Expression of P-glycoprotein in 10 days old LS174T cells (sample 1), 
in 10 days old LS174T cells following 6 days exposure to 10 µM rifampicin (sample 
2) and 21 days old Caco-2 cells (sample 3). The expression of P-glycoprotein was 
detected by incubating the blot membranes with PgP Sc13131 Mdr [G-1] mouse 
monoclonal IgG2b antibodies. The mouse anti-B-actin was used as control to 
normalize the gel loading and western blot transfer. Graph shows relative P-







































































This study was divided into two phases: Phase 1 (Helicobacter pylori and P-
glycoprotein expression) and Phase 2 (Helicobacter pylori attachment to gastrointestinal 
cell lines). 
 
5.1 Phase 1: Helicobacter pylori and P-glycoprotein expression  
 
5.1.1 Participant demographics 
 
It was initially anticipated that it would be possible to recruit 200 participants in one 
year for our research based on the number of patients referred for upper gastroendoscopy 
at Sir Charles Gairdner Hospital in 2009. However, the number of patients reduced in 
2010 and 2011 as more patients were referred for the lower gastroendoscopy rather than 
upper endoscopy. Despite this 91 subjects were recruited which provided an adequate 
sample size to give good precision to the prevalence estimate of P-glycoprotein 
expression in H. pylori–positive patients. 
 
Dyspepsia was the most common indication for endoscopy in our study followed by 
anaemia and epigastric pain. Keren et al [390] reported that dyspepsia and anaemia 
remain the commonest reasons of endoscopy referral, especially in patients aged more 
than 45 years old. Dyspepsia refers to chronic or recurrent pain centered in the upper 
abdomen [391]. The prevalence of dyspepsia is around 20-40% of the population and 
majority of them presented with functional dyspepsia [392]. As one of the criteria for 
functional dyspepsia is epigastric pain or epigastric burning [393], this may explain of 
why patients with epigastric pain were commonly referred for upper gastroendoscopy. 
Further, epigastric pain is a common organic symptom of gastro-oesophageal reflux 
disease (GORD) and peptic ulcer disease that should not be ignored [394]. Meanwhile, 





cause of anaemia with or without iron deficiency [395]. Iron deficiency anaemia occurs 
in less than 5% of adults but increases to 7% in geriatric patients [396]. Iron deficiency 
anaemia due to chronic blood loss is usually undetectable and becomes pronounce only 
when patients become symptomatic [397]. Endoscopy is a sensitive test for investigating 
the source of gastrointestinal bleeding; it can determine the cause of anaemia in between 
30 and 50% of patients [398]. 
 
In this study, the 40 to 49 years age group has the highest rate of participation followed 
closely by the 60 to 69 and 50 to 59 years age group. It was expected to see this age 
pattern as endoscopy is recommended for dyspeptic patients over the age of 45 or those 
with certain alarm symptoms such as weight loss, recurrent vomiting, dysphagia, 
bleeding or anaemia [399]. Patients with dyspepsia who are younger than age 50 and 
without alarm features are commonly evaluated by one of three methods namely 
noninvasive testing for H. pylori, a trial of acid suppression or an initial endoscopy 
[400]. Although an age of 45 years appears to be a reasonable threshold for endoscopy, 
physicians should remain aware of the possibility of malignancy in younger patients and 
provide an early endoscopy if required [401]. Even if it is still unclear whether early 
endoscopy is necessary in cases of undiagnosed dyspepsia, one study did recommend 
endoscopy be undertaken in dyspeptic patients as young as 40 years of age to prevent 
undiagnosed gastric cancer cases in these younger patients [402]. Another study also 
suggested that the age threshold for endoscopy should be lowered in men in view of 
higher risk of cancer as opposed to women [403].  
 
Normal upper gastrointestinal tract anatomy (normal endoscopy) was the most common 
finding in our study, followed by peptic ulcer disease. The higher percentage normal 
endoscopies among the younger participants compared to the older group was similar to 
the findings of Aduful et al [404]. It has been shown that dyspepsia is strongly 
associated with normal endoscopy [405]. Hence, with an open-access system and high 
number of referrals for dyspepsia, it is not surprising a normal endoscopy finding was 
common. Kerrigan et al [406] reported that as many as 40% of upper gastrointestinal 





not be dismissed as it may rule out serious upper gastrointestinal disease diagnosis. It 
also provides strong reassurance of good health for both patients and medical 
practitioners leading to less empirical therapy and reduced medication costs.  
 
Endoscopies have been reported to detect peptic ulcer disease in about 5.3% of 
dyspeptic Canadians and 15.7% of Danes [407]. Peptic ulcer disease is commonly 
associated with H. pylori infection and the increased use of non-steroidal anti-
inflammatory drugs (NSAIDs) since the 1950`s [408]. The American Society for 
Gastrointestinal Endoscopy (ASGE) recommends for upper gastroendoscopy to 
investigate peptic ulcer disease in patients aged more than 50 with new onset of 
dyspepsia, as well as in patients of any age with alarm symptoms including a family 
history of gastrointestinal malignancy, unexplained weight loss and anaemia [400].Over 
the past 15 years the incidence of peptic ulcer disease, duodenal ulcer and duodenitis 
cases world-wide have been reported to have significantly decreased following the 
introduction of proton pump inhibitors and better endoscopic techniques for the early 
disease detection [409]. The decrease in peptic ulcer disease cases has also been 
attributed to better standards of living affecting H. pylori transmission and wider use of 
empiric antibiotics [410].  
 
About 40% of our participants were using proton pump inhibitors pre-endoscopy.  
Pantoprazole remains the most common proton pump inhibitor used among our 
participants as opposed to esomeprazole and omeprazole. Proton pump inhibitors are 
normally prescribed in acid-related gastrointestinal disorders such as GORD, peptic 
ulcer disease and Zollinger-Ellison syndrome [411]. They are also indicated for the 
treatment of or prophylaxis against ulcers related to NSAIDs and as part of H. pylori 
eradication regimens. Pantoprazole was listed among 100 most costly drugs to 
Australian Government [412]. Both 20 mg and 40 mg pantoprazole have been 
demonstrated to be safe and effective in managing GORD [413]. It has been reported 
that pantoprozole provided prompt symptomatic relief in most patients with upper 






5.1.2 Helicobacter pylori: participant awareness and acceptance of 
screening or treatment (Questionnaire) 
 
The prevalence of H. pylori infection in Australian adults is lower than other developed 
countries [415]. This bacterial infection is most common amongst adults living with low 
socio-economic disadvantage or who were born overseas. Public awareness and 
acceptance towards screening of H. pylori are still limited although people have received 
information about the bacterium through the media [416]. Nevertheless, despite the 
perceived lack knowledge of H. pylori, it has been reported that most people would have 
screening for the bacterium if the opportunity existed. 
 
In order to evaluate participants’ awareness and acceptance of screening or treatment for 
Helicobacter pylori infection, two short questions were asked of our participants before 
they were prepared by the nurses for their gastroendoscopy. Almost half of the 
participants knew they have been tested and/or treated for H. pylori infection; the 
remainder did not or was unsure.  In all cases the screening would have been done by 
their general practitioner before being referred for an upper gastroendoscopy procedure. 
Currently, screening for H pylori does not occur at a state or national level within 
Australia [417]. Based on the Maastricht III consensus, patients are usually not offered 
H. pylori screening unless they are present with active peptic ulcer disease; 
uninvestigated dyspepsia without bleeding, anaemia, unexplained weight loss, 
progressive dysphagia, early satiety, recurrent vomiting, odynophagia, family history of 
gastric cancer or a previous oesophagogastric malignancy [for patient age less than 45 
years old]; low grade MALT lymphoma; after endoscopic resection of early gastric 
cancer or first degree relative with gastric cancer [418]. As H. pylori population 
screening would involve range diagnostic options (invasive methods or serologic tests), 
its cost, convenience and accuracy may vary. 
 
H. pylori screening is more preferred in the older age groups although the benefits of 
eradicating the bacterium in an asymptomatic population have yet to be established 





low-risk of gastric cancer, such as Australians and New Zealanders [420]. Screening for 
H. pylori, which has been linked to the future development of gastric cancer, is now 
considered to be an important tool in cancer prevention [421]. It has the potential to be 
cost-effective in the prevention of gastric cancer, particularly in high-risk populations 
[422]. Therefore, screening and eradication of H. pylori in populations at high-risk of 
gastric cancer are warranted [423], and this may include the indigenous populations of 
Australia and New Zealand [424-425].  
 
5.1.3  Helicobacter pylori infection status 
 
5.1.3.1 Specimen collection and transport 
 
H. pylori commonly reside in the stomach, particularly in the antral region [4]. At 
endoscopy, a sample from an area of a normal looking tissue should be taken from the 
antral region, approximately 2 cm away from the pylorus. Taking an area that has been 
affected by erosions or ulceration may limit the number of H. pylori present due to the 
damage to the epithelium or deprivation of the mucosa layer [426].  
 
Upon collection, our antral biopsy specimens were inoculated in sterile broth consisting 
of brain heart infusion broth 2% (BHI) with 20% glycerol before being transferred to the 
laboratory for H. pylori culture. All of our biopsies were sent to the laboratory within 
three hours after the specimen collections for bacterial culture. All the specimens in BHI 
broth were kept on dry ice before been transported to the laboratory. As H. pylori is very 
sensitive to dry conditions, rapid specimen transportation is crucial in order to maximize 
the diagnostic yield [427]. Previous reports had suggested the use of various transport 
and storage conditions to improve H. pylori recovery from gastric biopsies including 
Stuart`s media and glycerol containing media [428-429]. It has been shown that the 
recovery rates of H. pylori from gastric biopsies can be correlated with the storage time 
prior to culture, regardless of whether the specimen is kept in BHI or not [430]. In 
general, transport at a low temperature is essential to get sufficient H. pylori recovery 






5.1.3.2 Bacterial culture 
 
Transit time upon specimen arrival at the laboratory has been recognized as one of the 
major limitations for H. pylori recovery, therefore biopsies should be cultured within 4 
to 24 hours [429]. Ideally, at least four biopsies should be cultured but it has been 
reported that about 95% of H. pylori can be yielded from just one antral biopsy [431]. H. 
pylori is a relatively slowly growing bacterium and could be overgrown by the other 
organisms found in the biopsy [432].  
 
Overall, about 23% of samples we tested were positive for H. pylori infection based on 
positive cultures. A prolonged incubation period and correct atmosphere conditions for 
H. pylori also helped in yielding a satisfying outcome in our study. At first, the agar 
plates containing biopsies smears were left for about three days in a dedicated CO2 
incubator with daily inspection to see any growth. Some plates showed H. pylori growth 
after five days while others required longer incubation periods. According to Yin et al 
[433], prolonged incubation is necessary for certain strains of H. pylori, although a 10 
days incubation was sufficient for H. pylori growth on a non-selective media and shorter 
times were required with selective media [434]. All the plates with positive growth were 
re-cultured for a second and third time in order to get a clean and pure H. pylori colony 
for subsequent identification analyses.  
 
By using dry ice to immediately freeze samples upon endoscopy and keep them frozen 
until they went into the -80°C freezer, we were able to culture H. pylori from the 
biopsies (3 positives from 10 biopsies) even though the samples had been stored for 
more than three months. Evidence has shown that the bacteria recovery is better at a 
storage temperature of -70 °C than -20 °C [428]. It has been reported that freezing 
biopsy specimens might result in decreased H. pylori colony counts [435], however 
others have suggested that the loss is related to the initial number of organisms rather 
than the freezing duration [436]. Meanwhile, long term frozen specimens require a 





results in the H. pylori growing slowly [437]. However, in our study the use of a 
specialised laboratory that only focused on H. pylori work, dry ice to preserve the 
integrity of biopsies, shorter times between sample collection and analysis, combined 
with prolonged culture plate incubation periods contributed to good H. pylori recovery 
rates. 
 
5.1.3.3  Polymerase chain reaction 
 
One limitation in using a culture method to yield H. pylori is that the bacterium has a 
patchy distribution in the stomach [438]. Therefore, using bacterial culture alone may 
fail to detect the H. pylori especially if a small biopsy is used. H. pylori may also exist in 
coccoid forms and these forms may escape detection by culture [439]. Culture provides 
a good outcome in detecting H. pylori infection but does require a certain length of time 
for the bacteria isolation and subsequently delays the treatment implementation [440]. 
 
For those reasons, all our specimens were also tested for presence of H. pylori by 
polymerase chain reaction [PCR] detecting the vacA and 16S rRNA genes. All of the H. 
pylori culture-positive specimens were also tested positive using PCR. This resulted in 
the number of samples confirmed as H. pylori positive increasing to 30.7%, 
demonstrating that the PCR assay was a more sensitive method compared to culture; 
which is in agreeance with the literature. In determining H. pylori infection status, PCR 
is regarded as having the highest diagnostic sensitivity, followed by histology, culture 
and the rapid urease test [440]. However, the use of PCR in detecting H. pylori infection 
from gastric biopsy specimen requires good laboratory expertise and technical handling 
[441].  
 
A good technique for the DNA extraction from tiny biopsies is mandatory to ensure the 
collection of an adequate amount of DNA while making sure that the DNA is not 
damaged and remains uncontaminated to avoid any false-positives from the fragmented 
DNA. There are a number of methods of DNA extraction from biopsies including the 





boiling method yields much less DNA than phenol-chloroform extraction [445] but the 
latter is time consuming, toxic and may contaminate the resultant nucleic acid [446]. In 
this study, EDNA-Hispex
TM
 (Saturn Biotech, Western Australia) was used to extract the 
DNA from the biopsy samples and the absorbance method was used to determine 
bacterial DNA concentration and level of DNA purification. By using the EDNA-
Hispex
TM
, we were able to extract between 55 to 200 ng/µL of nucleic acid, more than 
enough for the PCR assay. Although the PCR assay used has the ability to detect copies 
of nucleic acid sequences at a very low level, a suitable PCR condition must be 
established to optimize the DNA fragment amplification [447]. For instance, the 
presence of in vivo Taq polymerase inhibitors may influence the assay result [448], 
hence the ‘Hot Start’ activation was applied in our PCR assay. The ‘Hot Start’ method 
avoids any non-specific DNA amplification by inactivating the Taq polymerase at lower 
temperature to improve the PCR performance [449-450]. Using a 35 cycles yielded a 
sufficient product in our PCR assay although it is recommended to use longer cycles - up 
to 45 cycles- to detect low copy number targets [450].  
 
In view of greater accuracy of detecting the H. pylori by PCR is depending on the 
primers used [451], the suitable choice of primers must be planned carefully to avoid 
any false positive or false negative results. We used two different set of primers that 
gave two specific bands: –  109 bp (16s rRNA) and 700 bp (vacA) and a pure H. pylori 
DNA sample (H. pylori 26695, courtesy of Ondek Pty Ltd, Australia) was employed as 
the internal control. We observed that all our PCR positive samples showed positive 
bands for both 16S rRNA and vacA. The 16s rRNA was chosen to differentiate H. pylori 
from other Campylobacter strains [452] while vacA gene is present in all H. pylori 
strains [453]. Both vacA and 16S rRNA have been reported to have equal sensitivities, 
99% and 98% respectively, in detecting H. pylori from biopsies [380]. Additionally, the 
16S rRNA gene PCR assay has been shown to have a very high sensitivity, in that it is 
able to detect as little as 0.01 pg of H. pylori DNA or approximately five organisms 
[454]. A satisfactory PCR assay is accepted when the internal control and/or the H. 
pylori band are visible on the agarose gel [455]. False negative and false positive 






In our study, the PCR assays were performed using 0.1 µg of purified H. pylori DNA 
with the optimal MgCl2 concentration of 2.5mM. The PCR assay was repeated twice to 
avoid any false positive or false negative results. We also observed a stronger specific 
signal for DNA extracted from a pure H. pylori culture compared that from H. pylori-
positive specimens obtained from biopsy. Unlike Chisholm et al [380], we did not 
observe the presence of non-specific bands that are believed to originate from the pool 
of DNA from human biopsies. This may be due to the high purification level of DNA in 
our study. It is important as any presence of non-specific bands may interfere with the 
assay sensitivity due to competition between co-amplification of the targeted and non-
targeted DNA fragments.  
 
5.1.3.4 Histology and rapid urease test   
 
Histology was not a routinely used to investigate H. pylori status in our study. Out of the 
10 samples from our study cohort that were sent to the hospital pathology laboratory, 
only one was confirmed positive by histology. The histology was requested by the 
gastroenterologist upon the endoscopy for various reasons. The biopsies for histology 
examination were embedded in fixed paraffin and transported in phosphate buffered 
formalin to the hospital pathology laboratory.  
 
In practice, paraffin-embedded specimens are usually stained with haematoxylin–eosin 
for morphologic examination and detection of Helicobacter-like organisms [456]. The 
histological identification of H. pylori infection includes modified Giemsa, Warthin-
Starry, Gimenez, Genta and immunohistochemically staining using polyclonal 
antibodies to H. pylori. The latter is regarded as the gold standard for histology due to its 
high specificity for H. pylori identification [457]. Histology also has been regarded as 
the least accurate method in detecting H. pylori as it is depended on the examiner`s 
expertise [458] and sampling variation [459]. There were discrepancies in whether 
histology is reliable in detecting H. pylori in view of its sensitivity and specificity as 





has been reported that sensitivity and specificity of histology may reach up to 95% 
especially when two or more biopsies are used [463]. Although the cost of conducting 
histology and PCR are similar, the former method requires considerable time to provide 
a result as opposed to short turn-around time using PCR [464].  
 
Nearly 47% of our participants who underwent rapid urease test (CLOtest) were 
confirmed positive for H. pylori. The rapid urease test is conveniently conducted in the 
endoscopy suite and is recommended as the first choice as the result is obtained within 
hours [465]. The test is based on the principle of urease that has been released by H. 
pylori catalyzing the hydrolysis of urea into ammonia and subsequently increasing the 
local pH [466]. It has been reported that the rapid urease test has a high specificity but 
low sensitivity [467]. However, a comparison study showed that CLO test kit (Delta 
West Pty Australia) could detect the presence of H. pylori from the biopsies that tested 
negative by culture [468]. This discrepancy may be due to the fact that the rapid urease 
test sensitivity is dependent on the bacteria load in the biopsies as well as the total level 
of urease production and number of biopsies used [469]. 
 




It has been thought that gender-differences in P-glycoprotein expression contributed to 
the disparity in level of P-glycoprotein expression [470]. In this study, we demonstrated 
that gender had no influence to the human gastrointestinal P-glycoprotein expression 
which is in agreement with other researchers [471, 472]. Maclean and colleagues [473] 
also reported no gender specific differences in P-glycoprotein expression observed along 
rats’ intestines. Unlike intestinal P-glycoprotein, hepatic P-glycoprotein expression has 
been shown to be two-fold higher in males than females [474]. For instance, the 
elimination of verapamil, a P-glycoprotein substrate, is faster in women than men [475]. 
The difference in verapamil pharmacokinetics may be due to P-glycoprotein expression 





CYP3A4 [476]. Hence, gender may contribute part of variable drug responses and drug 
toxicities of P-glycoprotein substrates but the exact mechanism is still controversial.  
 
Given the potentially important effects that age may have on P-glycoprotein expression 
in intestine which may subsequently influence the pharmacokinetics of certain drugs, we 
also studied the difference of P-glycoprotein expression across age groups. Our study 
did not demonstrate any significant changes in P-glycoprotein expression levels across 
the various age groups based on analysis of antral and duodenal P-glycoprotein samples. 
There is a report suggesting that P-glycoprotein expression levels in the upper part of the 
intestine increase with age in type 2 diabetes obese mice associated with monosodium 
glutamate treatment [477]. However, we could not find any similar literature pertaining 
to the association between age and human intestinal P-glycoprotein expression.  
  
Unlike the gastrointestinal tract, altered P-glycoprotein expression and function 
associated with ageing has been demonstrated in blood brain barrier and peripheral 
blood lymphocytes [478]. Pilarski et al [479] demonstrated that P-glycoprotein on T and 
B lymphocytes to be lowest during childhood then increased towards adulthood before 
decreasing again after age 60. Another study in healthy subjects aged 0 to 86 years 
showed that P-glycoprotein expression in peripheral blood lymphocytes was highest in 
cord blood and declined progressively with age [480]. Decreases in P-glycorprotein 
expression at the blood brain barrier have also been associated with ageing [481]. For 
example, increases in the volume of distribution of verapamil in the range of 18% to 
38% were observed with normal ageing within several brain regions, such as frontal, 
temporal, medial temporal and anterior and posterior cingulate regions. The increased 
volume distribution was suggested to be caused by the combination of higher 
permeability and decreased P-glycoprotein function associated with ageing [482-483].  
 
In this study, we observed that P-glycoprotein expression was significantly higher in the 
duodenum than the antrum. This finding is in agreement with the others who have 
investigated P-glycoprotein activity along the gastrointestinal tract [484-485]. It is 





tissue with respect to the orally administered drugs, particularly for those given in 
controlled compound release preparations [486]. The small intestine represents the 
principal site of absorption for most ingested compounds including therapeutic and toxic 
substances [487]. The expression of P-glycoprotein has been observed to increase 
progressively by up to 5-fold from the proximal to the distal region of the small intestine 
and its corresponding mdr1 mRNA has also been detected [473,488]. The expression of 
P-glycoprotein has also been found to increase from the duodenum to colon. Like P-
glycoprotein, other transporters such as BCRP\ABCG2 have also been found throughout 
the small intestine and colon. Unlike P-glycoprotein, MRP2 expression has been 
reported to be highest in the duodenum and subsequently to decrease to become 
undetectable towards the terminal ileum and colon [489]. 
 
Originally it was thought that it may be useful to use blood samples to predict the P-
glycoprotein expression in liver or intestine in our study; however results from the 
literature are inconclusive regarding the value of using P-glycoprotein expression in 
peripheral blood mononuclear cells [490]. For example, Albermann and colleagues 
[491] reported that there was no correlation between hepatic and intestinal P-
glycoprotein expression with peripheral blood mononuclear cells expression. For that 
reason, peripheral blood mononuclear cells were not used as an indicator for the 
transporter level in the intestine in our study. Instead, P-glycoprotein levels were directly 
determined from biopsy specimens.  
 
In our study, the levels of P-glycoprotein expression in the antrum and duodenum were 
not found to be influenced by proton pump inhibitor use prior to endoscopy. In this 
clinical setting, proton pump inhibitors such as omeprazole, lansoprazole and 
pantoprazole are commonly used to treat patients with acid related diseases including 
peptic ulcer disease and GORD [492]. The proton pump inhibitors are characterized as 
substrates and/or inhibitors for P-glycoprotein [493]. Therefore, proton pump inhibitors 
may influence both intestinal first-pass metabolism and hepatic clearance [494]. As most 





endoscopy, it was important to determine whether this exposure had had any influence 
on P-glycoprotein expression. 
 
5.1.4.2 P-glycoprotein expression in presence of Helicobacter pylori 
 
Our study showed that P-glycoprotein expression increased proportionally along the 
gastrointestinal tract. P-glycoprotein along with many other proteins such as tight 
junction and trefoil peptides that are expressed by epithelial cells are directly or 
indirectly involved in maintaining the gut’s protective barrier [495]. Disturbances of the 
mucosa epithelial cells may lead to the development of mucosa inflammation, which 
triggers a variety of cellular responses in intestinal cell layers including P-glycoprotein 
expression which is amongst the first to defend the mucosa layers.  
 
In this study, we found that P-glycoprotein expression in the antrum was increased 
significantly in the presence of H. pylori. H. pylori mostly resides within the gastric 
mucous layer and the bacteria is exclusively detected in the surface mucous layer, which 
becomes thinner in the infected stomach [496]. H. pylori is considered to be an 
extracellular pathogen and its attachment to gastric epithelial cells resembles that of the 
enteropathogenic Escherichia coli [497]. The bacterial attachment to human antral 
primary epithelial cells has been described by Heczko et al [498]. They reported that H. 
pylori was observed to display various morphological changes (between spiral, U-
shaped, donut and coccoid forms) as well as bacterial membrane enlargement during 
attachment giving rise to the unique features of H. pylori infection in the gastric mucosa. 
H. pylori might also induce cell cycle arrest by p53 expression interference and 
subsequently reduce the ability of damaged cells in vivo to repair significant cell injury 
[499].  
 
In this present study, we also demonstrated that the subjects who were H. pylori-positive 
and have received multiple courses of eradication therapy had higher P-glycoprotein 
expression (antrum over duodenum) compared to the control group (i.e. H. pylori 





is a transporter that facilitates excretion of substrates from the systemic circulation into 
the gut lumen [500], the high levels of expression seen in the study subjects could be 
explained as an attempt by the gut mucosa to protect itself against infection. It could also 
be a result of a stress-related induction of P-glycoprotein as has been suggested to occur 
in other tissues in the body such as in blood brain barrier [501]. The high levels of 
expression of P-glycoprotein in gut mucosa may also limit the absorption of drugs that 
are known to be P-glycoprotein substrates following oral administration, whilst at the 
same time protecting the host against any orally ingested toxins [502].  
 
In keeping with our data, there have been other reports related to P-glycoprotein 
regulation in the presence of endotoxin-induced inflammation in human and animal 
intestinal cells. For example, P-glycoprotein is believed to prevent the accumulation of 
inflammation-inducing bacteria such as Helicobacter spp. as demonstrated in knock-out 
mice with colitis [503]. Further, human MDR1 mRNA expression has been reported to 
increase in Caco-2 cells treated with proinflammatory cytokines and macrophages, yet 
the mRNA expression of CYP3A4 was found to be decrease [504]. In contrast, the 
activity of intestinal P-glycoprotein in rats was found to be reduced during acute 
inflammation [505]. Similarly, interleukin-10 deficient enterocolitis mice also had 
reduced P-glycoprotein expression along the intestine [506]. As inflammation usually 
follows enterotoxin bacterial invasion, these last two reports suggest the act of 
inflammation may counter any direct increase of P-glycoprotein expression. 
Nevertheless, with H. pylori infection, we found that the efflux protein was found 
expressed more in the antrum which may be a mechanism to protect the membrane 
mucosa.  
 
5.1.4.3 Exploitation of P-glycoprotein expression in Helicobacter 
pylori eradication therapy 
 
Knowing that P-glycoprotein expression is increased in the presence of H. pylori raises 
the question is higher P-glycoprotein expression responsible for the H. pylori eradication 





influenced by P-glycoprotein activity as their subjects with higher basal P-glycoprotein 
tended to fail the eradication therapy. In a later study, Babic et al [507] reported H. 
pylori infection was associated with higher levels of P-glycoprotein expression, and 
those patients who experienced treatment failures had significantly higher levels 
compared to those who were treated successfully. They suggested that P-glycoprotein 
could be one of the causes treatment failure in patients with H. pylori and that is 
important to assess the P-glycoprotein expression before the starting the eradication 
therapy.  
 
Although increased P-glycoprotein levels may lessen the oral bioavailability of 
antibiotics which are substrates for P-glycoprotein (Figure 5-1), this action may 
potentially be beneficial in the case H. pylori eradication. More antibiotic will be 
available in the extracellular gastric mucus where H. pylori normally resides thus 
enhancing their local bacteriostatic or bacteriocidal effects. For example, macrolides 
produce bacteriostatic effect on H. pylori by inhibiting the ribosomal subunit in the 
bacteria cell to block the protein synthesis which later stops the bacteria from 
reproducing [508]. Macrolides at high concentrations may also demonstrate bactericidal 
activity [509]. As more P-glycoprotein gets expressed on the lumen cell mucosa it is 
possible that there are higher macrolide concentrations extracellularly leading to a 
bactericidal effect on the H. pylori.  
 
In our study, more than half of our subjects who had failed eradication therapy showed 
cross-resistance between metronidazole and clarithromycin. The dual resistance between 
macrolides and metronidazole is quite common and frequently reported [510-513]. 
Clarithromycin resistance is the main risk factor for the failure of first line therapy to 
eradicate H. pylori [514]. The efficacy of metronidazole-based triple therapies was 
reduced by 18-38% with metronidazole resistance [515]. About 90% of our resistance 
subjects were cured after been treated with second-line regimen consisting of rifabutin, 
amoxicillin and rabeprazole. Recently, Tay and colleagues [516] had demonstrated that 







Figure 5-1: Illustration of the possible implications of higher P-glycoprotein expression in the presence of Helicobacter 








quadruple therapy combinations of proton pump inhibitor, amoxicillin, rifabutin and 
ciprofloxacin. The eradication rate went down slightly to 94.2% by using the alternative 
quadruple therapy of proton pump inhibitor, bismuth subcitrate, rifabutin and 
ciprofloxacin.  Rifabutin is a derivative of rifamycin S [517] and is suggested to be an 
inducer for both P-glycoprotein and CYP3A4 as it is structurally related to rifampin 
[518]. Interestingly, rifabutin can inhibit H. pylori at very low concentrations [519] and 
its effects are not influenced by gastric pH [520]. With the current finding that H. pylori 
induces P-glycoprotein, high level of gut P-glycoprotein expression may then assist 
antibiotic eradication therapy for H. pylori as a protective mechanism which may be 
exploited through the use of P-glycoprotein inducers, such as rifabutin, in eradication 
regimens.  
 
Whilst use of rabeprazole in H. pylori eradication was found to achieve similar 
eradication rates as omeprazole or lansoprazole when given with amoxicillin or 
clarithromycin [521], rabeprazole gives more consistent and better symptom relief to the 
patients [522]. Amoxicillin has low H. pylori resistance rates [523]. It gives rapid 
accumulation on the antral mucosa [524] and the minimum inhibitory concentration 
reduces when the gastric pH increases [525]. Amoxicillin may destroy the bacterial 
membrane, causing transmembrane efflux system impairment, trapping the macrolides 
inside the cell [526]. High levels of intracellular macrolides would then prevent any final 
attempt by the bacteria to prevent damage to its ribosome.  
 
Although the resistance towards the H. pylori eradication may not occur as a result of P-
glycoprotein alone, the association of over-expression of these drug efflux transport 
protein and resistant subjects cannot be dismissed. Our study contributes to the findings 
that subjects with H. pylori infection do have elevated P-glycoprotein levels and 
therefore may be have an increase of risk of drug interactions that involve P-











MDR1 C3435T polymorphism has been associated with numerous diseases including 
gastric cancer [11] and breast cancer [527]. In this present study sought to investigate the 
association between this particular P-glycoprotein gene polymorphism and H. pylori 
infection, and its potential impact on eradication therapy.  
 
For the MDR1 C3435T polymorphisms, the distribution of CC, CT and TT alleles in both 
H. pylori-positive and H. pylori-negative groups were similar to that predicted from the 
literature [528-529] in that about half of the study population carry 3435CT allele and 
the other half carry either 3435CC or 3435TT allele. To the best of our knowledge, there 
is no other study available describing the MDR1 C3435T genotype distribution among 
Australians. Table 5.1 outlines the comparison between Australians recruited from our 
study and other ethnic groups regarding the allele frequencies for the MDR1 C3435T 
polymorphisms.  
 
Interestingly, a similar MDR1 C3435T distribution has also been observed in New 
Zealander and Asian (Malay and Chinese) populations. Close geography between 
Australia and New Zealand with other parts of South East Asia may explain this pattern 
of genotype distribution possibly due to high migration between these countries. The 
Singaporean population also showed the same pattern of MDR1 C3435T genotype 
distribution, where half of the studied population carries either heterozygous or 
homozygous allele, however the 3435CC frequency was lower than 3435TT [529].  
However, Li et al [529] study did not represent all ethnic groups from Singapore rather 
only those of Chinese origin were recruited; these Chinese are predominantly 
descendents of migrants from south China. Nevertheless, the described distribution of a 
functional single-nucleotide polymorphism in the human MDR1C3435T gene within the 






Table 5-1: Comparison between Australians and other ethnic groups regarding the 




Genotype frequency (%) Reference 
3435CC 3435TT 3435CT 
Australians 91 22% 31% 47% Current 
study 
Asians Malay 99 25% 28% 46% [528] 
Chinese 98 25% 32% 44% 
Indians 93 18% 43% 39% 
Chinese 265 32% 20% 48% [529] 
Iranians 126 53% 61% 42% [530] 
Indians 147 12% 52% 36% [531] 
Ecuadorians 317 25% 22% 53% [532] 
Romanians 102 25% 22% 54% [533] 
Singaporean 224 28% 22% 50% [534] 
New Zealander 160 21% 27% 52% [535] 
Japanese 114 35% 12% 53% [536] 
Polish 122 42% 17% 41% [537] 
French 81 35.8% 42% 22.2% [538] 












5.1.5.2 MDR1 C3435T polymorphisms and Helicobacter pylori 
infection 
 
In our study, P-glycoprotein expression in the antrum in H. pylori-positive and H. 
pylori-negative groups were found to be lowest in the 3435TT genotype, followed by 
3435CT and 3435CC genotypes, respectively. Overall, all the MDR1 C3435T genotypes 
showed an increased level of P-glycoprotein expression in the presence of H. pylori 
infection. Interestingly, the difference was most marked in 3435TT genotypes sub-group. 
This observation may explain the findings of Tahara et al [11] who reported that 3435TT 
genotypes have lower risk of gastric cancer. In their study, subjects with 3435TT 
genotype were found to be less likely to be infected with H. pylori or develop gastric 
cancer. Reduced prevalence of gastric cancer in the 3435TT genotype sub-group may 
then be a reflection of their ability to hyper-express P-glycoprotein in the presence of H. 
pylori infection thus enhancing its protective effect. 
 
All the MDR1 C3435T genotypes in our resistant subjects also showed increases in P-
glycoprotein expression in the presence of H. pylori, with the 3435TT carriers showing 
the greatest increases (p = 0.056). Unfortunately, our inability to recruit larger numbers 
of patients diminished the power of the study and our ability to demonstrate statistically 
significance differences. Nevertheless, this finding supports our earlier theory that 
3435TT carriers are capable of inducing more P-glycoprotein compared to other MDR1 
genotypes in the presence of H. pylori infection. Earlier, Tahara et al [11] reported that 
3435TT carriage was associated with a higher degree of atrophy and intestinal 
metaplasia. These authors agreed that MDR1 C3435T polymorphism influences H. 
pylori-related inflammation in the stomach, especially in older subjects. Meanwhile, 
3435CC carriage has been seen at higher frequencies amongst patients with advanced 
gastric cancer compared with healthy volunteers [540]. Interestingly, Gawrońska-
Szklarz et al [541] demonstrated that the 3435TT genotype was associated with 
successful eradication after the first cycle of triple therapy. Therefore, the ability to 





inflammatory conditions in the gut mucosa that are caused by the H. pylori and 
achieving better therapy outcomes.  
 
Our proposition requires further investigation as Sugimoto et al [12] showed that 
patients with 3435CT genotype made up nearly 50% of those patients with gastric cancer 
and no significant difference was observed in gastric cancer risk across the three 
genotypes. Similarly, Sabahi and colleagues [542] also demonstrated that no significant 
association between the gastric cancer and MDR1 genotypes in an Iranian population. 
Additionally, Salagacka et al [308] demonstrated that no significant difference was 
found in the genotype distribution between subjects with peptic ulcers and the healthy 
population, although the authors did observe a positive trend towards higher incidence of 
this disease among 3435TT carriers.  
 
As our study focused neither on peptic ulcer disease nor gastric cancer but rather on the 
presence of H. pylori and its influence on P-glycoprotein expression in the antrum and 
duodenum, this could explain the conflicting results between our study and other studies. 
Regardless, the increased capacity to induce P-glycoprotein in the presence of H. pylori 
among 3435TT carriers seen in our study has not been previously reported and this 
information could be important in understanding of why patients response differently 
towards their infections and eradication therapy. The use of MDR1 C3435T genotyping 
has yet to be fully explored, although it has been suggested earlier that the different 
distribution of the functional alleles of this gene within the different populations or 
diseases may be helpful in individualizing pharmacotherapy. However, these particular 
genotypes may be influenced by the ethnicity [543] and pervasive environmental factors 
such as alcohol consumption [544] adding to the difficulties in achieving a conclusive 
result on this matter.  
  
The risk of diseases such as renal and breast cancer have been demonstrated to be 
influenced by MDR1 C3435T, but little is known about H. pylori-related diseases [545]. 
As opposed to gastric cancer risk, a strong association between MDR1 C3435T and 





study in Iranian patients with ulcerative colitis [547]. Ulcerative colitis is an 
inflammatory bowel disease of unknown etiology and studies has been done to 
investigate whether Helicobacter strains may be a cause for this disease [548]. H. pylori 
has been isolated from the ulcerative colitis patients, however its presence was not found 
to be associated with the disease. This might be due to the fact that Helicobacter strains 
rarely colonize the lower part of human gastrointestinal tract, although several studies 
have demonstrated that some Helicobacter strains present in the gastrointestinal tract of 
mice can induce inflammation of the colon [549-550]. Using a more sensitive PCR 
assay, another study found that H. pylori strains were more frequently isolated in the 
intestinal mucosa of subjects with ulcerative colitis-like Crohn’s disease than in 
intestinal mucosa of the control group [551]. Though no other Helicobacter species were 
isolated from the intestinal mucosa, these authors agreed that this observation could be 
secondary to the genesis behind the Chron`s disease rather than present of H. pylori 
alone. 
 
It was reported earlier that 3435TT allele was associated with higher plasma levels of 
MDR1 substrates [189]; this may be beneficial in achieving better treatment outcome for 
some drugs whilst for others may increase the risk of toxicity. In a Japanese population, 
lansoprazole plasma levels were found to be influenced by the MDR1 C3435T 
polymorphisms [552]. In this study the 3435TT carriers showed the highest lansoprazole 
plasma level among the three MDR1 genotype groups during 15 days of drug 
administration, however interestingly no difference was seen in intragastric pH. It was 
concluded that MDR1 C3435T polymorphisms only influenced the drug 
pharmacokinetics rather than pharmacodynamics of lansoprazole. 
 
Gawronska-Szklarze et al [541] have reported the eradication rate of H. pylori was also 
found higher in Caucasians with 3435TT genotype than that in 3435CC subjects. 
However, the influence of ethnicity in MDR1 C3435T polymorphism was once again 
highlighted when a lower eradication rate was reported among 3435TT carriers when an 
H. pylori eradication regimen consisting of lansoprazole, clarithromycin and amoxicillin 





by Oh et al [351] who reported the lowest cure rates for H. pylori were achieved among 
3435TT carriers in Korea. These variations in the observations from studies from around 
the world suggest that MDR1 C3435T may not be the only predictor of the success of H. 
pylori eradication therapy. Hence, larger epidemiology studies are warrant to investigate 
the relationship between P-glycoprotein polymorphism and H. pylori eradication rates.  
 




Most proton pump inhibitors will undergo hepatic biotransformation via the hepatic 
cytochrome P450 2C19 isoenzyme [553]. The impact of the CYP2C19 pathway on the 
metabolism of proton pump inhibitors is most pronounce for omeprazole and 
esomeprazole followed by pantoprazole, lansoprazole and rabeprazole respectively. The 
differences for omeprazole and esomeprazole compared with other proton pump 
inhibitors are the result of their significant inhibition of CYP2C19, which is mainly 
responsible for their metabolic clearance [554].  
 
5.1.6.2 CYP2C19 genotype among resistance subjects 
 
In our study, only the pattern of distribution according to five different allelic patterns of 
CYP2C19 genotypes among resistance subjects was examined. Of these 38.1% of 
subjects were categorized as extensive metabolizers while another 33.3% were the 
passive metabolizers. In passive metabolizers, a splice defect in exon 5 (CYP2C19*2; 
single base change G>A), and a premature stop codon at position 636 of exon 4 
(CYP2C19*3; single base change G>A) are commonly observed where it will 
subsequently result in a truncated protein and an inactive enzyme. Therefore, in these 
subjects the area under the plasma concentration-time curve of omeprazole and 
esomeprazole should be markedly increased and the clinical effect of these proton pump 






There was no conclusive evidence from our study as to whether the different CYP2C19 
genotypes contributed to the success of H. pylori eradication therapy as it was limited by 
small number of subjects in each subgroup. The CYP2C19 genotyping was investigated 
based on the fact we were not able to demonstrate that MDR1 C3435T was the only 
factor that was influencing the outcome of H. pylori eradication. It would have been 
better if we were able to recruit a larger number of resistant subjects; however, this was 
not possible given the limited operating days of the Helicobacter clinic and small 
number of referrals for H. pylori treatment resistance.  
 
Nevertheless, based on the available literature, the efficacy of proton pump inhibitors in 
the treatment of H. pylori infections could be related to the CYP2C19 genotypes [556]. 
Furuta et al [555] suggested that CYP2C19 polymorphism affecting proton pomp 
inhibitor metabolism could impact on the chance of a cure in H. pylori-positive patients 
who were treated with a two week dual therapy regimen with omeprazole and 
amoxicillin. The cure rates for H. pylori infection in their study were only 28.6% in the 
extensive metabolizers as compared to 100% in the passive metabolizers. The influence 
of the CYP2C19 genotype on H. pylori eradication regimens containing omeprazole has 
also been demonstrated by report by Tanigawara and colleagues [557]. In a group of 108 
subjects who were treated with either quadruple treatment without a proton pump 
inhibitor, dual therapy with omeprazole and amoxicillin or triple treatment with 
omeprazole, amoxicillin and clarithromycin, they found that the H. pylori 
eradication rates for the extensive metabolizers were only 50% and 86% for the dual and 
triple treatments, respectively as opposed to 100 % in the passive metabolizers treated 
with omeprazole and antibiotics.  
 
In our study, rabeprazole was used to replace omeprazole or esomeprazole to eradicate 
H. pylori among resistance subjects. Rabeprazole is a newer proton pump inhibitor and 
although triple therapy with this proton pump inhibitor combined with amoxicillin and 
clarithromycin is effective, the eradication rate is not dependent on CYP2C19 genetic 
polymorphisms [558-560]. Previously, Horai et al [561] reported that CYP2C19 





However, a meta-analysis by Padol et al [562] stated that the impact of CYP2C19 
polymorphism on H. pylori eradication rates was only clinically important when subjects 
were prescribed with omeprazole as one of the components in their dual or triple therapy 
but not in the case of lansoprazole or rabeprazole. Such contradicted reports raise the 
question as why no impact on H. pylori eradication therapy have been demonstrated. 
 
Additionally, the CYP2C19*2 polymorphism occurs almost exclusively in Caucasians 
while the CYP2C19*3 occurs primarily in Asians [563]. In Caucasians and African-
Americans, about 2 to 3% of individuals can be characterized as passive metabolizers. In 
Asian populations, the percentage of passive metabolizer is about 15 to 20% [555]. 
Therefore, the large interindividual and interethnic variability in the pharmacokinetics of 
proton pump inhibitors may also be explained CYP2C19 genetic polymorphism. 
 
5.2 Phase 2: Helicobacter pylori attachment to gastrointestinal cell 
lines 
 
5.2.1 Bacterial attachment study with Caco-2 cell lines 
 
The ability of bacteria to adhere and colonize the gastrointestinal cells is important in 
their pathogenesis [564]. The bacteria also need to produce certain extracellular 
substances to help them invade cells to overcome any host defence mechanisms. Several 
agents including cyclosporine and its analogue valspodar (PSC-833) are capable of 
modulating and decreasing P-glycoprotein expression in vitro [565]. The approach of 
this current study was to abruptly block the P-glycoprotein expression in the Caco-2 
cells with a use of P-glycoprotein inhibitor with the purpose of understanding the 
bacterial attachment to the human gastrointestinal cells as has been done previously in 
the laboratory [389]. The extent of H. pylori attachment to Caco-2 cell lines were 
represented by the intensity of bacterial fluorescence that corresponded to the amount of 






In this study, a constant increase of H. pylori G27 and H. pylori J99 attachment to the 
control Caco-2 cells were observed over the 4 hour of incubation period. When PSC-833 
was introduced to the cell lines, further bacterial attachment was measured for both H. 
pylori strains. PSC-833 is a potent inhibitor of P-glycoprotein and displays a competitive 
manner by blocking the ATPase pump to inhibit P-glycoprotein function [567-568]. 
Defective efflux transport of P-glycoprotein subsequently allows more bacteria to attach 
to the cell lines. Further, it is known that the first step in bacterial infection is adherence 
and growth on the enteric epithelium surface with or without subsequent invasion of the 
cell [566]. Upon colonization, there is a transient period between 1 to 20 days of post-
infection prior to the establishment of H. pylori persistence [569]. Among the strategies 
utilized by H. pylori to survive and persist in the gastric lumen are the inhibition of the 
gastric epithelial cell apoptosis and compensatory gastric epithelial hyperproliferative 
responses [570]. An intracellular location of H. pylori in human gastric epithelial cells is 
probably uncommon in H. pylori colonization [571], however H. pylori also have been 
observed inside the infected epithelial cell lines [572]. Chu et al [573] found that H. 
pylori invaded the epithelial cell lines and multiplied either on the plasma membrane or 
in double-layer vesicles. For these reasons, P-glycoprotein is important as defence 
mechanism in the earlier stage during the bacterial attachment in which this efflux 
transporter is exquisitely positioned to resist further bacterial invasion or production of 
substances that are allegedly harmful. Our earlier results support the hypothesis that 
normal response to H. pylori infection is the increased expression of P-glycoprotein 
presumably to provide a protective barrier. 
 
The Caco-2 cells are known to express high levels of P-glycoprotein mRNA and protein 
[574]. Rahimifard et al [575] demonstrated that a number of H. pylori strains were able 
to attach to various cell lines including HepII, HeLa, SW742, AGS, HT29/219, HT29 
and Caco-2 cells. Interestingly, in that study, negligible H. pylori attachment was seen 
with Caco-2 cells. Taking into consideration that Caco-2 cells express high levels of P-
glycoprotein in comparison to other cell lines, the minimal H. pylori attachment to Caco-
2 cells may explain the early response to the bacterial colonization by P-glycoprotein in 





an increasing bacterial attachment to the control Caco-2 cells over the 4 hour incubation 
period. When PSC-833 was used to block P-glycoprotein function in Caco-2 cells, the 
bacterial attachment was considerably increased, in comparison with the corresponding 
control cell lines supporting that P-glycoprotein expression by the gut is important in 
maintaining homeostasis in the gastrointestinal tract through modulation of intestinal 
responses to H. pylori infection. 
 
Similar trends in bacterial attachment were observed when E. coli W and S. aureus were 
used in our study. Both bacteria were selected as positive controls as their attachment to 
Caco-2 cells were previously demonstrated to be significantly increased (up to 3 fold) 
when PSC-833 was introduced [389]. As E.coli W and S. aureus are commonly present 
in the gastrointestinal tract, it was concluded that P-glycoprotein expression may prevent 
the bacterial attachment to the human gastrointestinal tract, avert the bacterial toxicity 
and subsequently reduce the risk of gastrointestinal diseases. In another report, Caco-2 
cell lines were infected with enterohaemorrhagic E. coli O157 to determine whether the 
bacteria could penetrate the cells monolayers and translocate its verotoxin from the 
intestinal tract lumen to the underlying tissue to cause the haemolytic uraemic syndrome 
[576]. The strain of E. coli tested in that study was found not to penetrate the Caco-2 cell 
monolayer system to cause the infection. This finding can be explained by those of our 
study and Crowe [389] in which increased P-glycoprotein expressions was shown to 
restrict bacterial attachment, and hence reduce the potential for invasion. These findings 
emphasize the important role of P-glycoprotein as a protection barrier in the gut. 
 
S. aureus has been reported to adhere to the human colonic mucosa and its treatment 
could be complicated with emergence of antibiotic resistance among some strains [577]. 
Increased intestinal colonization is one of the causes for S. aureus treatment resistance 
[578]. As the first line of defence, intestinal epithelial cells make up a selectively 
permeable epithelial barrier function, preventing the uncontrolled passage of antigens 
and potentially harmful microorganisms from the intestinal lumen into the blood and 





of P-glycoprotein expression on the gastrointestinal cells are critical to function as 
barrier for initial bacterial attachment. 
 
5.2.2 Bacterial attachment study with LS174T cell lines 
 
The LS174T cell lines were established in 1974 from a moderately well differentiated 
primary colon adenocarcinoma by trypsinization of the parent cell line, LS180 [580-
581]. Certain drugs such as amprenavir, nelfinavir and ritonavir have been shown to 
strongly induce the P-glycoprotein level in LS174T cell lines [582]. The expression of 
P-glycoprotein is mediated by human pregnane X receptor (PXR), a member of the 
nuclear receptors superfamily encoded by NR112 [583]. In normal tissues, PXR is 
highly expressed in the liver and intestine to regulate CYP3A4 and MDR1 genes [574]. It 
has been reported that PXR is endogenously expressed in LS174T cells and rifampicin, a 
human PXR agonist induces MDR1 expression [575-576]. Similar to other studies 
[389,587], we were able to increase the level of P-glycoprotein expression in LS174T 
cells. However, both the control LS174T cells and rifampicin induced LS174T cells 
exhibited P-glycoprotein levels below that of the Caco-2 cells.  
 
As positive controls, both E. coli W and S. aureus demonstrated a significantly reduced 
attachment to LS174T cells when rifampicin was used to induce the P-glycoprotein 
expression. Our data matched that from study by Crowe [389] which demonstrated a 
decrease in bacterial attachment to the cell lines with rifampicin enhanced P-
glycoprotein expression. The decrease in bacterial attachment was completely reversed 
by the use of PSC-833, a P-glycoprotein inhibitor, leading to an increase in bacteria 
binding to the LS174T cell lines. Further, the greater influence on S. aureus attachment 
with LS174T could be due to effects on both bacterial adherence and invasiveness. S. 
aureus demonstrated a higher fluorescence level of bacterial attachment to the LS174T 
cells compared to E. coli due to it be an invasive pathogen compared to non-invasive E. 






Unlike E. coli W and S. aureus, the attachment of H. pylori G27 and H. pylori J99 in our 
present study seemed to be unaffected by the level of P-glycoprotein expression in 
LS174T cell lines. The differences in H. pylori attachment to the LS174T cell lines with 
that in the Caco-2 study may be explained by the amount of P-glycoprotein expression 
present in the cell lines themselves. As shown in our Western Blot Analysis, LS174T 
cells had less P-glycoprotein than Caco-2 cells even though rifampicin was used to 
induce the MDR1 expression. H. pylori might be able to escape the barrier function 
formed by the P-glycoprotein that has been shown to limit the bacterial attachment, in 
the absence of high P-glycoprotein expression. It is assumed that H. pylori would begin 
to attach to gastric epithelium lining once the P-glycoprotein expression falls below a 
certain threshold. Moreover, H. pylori is known to have the ability to undermine the 
innate and adaptive immune systems of the host by assuming different shapes during the 
initial colonization process [588]. H. pylori also has the ability to produce urease to 
elevate the pH of its environment. In that way, H. pylori may entirely escape the host 
defence mechanism. Without high P-glycoprotein expression available to prevent the 
bacteria from attaching to the gastrointestinal cells, a cascade of H. pylori proliferation 
and toxin secretion will facilitate disease development [589].  
 
The differences in H. pylori attachment to the LS174T cells and Caco-2 cells may also 
be explained by the different levels of mucin mRNA expression in these cell lines. Only 
part of the colonizing H. pylori attach directly to the epithelial cells as most of them stay 
in the mucus layer of the superficial gastric mucosa and bind to the highly glycosylated 
mucins [590]. The aggregation of H. pylori around mucins will protect the bacteria from 
the surrounding environment and immune factors in the gastric mucosa layer [591]. The 
gel-forming mucin, MUC2 is expressed in goblet cells of native intestinal epithelium 
and intestinal metastasis of gastric mucosa but not in the normal gastric epithelium 
[592]. In contrast, the MUC5AC gene is mainly expressed in the gastric mucosa. The 
LS174T cells expressed a relatively high MUC2 but low MUC5AC mRNA level. 
Meanwhile, the MUC5AC mRNA was highly expressed in the Caco-2 cells and its 
MUC2 mRNA level was too low. Altered expression of MUC2 was reported to be 
related to the development of colorectal cancer where MUC2 suppression was found to 






The exact underlying mechanism behind how P-glycoprotein prevents bacterial 
attachment remains unknown. P-glycoprotein may act as a conduit for cytoplasmic agent 
such as endogenous antimicrobial peptides to appear on the plasma membrane of cells 
[375]. If it is true, the action may be cell line specific, in that bacterial attachment would 
be inhibited depending on type of factors mediated by P-glycoprotein in those cells. It is 
possible that LS174T and Caco-2 cells have different expression of these yet to be 
determined factors. In general, H. pylori has been established as the major causative 
agent of human gastritis and is an essential factor in peptic ulcer disease and gastric 
cancer. Our study has demonstrated that the attachment of H. pylori to gastrointestinal 
cell lines is influenced by level of P-glycoprotein expression, which along with other 
factors such as the production of adherence factors and the ability to change shape 
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CHAPTER 6 SUMMARY OF FINDINGS, CONCLUSIONS, 
RESEARCH LIMITATIONS AND FUTURE RESEARCH 
RECOMMENDATIONS 
 
6.1 Summary of findings 
 
The primary aim of the study was to determine whether P-glycoprotein expression in the 
human gastrointestinal tract influences H. pylori eradication therapy. Specifically, the 
study aimed to answer the following questions: 
 Is there an association between P-glycoprotein expression and H. pylori 
infection?  
 What is the relationship between P-glycoprotein expression and its genetic 
variant, particularly MDR1 C3435T?  
 What is the influence of P-glycoprotein expression on H. pylori treatment 
resistance?  
 Is the extent of H. pylori binding to gastrointestinal epithelial cell lines 
influenced by the presence of potent P-glycoprotein inducers and inhibitors?  
 
This study was divided into two phases – Phase 1 (Helicobacter pylori and P-
glycoprotein expression) and Phase 2 (Helicobacter pylori attachment to gastrointestinal 
cell lines). For Phase 1, a total of 91 participants from Sir Charles Gairdner Hospital, 
Nedlands, Western Australia were recruited from October 2010 to July 2011. For each 
patient, antral and duodenal biopsies along with venous blood samples were obtained for 
the laboratory analysis. For Phase 2, Caco-2 and LS174T cells were used to determine 
H. pylori attachment to the gastric epithelial cells within certain incubation periods in 
the present of the P-glycoprotein inhibitor (PSC-833) and the inducer (rifampicin).    
 
It was found in Phase 1 that P-glycoprotein expression was induced by H. pylori in the 
upper gastrointestinal tract. Further, the 3435TT carriers demonstrated a greater capacity 





observed reduce risk of developing gastric cancer. The H. pylori treatment resistance 
subjects also demonstrated higher P-glycoprotein expression in the antrum. In the Phase 
2 of the study, it was found that initial binding of H. pylori was reduced depending on 




P-glycoprotein expression in the upper gastrointestinal tract is induced by H. pylori and 
there is a positive association between P-glycoprotein expression and MDR1 C3435T 
polymorphisms. This is also true in H. pylori-treatment resistant subjects although no 
link between treatment resistance and P-glycoprotein expression was demonstrated. 
However, based on the fact that we were able to demonstrate that attachment of H. 
pylori to gastrointestinal lines is influenced by P-glycoprotein expression, we would 
suggest that the use of a P-glycoprotein inducer, such as rifabutin, may be beneficial in 
their eradication regimens.  
 
6.3 Research limitations and future research recommendations  
 
This study provided a new insight on the ability of 3435TT carriers to induce P-
glycoprotein expression in the presence of H. pylori to the greater extent than 3435CC 
and 3435CT carriers. This finding may provide a possible explanation for differences in 
observed complication rates, notably the development of gastric cancer, based on 
genotype. However, as genetic polymorphism varies inter-individually and inter-
ethically, larger scale epidemiology studies need to be undertaken in order to determine 
the exact influence of MDR1 C3435T on H. pylori infection treatment outcomes and 
complications. 
 
This study also postulated that the use of a P-glycoprotein inducer, such as rifabutin may 
be beneficial in the H. pylori eradication regimens among the resistance subjects.  It is 
important to note that in this study, the baseline P-glycoprotein expression was not 





therapy. Before the recruitment, P-glycoprotein expressions among resistance subjects 
may have already been elevated by chronic H. pylori infection. Hence, to determine if in 
fact a relationship does exist between P-glycoprotein expression and H. pylori 
eradication regimen efficacy, a large study needs to be conducted in which P-
glycoprotein expression is measured at baseline and at the time at which the patients is 
deemed to be resistant. Further, it is important that CYP2C19 polymorphism is also 
evaluated in a larger population with treatment resistance, as this may influence proton 
pump inhibitor efficacy. 
 
BCRP2 is expressed abundantly on the human liver, placenta and intestines, however to 
date there are no literature available on the influence of H. pylori to the BCRP2 
expression level in the intestines. Determining whether H. pylori infection could up-
regulated ABCG2 expression would be beneficial as this particular protein has broad 
and overlapping substrate specificities with P-glycoprotein which may also relevant in 
clinical drug resistance. Future studies should address the influence of H. pylori on 
BCRP2, along with other protein transporters in human intestines, as well as implication 
of polymorphism in the protein gene affecting the pharmacokinetics of substrates used in 
H. pylori eradication therapy.  
 
In this study, it was found that resistant subjects showed higher relative antral P-
glycoprotein expression compared to the H. pylori- negative group but they expressed 
similar protein level with H. pylori-positive-treatment naive subjects. Further, in the 
resistant group, all patients showed an increasing trend towards elevated P-glycoprotein 
levels in the presence of H. pylori irrespective of their C3435T polymorphism. It was 
difficult to conclude that P-glycoprotein alone causes treatment resistance, therefore 
studies on other ABC transporters that also present in the intestines should be 
undertaken in future. 
 
P-glycoprotein (MDR1) is polymorphic and there is strong linkage between its SNPs 
such as C1236T, G2677A/T and C3435T. The influences of C1236T and G2677A/T 





organ transplant patients. As C1236T and G2677A/T are closely related to C3435T, it 
would be beneficial to perform studies on the effect of other SNPs to the P-glycoprotein 
expression as well as H. pylori eradication therapy in future. 
 
One of the postulates in this study is that early attachment of H. pylori to the human 
gastrointestinal tract may be restricted by the level of P-glycoprotein expression as 
demonstrated with tissue culture. However, it is known that H. pylori infection usually a 
life-long and may asymptomatic, therefore it would be beneficial to use an animal model 
to determine the influence of P-glycoprotein expression on bacterial attachment over a 
long period. Importantly, if attachment varies dependent on environmental changes 
and/or virulence factors which may influence P-glycoprotein expression. It would be 
important to use multiple strains of H. pylori as it can be argued that different strains of 
H. pylori and the molecular basis of the pathogen virulence may influence P-


























Appendix I: List of P-glycoprotein substrates, inducers and inhibitors 
 
Substrate Inducer Inhibitor 
Actinomycin D Alfentanil Acetylsalicylic acid 
Aldosterone Amiloride Amiodarone 
Alpha-methyldigoxin Astemizole Atovarstatin 
Amiloride Atovaquone Bromocriptine 
Amitriptyline Azelastine Carvedilol 
Amoxicillin Azidopine Ceftriaxone 
Amprenavir Azithromycin Cefoperazone 
Atorvastatin B-carotene Chlorambucil 
Azelastine Bepridil Chloropromazine 
Beta-acetyldigoxin Biricodar Cisplatin 
Bisantrene B-carotene Clarithromycin 
Bunitrolol Carbamazepine Cyproheptadine 
Carbamazepine Chloroquine Colchicine 
Carvedilol Clotrimazole Cyclosporine 
Celiprolol Cortisol Daunorubicin 
Cetrizine Darunavir Delavirdine 
Chloropramazine Desethylamiodarone Dexamethasone 
Chloroquine Desipramine Diltiazem 
Cimetidine Dexamethasone Doxorubicin 
Ciprofloxacin Dipyidamole Elacridar 
Citalopram Disulfiram Emetine 
Colchicine Doxazosin Erythromycin 
Corticosteroids Elacridar Etoposide 
Cortisol Emetine Fluorouracil 





Substrate Inducer Inhibitor 
Daunorubicin Felodipine Flupenthixol 
Debrisoquine Fenofibrate Hydrocortisone 
Dexamethasone Fentanyl Hydroxyurea 
Digitoxin Flavonoids Indinavir 
Digoxin Fluphenazine Insulin 
Diltiazem Fucidin Itraconazole 
Dipyridamole Glyburide Ketoconazole 
Docetaxel Gramicidin D Lansoprazole 
Domperidone Haloperidol Mefloquine 
Doxepine Hydrocortisone Methadone 
Doxorubicin Kempferol Metrotrexate 
Doxycycline Levothyroxin Miconazole 
Emetine Lidocaine Midazolam 
Enoxacin Loperamide Mitoxantrone 
Epirubicin Loratadine Morphine 
Erythromycin Lovastatin Nelfinavir 
Estradiol Maprotiline Nevirapine 
Etoposide Mefloquine Nicardipine 
Fexofenadine Methadone Nifedipine 
Glyburide Mibefradil Omeprazole 
Gramicidin Midazolam Paclitaxel 
Grepafloxacin Mitomycin C Pantoprazole 
Hydrocortisone Nelfinavir Paroxetine 
Imatinib Nicardipine Pentazocine 
Indinavir Nitrendipine Phenobarbital 
Irinotecan Norverapamil Phenothiazine 
Itraconazole Ofloxacin Phenytoin 
Ivermectin Omeprazole Prazosin 
Ketoconazole Paclitaxel Probenecid 





Substrate Inducer Inhibitor 
Levodopa Phenobarbital Propafenone 
Levofloxacin Phenothiazines Propanolol 
Loperamide Phenytoin Quinidine 
Losartan Pimozide Quinine 
Lovastatin Piperine Rabeprazole 
Mefloquine Probenecid Reserpine 
Methylprednisoline Progesterone Retinoid acid 
Mibefradil Promethazine Rifampicin 
Mithramycin Propafenone Ritonavir 
Mitomycin C Propanolol Saquinavir 
Mitoxantrone Quercetin Sertaline 
Morphine Quinidine Sirolimus 
Nelfinavir Quinine Spironolactone 
Nicardipine Reserpine Tacrolimus 
Nifedipine Retinoic acid Tamoxifen 
Nizatidine Rifampicin Trazodone 
Nortriptyline Saquinavir Valsopodar 
Olanzapine Setraline Verapamil 
Ondansetron Simvastatin Vinblastine 
Paclitaxel Sirolimus Vincristine 
Paroxetine Spironolactone Yohimbine 
Pentazocine St John Wort`s - 
Phenobarbital Tacrolimus - 
Phenothiazine Tamoxifen - 
Phenytoin Tariquidar - 
Prednisolone Telithromycin - 
Progesterone Terfenadine - 
Quetiapine Testosterone - 
Quinidine Tetrabenzine - 





Substrate Inducer Inhibitor 
Rapamycin Trifluopromazine - 
Rifampin Troglitazone - 
Risperidone Valinomycin - 
Ritonavir Valspodar - 
Rhodamine 123 Vinblastine - 
Saquinavir - - 
Sertaline - - 
Sirolimus - - 
Sparfloxacin - - 
Tacrolimus - - 
Talinolol - - 
Tamoxifen - - 
Taxol - - 
Teniposide - - 
Terfenadine - - 
Tetracycline - - 
Topiramate - - 
Topotecan - - 
Triamcinolone - - 
Trimipramine - - 
Valinomycin - - 
Valspodar - - 
Vecuronium - - 
Venflaxine - - 
Vinblastine - - 















































































































Oral presentation at 7
th
 conference on New Frontiers in Microbiology and Infection - 
Helicobacter pylori - from basic science to clinical issues. Villars sur Ollon, Switzerland 
[2- 6 October 2011] 
 
Expression of P-glycoprotein in Helicobacter pylori positive patients 
Marhanis Omar, Andrew Crowe, Hooi Ee
1
, Jeff Hughes 
School of Pharmacy, Curtin University, Western Australia.  
 
Background: Proton pump inhibitor and antibiotics had successfully treats up to 90% of 
Helicobacter pylori-positive cases. However, there are therapy resistant cases reported. Since P-
glycoprotein, a drug efflux transporter protein has defensive roles in drug distribution and 
mechanism, it was of interest to examine its possible role that contributed to successful of H. 
pylori eradication therapy. Aim: To determine whether H. pylori and MDR1 C3435T 
polymorphism influence P-glycoprotein expression upper gastrointestinal tract Method: 76 
subjects were recruited from October 2010 to July 2011 upon their informed consent. H. pylori 
status was confirmed from culture and polymerase chain reaction. Subjects then were divided 
into H.pylori-positive and –negative groups. Their antral and duodenal biopsies were taken for 
Western Blot Analysis. RLFP-PCR was used to determined MDR1 C3435T polymorphism from 
blood DNA. Results: There is a significant difference between P-glycoprotein in antrum and 
duodenum [ p <0.0001] of all participants. Positive correlation was detected between P-
glycoprotein expression and H. pylori status [r
2
 =8.7%, p = 0.0185]. P-glycoprotein expression 
was found higher in subjects with H. pylori-positive. For MDR1 [C3435T] polymorphism, 
subjects with TT genotype had a significantly lower P-glycoprotein expression than CC 
genotype in their antral biopsies. Conclusion: P-glycoprotein expression is associated with the 
presence of H. pylori in upper gastrointestinal tract. TT genotype appeared to be associated with 









Poster presentation at Keystone Symposia on Proteomics, Interactomes, Stockholm, 
Sweeden [7-12 May 2012] 
 
Do Helicobacter pylori and MDR1 C3435T polymorphism influence P-glycoprotein 
expression in human ? 
Marhanis Omar, Andrew Crowe, Jeffery Hughes 
School of Pharmacy, Curtin University, Western Australia 6102 Australia 
 
P-glycoprotein is a large transmembrane glycoprotein of approximately 170kDa that belongs to a 
large superfamily of highly conserved ATP-binding cassette [ABC] transporters. Various in-vivo 
and in-vitro studies have shown that certain gastrointestinal bacteria or drugs would inhibit or 
induce P-glycoprotein expression. The aim of this study was to determine if presence of 
Helicobacter pylori and multidrug resistance 1 protein [MDR1] C3435T polymorphism 
influence P-glycoprotein expression in the upper gastrointestinal tract. A total of 76 subjects who 
underwent an upper gastroendoscopy procedure were recruited. Antral and duodenal biopsies 
were collected for P-glycoprotein analysis. Blood samples were analyzed for MDR1 [C3435T] 
polymorphism. In this study, P-glycoprotein expression was found higher in subjects with H. 
pylori-positive. For MDR1 [C3435T] polymorphism, subjects with TT genotype had a 
significantly lower P-glycoprotein expression than CC genotype in their antral biopsies. The 
homozygous TT subjects with H. pylori also demonstrated a significant difference in their P-
glycoprotein expression compared to H pylori–negative subjects. As for conclusion, the level of 
P-glycoprotein expression in the upper gastrointestinal tract is associated with H. pylori infection 
and TT genotype appeared to be associated with lower P-glycoprotein expression than CC 











Poster presentation at Joint ASCEPT-APSA 2012 Conference, Sydney Australia [2-5 
December 2012]. 
 
P-glycoprotein expression level in treatment - resistant Helicobacter pylori patients 
Marhanis S Omar, Andrew Crowe & Jeffery Hughes. School of Pharmacy, Curtin University 
 
Introduction. There appears to be an increasing incidence of Helicobacter pylori becoming more 
resistant to antibiotic therapy, which is resulting in a reduction in complete H. pylori eradication 
in patients.Aims. We aimed to assess the P-glycoprotein expression levels among subjects who 
were H. pylori-positive and received multiple courses of eradication therapy [resistant group] to 
determine whether the presence of H. pylori increased the expression of this efflux protein. The 
profile of the MDR1 C3435T polymorphism also been investigated. Methods. Eleven subjects 
were recruited for this study during their hospital visit for upper gastrointestinal examinations. 
H. pylori infection status was confirmed by rapid urease test and bacterial culture. Antibiotic 
sensitivity testing was performed by E-test. P-glycoprotein expressions from the antral and 
duodenal biopsies were measured by Western Blot. Genotyping for MDR1 C3435T of each 
resistant subject was performed using polymerase chain reaction and restriction fragment length 
polymorphism analysis. The data was compared with two other groups, recruited from our 
previous study, namely H. pylori-negative [n = 54] and H. pylori-positive but treatment naive [n 
= 22]. Results. The resistant group did show higher P-glycoprotein expression levels [antrum 
over duodenum ratio] compared to the H. pylori- negative group [p = 0.0361]. The levels of P-
glycorprotein expression in the resistant group was observed to be similar to H. pylori-positive 
but treatment naive group [p=0.319]. In the resistant group, all three MDR1 C3435T genotypes 
showed an increasing trend of P-glycoprotein expression with the presence of H.pylori. Most 
subjects demonstrated resistance to clarithromycin [72%], metronidazole [63.6%] or both 
[54.5%]. Discussion. H. pylori infection induces the expression of P-glycoprotein in antrum. 
Increasing P-glycoprotein at the gut level may assist antibiotic therapy for H. pylori if the drug 
regime chosen consisted of P-glycoprotein substrate due to the increased duration and drug 
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